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INTRODUCTION 
Hypertensive disorders, intrauterine growth restriction (IUGR) and spontaneous preterm 
birth are pregnancy outcomes with a major impact on maternal and neonatal and child 
health with largely unknown causes. Tabel 1 shows the definitions of the different 
disorders. The leading hypotheses for hypertensive disorders and IUGR strongly rely on 
disturbed placentation in early pregnancy. 
1.1 Hypertensive disorders 
Hypertensive disorders, including pregnancy-induced hypertension (PIH) and pre-
eclampsia, are common complications in pregnancy1,2. In particular pre-eclampsia and to a 
lesser extend PIH are associated with an increased maternal and fetal morbidity and 
mortality. PIH and pre-eclampsia are pregnancy-specific diseases. The prevalence of pre-
eclampsia is reported between 2 and 8%.  
The cause of pre-eclampsia remains largely unknown. Its pathogenesis is described as an 
abnormal placenta development3. The first (placental) stage of the disease might include an 
atypical maternal immune response to trophoblasts, resulting in a failure in trophoblast 
invasion. Episodes of placental hypoxia or reperfusion result in oxidative stress, 
subsequent apoptotic and necrotic disruption of syncytial architecture, and release of 
various components from the intervillous space into the maternal circulation. The second 
stage of the systemic maternal disease is associated with exaggerated endothelial activation 
and a generalised hyperinflammatory state compared to normal pregnancy. 
1.2 Intrauterine growth restriction 
IUGR is associated with perinatal morbidity and mortality rates are 4-8 times higher for 
infants with IUGR. IUGR affects 3-10% of pregnancy4.
IUGR can be a manifestation of fetal, placental, or maternal determinants or combinations 
of those. Many of the cases of IUGR are the result of ischemic placental disease. This term 
refers to a disease process of the placenta that clinically manifests as IUGR isolated with 
the lack of clinical evident maternal disease e.g. systemic infection and neonatal disease 
e.g. chromosomal abnormalities. The involvement of abnormal placentation in IUGR is 
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clinically evident if complicated by pre-eclampsia as maternal manifestation, abruption, or 
a combination of these disorders5,6. All of these disorders may be associated with preterm 
birth or fetal loss and represent late manifestations of abnormal placental development
dating from the earliest stages of pregnancy. Uteroplacental blood flow may be diminished 
by faulty development, acquired obstruction, or disruption of the uteroplacental 
vasculature. Obstetrical complications (eg, pre-eclampsia) associated with vasculopathy 
and/or reduced maternal blood volume or blood pressure diminish uteroplacental perfusion 
and result in IUGR7,8. 
1.3 Spontaneous preterm birth  
Preterm birth is the leading cause of infant morbidity and mortality in the industrialized 
world. Given that low and very low birthweight newborns are at the highest risk of early 
death or disability, major focuses of obstetrical research include the pathogenic processes 
leading to preterm birth and development of preventive interventions. Approximately 70 
percent of preterm deliveries occur spontaneously. 
The cause for preterm birth is in many situations unknown. There is compelling clinical 
and research evidence to suggest that a number of pathogenic processes can lead to a final 
common pathway that results in spontaneous preterm birth. The four primary processes 
include premature activation of the maternal or fetal hypothalamic-pituitary-adrenal axis, 
exaggerated inflammatory response/infection, abruption (decidual hemorrhage) and 
pathological uterine distention. Spontaneously preterm birth is associated with 
histopathological evidence of abnormal placentation9. Premature fetal hypothalamic-
pituitary-adrenal activation can result from the stress of uteroplacental vasculopathy. One 
study described that spontaneous preterm birth was associated with a lack of normal 
physiologic conversion of maternal spiral arteries10.
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Table 1 definition hypertensive disorders in pregnancy, intra-uterine growth restriction and 
spontaneous preterm birth 
              Definition
Disorder
RCOG 2011 ISSHP 2000 ACOG
Chronic or pre-existent 
hypertension
an absolute blood pressure ≥140/90 
mmHg measured preconceptionally or 
before the 20th week of pregnancy
an absolute blood pressure ≥140/90 
mmHg measured preconceptionally or 
before the 20th week of pregnancy
an absolute blood pressure ≥140/90 
mmHg measured preconceptionally or 
before the 20th week of pregnancy
Pregnancy-induced 
hypertension
de novo hypertension (an absolute blood 
pressure ≥140/90 mmHg) without 
proteinuria, after the 20th gestational week
de novo hypertension (an absolute blood 
pressure ≥140/90 mmHg) without 
proteinuria, after the 20th gestational week
blood pressure of 140mmHg systolic or 
higher or 90mmHg or higher that occurs 
after 20 weeks of gestation in a woman
with previously normal blood pressure
Pre-eclampsia pregnancy-induced hypertension and 
proteinuria (≥ 0.3grams in a 24-hour urine 
specimen or ≥ 2 + [1 g/l] on a voided 
specimen, or ≥ 1+ [0.3 g/l] on a 
catheterised specimen)
de novo hypertension (an absolute blood 
pressure ≥140/90 mmHg), returning to 
normal postpartum AND proteinuria (≥ 
0.3grams in a 24-hour urine specimen or
protein/creatinine ratio≥ 30mg 
protein/mmol creatinine)
blood pressure of 140mmHg systolic or 
higher or 90mmHg or higher that occurs
after 20 weeks of gestation in a woman 
with previously normal blood pressure
AND proteinuria, defined as urinary 
excretion of 0.3g protein or higher in a 
24-hour urine specimen
Severe hypertension diastolic blood pressure ≥ 110mmHg on 
two occasions or systolic blood pressure 
≥ 160mmHg on two occasions
diastolic blood pressure ≥ 110mmHg on 
two occasions or systolic blood pressure ≥ 
160mmHg on two occasions
blood pressure of 160mmHg systolic or 
higher or 110mmHg diastolic or higher 
on two occasions at least 6 hours apart 
while the patient is on bed rest
Severe pre-eclampsia pre-eclampsia with severe hypertension 
and/or with symptoms, and/or elevated 
liver enzymes and low platelet count
no consensus pre-eclampsia with severe hypertension 
or and at least one of the severe criteria:
Early onset pre-eclampsia pre-eclampsia before a gestational age of 
34 weeks
pre-eclampsia before a gestational age of 
34 weeks
Late-onset pre-eclampsia pre-eclampsia after a gestational age of  
34 weeks
pre-eclampsia after a gestational age of  
34 weeks
HELLP syndrome haemolysis, elevated liver enzymes and 
low platelet count
haemolysis, elevated liver enzymes and 
low platelet count
Severe criteria no consensus
Symptoms severe headache; visual disturbance; 
epigastric pain or vomiting
oliguria of less than 500ml in 24 hours
cerbral or visual disturbances
pulmonary edema or cyanosis
epigastric or right upper-quadrant pain
fetal growth restriction
Proteinuria creatinine ratio is greater than 
30mg/mmol or a validated 24-hour urine 
collection result shows greater than 
300mg protein
≥ 0.3grams in a 24-hour urine specimen 
or protein/creatinine ratio≥ 30mg 
protein/mmol creatinine
5 g or higher in a 24-hour urine specimen 
or 3+ or greater on two random urine 
samples collected at least 4 hours apart
Biochemical and 
haematological 
impairment
platelet count < 100x109/L, abnormal 
liver enzymes (ALT or AST rising to 
above 70U/L)
impaired liver function, 
thrombocytopenia
general Gardosi Generation R
Intrauterine growth 
restriction (IUGR)
intrauterine fetal growth that deviates 
from expected norms
classification of birth weight using 
customized centiles adjusted for 
gestational age, parity, ethnicity and 
parental height and weight 
(www.gestation.net)
sex specific gestational age adjusted-birth 
weight below P2.3
Spontaneous preterm birth a spontaneous delivery before a 
gestational age of 37 weeks
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Objective of the thesis 
Defective deep placentation has been associated with a spectrum of complications of 
pregnancy including pre-eclampsia, intrauterine growth restriction, spontaneous preterm 
birth, late spontaneous abortion and abruption placentae8. The major obstetrical syndromes 
are associated with defective deep placentation, which may be associated with different 
degrees of restricted remodelling and obstructive lesions of spiral arteries in the junctional 
zone or inner myometrium8.
Due to the unknown pathogenesis of placental related disorders prevention, prediction and 
rational treatment are lacking. Proper antenatal care and timely delivery is the most 
important part of preventing complications of placental related disorders in pregnancy. The 
identification of risk factors for these disorders at an early stage of pregnancy, could 
increase awareness and support timely detection. Moreover, new knowledge on risk factors 
might play a role in unravel the pathogenesis of placental related disorders in pregnancy. 
Potential new risk factors, shared and different risk factors probably helps to elucidate the 
underlying pathogenetic mechanisms of placental related disorders. Generation R, a large 
prospective cohort study, has opened up these opportunities11. The existing literature 
suggests that socioeconomic status has its impact on health, which starts already in 
pregnancy. A low maternal socioeconomic status at time of pregnancy has been shown to 
increase the risk for low birth weight, prematurity and perinatal mortality. Socio-economic 
status as a risk factor of hypertensive disorders in pregnancy has been studied extensively 
in the Generation R Study. Models that can easily be used in a antenatal care setting will 
help to recognize those who are at risk. Pre-eclampsia in a previous pregnancy is an 
important risk factor for recurrent pre-eclampsia in subsequent pregnancies and pre-
eclampsia is a risk for cardiovascular diseases in later life12. Risk assessments in pregnancy 
or later life are commonly determined by epidemiologic studies through subjects' self-
report via personal interviews or mailed questionnaires self-administered questionnaires. 
Validation of self-reported pre-eclampsia will help to interpret results of studies, which 
examine associations between pre-eclampsia and different outcomes. 
Abnormal placentation is associated with pre-eclampsia, intrauterine growth restriction and 
spontaneous preterm birth. These disorders of deep placentation are characterized by the 
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degree of restriction of physiologic transformation of the spiral arteries and the presence of 
arterial lesions in the junctional zone of the myometrium of the placental bed8.  
The mechanism(s) that triggers abnormal placentation and results in a subsequent 
progression into the systemic maternal response are intense areas of research. Numerous 
factors are proposed to be involved among which oxidative stress, thrombofilia, 
immunological factors and (anti-)angiogenic factors. 
Haemostasis is a complex balance of activating and inhibitory pathways. Normal 
pregnancy is associated with hypercoagulation which is even more profound in 
complicated pregnancies13. It is necessary to describe the changes of components of the 
plasminogen-activator-system during normal pregnancy, to understand the involvement of 
the hemostatic imbalance in pregnancy-related complications. Placentation involves 
trophoblast invasion and angiogenesis and its success is dependent on vascular- and 
endothelial cell function14. An imbalance between circulating pro-angiogenic (PlGF) and 
anti-angiogenic (sFlt1) factors play a role in the etiology of different adverse outcomes of 
pregnancy. A series of studies showed a relationship between low PlGF and elevated sFlt1 
concentrations in the maternal circulation and the risk of pre-eclampsia15. This anti-
angiogenic profile has also been described in relation to growth restriction16. Circulating 
concentrations of especially PlGF and sFlt1 have been shown to be altered several weeks 
ahead of the onset of pre-eclampsia17.  
Imbalances of angiogenic (sFlt1 and PlGF) and hemostatic (PAI-2) factors as a mediating 
link between trophoblast failure and endothelial dysfunction might affect placentation, 
resulting in abnormal placentation and adverse pregnancy outcomes. The proteins could be 
a predictor for adverse pregnancy outcomes and might be a target for therapeutic 
intervention. Prerequisite for successful trophoblast invasion is degradation and 
remodelling of the uterine decidual extracellular matrix and apoptosis. Matrix 
metalloproteinases (MMP) play a crucial role in restructuring the extracellular matrix18,19.
Several members of this enzyme family are present at the fetal-maternal interface. The 
inability to produce sufficient matrix metalloproteinases may be an early manifestation of 
abnormal placentation in pregnancy related complications. Programmed apoptosis is 
regulated through annexin A5, which is expressed in syncytiotrophoblasts and endothelial 
cells. Polymorphisms that are functional promoter polymorphisms may affect transcription 
rate and the amount of protein synthesised. Determination of circulating biomarkers, 
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including key proteins, and polymorphisms that affect the amount of proteins, which are 
specific for angiogenesis might give more insight in the trigger for abnormal placentation, 
responsible for adverse pregnancy outcomes.  
Aims  
The main objectives of this thesis can be summarized as follows: 
A better understanding of the pathophysiologic mechanisms of placenta related disorders 
in pregnancy by; 
1. Assessment of maternal and paternal risk factors, which play a role in development 
of placenta related pregnancy complications.  
2. Investigation of early pregnancy circulating biomarkers in maternal blood 
(hemostatic and angiogenic factors) in relation to adverse pregnancy outcomes 
including pre-eclampsia.  
Outline 
This thesis is divided into two parts. Part 1 focuses on the assessment of maternal and 
paternal risk factors, which play a role in development of placental related pregnancy 
complications. Part 2 focuses on the investigation of circulating biomarkers in maternal 
blood (hemostatic and angiogenic factors) and adverse pregnancy outcomes. 
Part 1 
In chapter 2.1 we examine the maternal and paternal risk factors and development of pre-
eclampsia and PIH. In chapter 2.2 and 2.3 the associations of low socio-economic status 
and, pre-eclampsia and gestational hypertension are assessed. In chapter 2.4 we present the 
validation of a prediction model for the development of hypertension in pregnancy in 
nulliparous women, based on clinical measurements obtained routinely at the first 
antenatal visit. In chapter 2.5 we evaluate the reliability of self-reported pre-eclampsia, 
often used in epidemiological studies.
Part 2 
In chapter 3.1 we provide longitudinal data on activating and inhibitory components of the 
plasminogen-activator system during normal pregnancy. In chapter 3.2 we examined the 
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associations of determinant(s) of angiogenesis (sFlt1 and PlGF) and hemostasis (PAI-2) in 
maternal blood, and maternal and perinatal complications in pregnancy. In chapter 3.3 we 
focus on the determinants of angiogenesis (MMP9, MMP3 and annexin polymorphism) in 
maternal DNA and development of pre-eclampsia. 
Studypopulation 
The studies describing maternal and paternal risk factors, and the study describing sFlt1, 
PlGF and PAI-2 and adverse pregnancy outcomes were embedded within the framework of 
the Generation R Study. The Generation R Study is an ongoing population-based cohort 
study, designed to identify early environmental, biological and social determinants of 
growth, development and future health11,20,21,22. In total 9778 women enrolled in the 
Generation R Study, of whom 8880 women, 6384 partners and their children, of different 
ethnicities, and living in Rotterdam, the Netherlands enrolled prenatal. Enrolment was 
aimed in early pregnancy, but possible until birth of the child. Eighty% of the women was 
included before 18 weeks of gestation. Questionnaires, in early, mid and late pregnancy, 
were used to gather information about maternal and paternal socio-demografic, obstetrical, 
health-related and lifestyle determinants. Physical examinations, including maternal and 
paternal weight and height, and maternal blood pressure were obtained in early, mid and 
late pregnancy. Maternal blood samples were assessed in early and mid pregnancy. Several 
overlapping sources such as our own ultrasound facilities but also obstetric caregivers, and 
Municipal Health Services, provided information about maternal and perinatal outcomes, 
including gestational hypertensive disorders, intrauterine fetal growth, placental weight, 
birth weight, preterm birth and congenital anomalies. 
All children were born between April 2002 and January 2006. The study was approved by 
the Medical Ethical Committee of the Erasmus Medical Centre, Rotterdam. The 
Generation R Study follows the STROBE guidelines23,24.
The studies describing balances in angiogenesis or hemostasis in pregnancy were 
performed in different cohorts. In chapter 3.2, the study describing plasminogen activator 
and their inhibitors was performed in samples from a subgroup from a multicentred cohort 
study, coordinated from the University Hospital St Radboud in Nijmegen, the Netherlands, 
between 1987 and 199025. Maternal blood samples were assessed before pregnancy, 
throughout pregnancy and 6 weeks after pregnancy. 
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In chapter 3.3, the study describing “Matrix metalloproteinase-9 gene -1562C/T 
polymorphism” was performed in samples from a case control study, coordinated by the 
Leiden University Medical Centre, the Netherlands26. 
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ABSTRACT 
Introduction: 
Timely identification of risk factors enables antenatal management tailored to that 
individual, which may contribute to the prevention of perinatal and maternal morbidity and 
mortality. Therefore, we studied maternal as well as paternal risk factors in nulliparous and 
multiparous women in early pregnancy. 
Study design: 
This study was embedded in the Generation R Study, a population-based prospective 
cohort study from fetal life until young adulthood. Information about maternal and paternal 
characteristics, such as sociodemografic status, lifestyle habits, and obstetrical history was 
obtained in early pregnancy from questionnaires, medical records and physical 
examinations. Associations between early pregnancy risk factors and pregnancy-induced 
hypertension and pre-eclampsia were evaluated in logistic regression models. 
Results: 
Of all pregnant women, 231 (4.5%) developed pregnancy-induced hypertension and 127 
(2.5%) developed pre-eclampsia. For nulliparous women an increased BMI was associated 
with a three fold, European ethnicity with a two fold and family history of pre-eclampsia 
with a two fold increased risk for development of pregnancy-induced hypertension. For 
multiparous women an increased BMI and previous gestation hypertensive disorders were 
associated with an increased risk for developing pregnancy-induced hypertension (three 
and ten fold, respectively).  
The most important risk factors for nulliparous women who developed pre-eclampsia 
included advanced maternal age (five fold increased risk), twin pregnancies (five fold 
increased risk), an increased BMI (three fold increased risk), a Surinamese ethnicity (two 
fold increased risk) and a maternal low birth weight (three fold increased risk). In 
multiparous women risk factors for pre-eclampsia were previous gestational hypertensive 
disorder, an increased BMI and headache (ten fold, four fold and three fold, respectively). 
Low education and Dutch ethnicity were associated a four fold decreased risk for 
developing pre-eclampsia. A history of family hypertension was associated with pre-
eclampsia in neither nulliparous nor multiparous women. Paternal risk factors were not 
associated with development of pregnancy-induced hypertension nor pre-eclampsia. For 
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multiparous women paternal arthralgia showed a trend towards a risk for development of 
pre-eclampsia. 
Conclusion: 
Easily accessible risk factors in early pregnancy in nulliparous and multiparous women for 
pregnancy-induced hypertension and pre-eclampsia appear to be partly different. 
Suggested paternal risk factors could not be confirmed and new paternal risk factors were 
not identified. 
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INTRODUCTION 
Pregnancy-induced hypertension and pre-eclampsia, are common complications in 
pregnancy1. In particular pre-eclampsia and to a lesser extent pregnancy-induced 
hypertension are associated with an increased perinatal and maternal morbidity and 
mortality2,3. The first (placental) stage of development of pre-eclampsia is suggested to be 
related to impaired trophoblast invasion. Episodes of placental hypoxia result in oxidative 
stress and release of various components into the maternal circulation. The second stage
involves systemic exaggerated endothelial activation and a generalised hyperinflammatory 
state as compared to normal pregnancy1.
Since the etiology remains largely unknown, rational prevention of these disorders 
is not possible. Detection, appropriate antenatal care and timely delivery are thus the most 
important tools to prevent maternal and fetal complications. Timely detection will be 
enhanced by the identification of risk factors for hypertensive disorders at an early stage of 
pregnancy, increasing awareness and focussed surveillance. Several risk factors for the 
development of pre-eclampsia, which may be present at antenatal booking, have been 
described in a systematic review4,5. Specific risk factors described for pre-eclampsia 
include nulliparity, older age, high body mass index (BMI), family history of pre-
eclampsia, underlying renal disease or chronic hypertension, multiple pregnancy, more 
than 10 years between pregnancies, and a personal history of pre-eclampsia6. The expected 
rate of pre-eclampsia, when anyone of these risk factors is present, ranges from 3% to 
more than 30%, and many women have several risk factors6. Pre-pregnancy planning and 
health promotion even before conception offers the possibility to improve pregnancy 
outcomes as well. Modifiable risk factors including, obesity and smoking before 
conception, education, socioeconomic status and maternal diseases are important risk 
factors to consider known before pregnancy. More healthy women before pregnancy will 
result in more healthy pregnancies and less maternal morbidity and mortality. In addition, 
by studying risk factors for hypertensive disorders more knowledge will be gained in the 
insights of the etiology of hypertensive disorders.  
Paternal risk factors for gestational hypertensive disorders were less well studied. 
Therefore, within the Generation R study, which is a large prenatally recruited birth-cohort 
study with extensive assessments during pregnancy, we studied risk factors in early 
pregnancy for pregnancy-induced hypertension and pre-eclampsia, focussing potential new 
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maternal risk factors and paternal risk factors in addition to the factors already known,
described earlier6. Those risks appear to be in part different for nulliparous and 
multiparous women7. As multiparous women with a history of uncomplicated pregnancies 
have a minimal risk for pre-eclampsia of only 1 % or less, we stratified according to 
parity8.
METHODS 
Design 
This study was embedded in the Generation R Study, a population-based prospective 
cohort study from fetal life until young adulthood. The Generation R Study examines early 
environment and genetic determinants of growth, development and health in fetal life, 
childhood and adulthood9. The cohort included 8880 mothers, 6384 fathers and their 
children, of different ethnicities, and living in Rotterdam, the Netherlands from 2003 till 
2006. Enrolment was aimed in early pregnancy, but possible until birth of the child. 
Women and their partners were enrolled in the study at their routine ultrasound 
examination in pregnancy after written consent was obtained. Assessments in pregnancy, 
including anthropometrics of both parents and questionnaires were planned in early 
pregnancy. All children were born between April 2002 and January 2006. The study was 
approved by the Medical Ethical Committee of the Erasmus Medical Centre, Rotterdam.  
Maternal risk factors 
Information was obtained in one of the research centres by a physical examination of the 
pregnant woman and by questionnaire at enrolment. This self-reported home send 
questionnaire comprised information on maternal factors, included comorbidity, family 
history, lifestyle and pregnancy associated factors (about previous pregnancies and current 
pregnancy).  
Maternal factors 
Maternal age was categorized into two groups (<40 and ≥40 years)5. Height and weight of 
the mother were measured at enrolment. Body mass index was calculated as weight per 
height squared (kg/m2) and categorized into two groups (≤25 and > 25kg/ m2). Ethnicity 
was categorized into European, Surinamese, Turkish, Moroccan, Antillean, Cape Verdean 
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and other countries7, a categorization reflecting the most prevalent migrant groups. 
Education (highest completed educational level of the mother) was categorized into three 
levels: low (no education or primary school), mid (secondary school) and high (high 
school or university). 
Comorbidity 
Maternal comorbidity was defined as a mother having a chronic disorder, including 
chronic hypertension, diabetes, migraine and arthralgia (yes, no or don’t know). 
Family history factors 
The information provided on maternal birth weight was categorized as follows; less than 
2000g, 2000-2500g, 2500-3000g, 3000-4000g, more than 4000g and not known. Maternal 
low birth weight was defined as a maternal birth weight less than 2500g. Diseases in 
family of the mother asked for included diabetes, hypertension, pregnancy-induced 
hypertension and pre-eclampsia (no, yes, don’t know). 
Lifestyle factors 
Maternal smoking, alcohol, coffee and tea consumption habits were assessed by repeatedly 
applied questionnaires in pregnancy10,11. 
Pregnancy associated factors 
The questionnaire also comprised questions regarding outcomes of previous pregnancies 
(pre-eclampsia or pregnancy-induced hypertension, no or yes) as well as specific 
symptoms that had occurred during the first trimester of the current pregnancy. Symptoms 
asked for were headache, nausea and oedema. The information obtained was categorized 
into 2 groups (having these symptoms a few days a week or more, and once a week or 
less). 
Paternal risk factors 
Information on paternal risk factors was obtained at enrolment from a physical 
examination of the father and a self-reported questionnaire. Paternal anthropometrics, 
including weight and height were measured and body mass index was calculated as weight 
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per height squared (kg/m2). Characteristics of the father studied included age, ethnicity 
and chronic diseases of the father (diabetes mellitus, hypertension and arthralgia). The 
questionnaire also contained questions about diseases in the family, including chronic 
hypertension and diabetes. The information provided on paternal birth weight was 
categorized as follows: less than 2000g, 2000-2500g, 2500-3000g, 3000-4000g, more than 
4000g and not known. Paternal low birth weight was defined as a paternal birth weight less 
than 2500g. No questions on pregnancy-induced hypertension and pre-eclampsia in the 
family were included in the questionnaire for the father. Questions about lifestyle risk 
factors included smoking, alcohol, coffee and tea consuming and were categorized in yes 
or no. 
Maternal outcomes 
According to Dutch standards of antenatal care, all women whose pregnancies are 
complicated by hypertension, should deliver in a hospital under medical supervision of an 
obstetrician. The delivery reports of all study participants who delivered under medical 
supervision were retrieved and these reports were screened by a trained medical record 
abstractor. Selection was based on the delivery report mentioning any kind of hypertensive 
complications, cases of chronic hypertension, pregnancy-induced hypertension, pre-
eclampsia or HELLP syndrome (haemolysis, elevated liver enzymes, and low platelets). 
To confirm the diagnosis of chronic hypertension, pregnancy-induced hypertension or pre-
eclampsia, the same abstractor conducted, in addition, detailed reviews of the hospital 
charts of these women regarding blood pressure and laboratory analyses12. pregnancy-
induced hypertension and pre-eclampsia were defined according to the International 
Society for the Study of Hypertension in Pregnancy ISSHP criteria13. HELLP syndrome 
was defined as thrombocytes <100x109/l, and both ASAT (aspartate aminotransferase) and 
ALAT (alanine aminotransferase) >70 U/l and LDH (lactate dehydrogenase) > 600 U/L.
Population for analysis 
In total 8880 pregnant women were enrolled in the antenatal phase of Generation R Study. 
Figure 1 shows the study population flow chart. A subgroup enrolled before sixteen weeks 
of gestation (64%, n=5709). Women who had a termination of pregnancy, fetal death 
before twenty weeks of gestation or missing maternal pregnancy outcome were excluded  
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Figure 1 Study population flow chart 
Total pregnant
Population 
n = 8880
Analysis
Population
n = 5129
Multiparae
n = 1929
Nulliparae
n = 3162
PIH (n = 184)
Pre-eclampsia (n = 101)
Inclusion 
before 
16 weeks  
n = 5709
Exclusion:  
Termination of Pregnancy (n = 31) 
Fetal death < 20 weeks (n = 34) 
More pregnancies in GR (n = 383) 
Lost to follow up (n = 132)
PIH (n = 47)
Pre-eclampsia (n = 26)
Missing data on 
parity
n = 38
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from the present study. When women had participated with more than one pregnancy in 
generation R, only the first pregnancy was included in this analysis. In 38 cases (0.7%) 
information on parity was missing. The associations of the different risk factors with 
pregnancy-induced hypertension or pre-eclampsia were analyzed for the remaining 5091 
women. Different analyses were made for the subgroups of nulliparous women (62.1%, 
n=3162) and multiparous women (37.9%, n=1929). Paternal risk factors were analyzed in 
the subgroup of women that participated with their partner (79%, n= 4010). 
Data analysis 
The study assessed the associations of risk factors for pregnancy-induced hypertension and 
pre-eclampsia using logistic regression analysis. First crude, unadjusted odds ratios were 
calculated; thereafter different adjustments were made. Adjustment was resulting from an 
enter, forward and backward stepwise regression model. Adjustments were included in the 
analyses based on literature and on the condition that the effect in the forward and 
backward stepwise regression model changed more than 5%. For nulliparous women with 
pregnancy-induced hypertension we made adjustments for an increased body mass index 
and family hypertensive disorders. For multiparous women, adjustments were made for 
previous gestational hypertension. For nulliparous women with pre-eclampsia, adjustments 
were made for an increased body mass index and chronic hypertension, and for 
multiparous women adjustments were made in case of  previous pre-eclampsia. Finally, for 
nulliparous and multiparous women with pregnancy-induced hypertension or pre-
eclampsia, multiple adjustments (based on literature5) were calculated. Not all data are 
shown in the tables. For ethnicity we showed only the results for women with the 
European ethnicity compared to non-European ethnicity and the Surinamese ethnicity 
compared to non Surinamese ethnicity. For education we showed the results for women 
with the highest education compared women with the lowest and mid education.  
We compared women with pregnancy-induced hypertension or pre-eclampsia to a 
reference group. The reference group was defined as all women in the cohort without 
pregnancy-induced hypertension, pre-eclampsia or HELLP syndrome. We considered 
“Don’t know “ answers as missing. Finally, we assessed the associations of risk factors in 
the subgroup of women who developed a hypertensive disorder in pregnancy and 
compared women with pregnancy-induced hypertension to women with pre-eclampsia. 
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The Statistical Package of Social Sciences version 15.0 for Windows (SPSS Inc, Chicago, 
IL, USA) was used for all statistical analyses. 
Table 1. Maternal and paternal characteristics 
PIH Pre-
eclampsia
Reference PIH Pre-
eclampsia
Reference
Maternal related N=184 N=101 N=2864 N=47 N=26 N=1854
Age mean (sd) 29.1(4.8) 28.4(5.0) 28.7(4.9) 32.0(4.3) 30.3(5.4) 31.1(4.6)
Age>40years(%) 0.5 2 0.6 0 3.8 1.7
Missing(%) 0 0 0 0 0 0
BMI mean(sd) 26.8(5.2) 26.9(6.1) 23.8(4.1) 29.1(6.5) 28.3(5.2) 25.0(4.6)
BMI>25kg/m2(%) 52.2 51.5 28.7 70.2 65.4 42.4
Missing(%) 0.5 1 0.3 0 3.8 0.8
Ethnicity
European(%) 73.9 54.5 62.3 68.1 26.9 53.6
Surinamese(%) 8.2 15.8 8.0 2.1 15.4 8.0
Missing(%) 3.3 5.0 4.2 2.1 15.4 6.7
Education
High(%) 39.6 34.8 46.4 31.9 11.5 36.2
Mid(%) 51.1 55.4 43.1 44.6 34.6 42.5
Low(%) 4.3 5.0 5.5 17.0 34.6 12.6
Missing(%) 4.9 5.0 5.0 6.4 19.2 8.7
History
PE in history(%) - - - 6.4 11.5 1.6
Missing(%) 19.1 34.6 14.1
PIH in history(%) - - - 38.3 30.8 6.3
Missing(%) 12.8 19.2 13.8
Maternal comorbidity
Chronic hypertension
(%)
- 1.1 - - 1.2 -
Maternal diabetes(%) 0 2.0 0.3 0 0 0.5
Missing 10.9 7.9 12.3 10.6 30.8 14.0
Maternal birth weight 
<2500g
6.5 16.8 6.4 2.1 3.8 5.6
Missing(%) 16.8 15.8 18.4 27.7 34.6 19.4
Family history factors
Hypertension in 
family(%)
41.3 38.6 30.4 44.7 34.6 30.3
Missing 13.6 13.9 15.4 10.6 38.5 16.4
Nulliparous Multiparous
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Table1 Continued
# Headache a few days a week or more
RESULTS 
Maternal and paternal characteristics of the studypopulation are described in table 1.  
In the subgroup of 5129 women who were included before 16 weeks gestational age, 4.5% 
developed pregnancy-induced hypertension and 2.5% developed pre-eclampsia (figure 1). 
PIH Pre-
eclampsia
Reference PIH Pre-
eclampsia
Reference
N=184 N=101 N=2864 N=47 N=26 N=1854
Diabetes in family(%) 19.0 17.8 15.0 17.0 19.2 13.2
Missing 12.0 12.9 12.0 14.9 38.5 12.0
Smoking(%) 8.7 8.9 10.5 10.6 7.7 12.0
Missing(%) 9.8 7.9 10.6 8.5 30.8 12.7
Alcoholics(%) 8.7 9.9 13.9 8.5 0 14.8
Missing(%) 9.2 5.9 10.3 8.5 26.9 12.2
Coffee(%) 38.6 43.6 44.3 48.9 38.5 49.5
Missing(%) 8.7 6.9 10.2 10.6 26.9 12.7
Tea(%) 85.9 87.1 82.4 80.9 65.4 79.7
Missing(%) 8.7 6.9 10.2 10.6 26.9 12.6
Twin pregnancy(%) 0.5 3.0 0.7 2.1 3.8 1.2
Missing(%) 20.7 24.8 16.6 34.0 34.6 18.7
Headache(%)# 25.0 36.6 27.7 29.8 42.3 30.6
Missing(%) 13.6 8.9 11.6 17.0 26.9 16.1
Participation(%) 88.6 77.2 83.6 83.0 50.0 70.4
Hypertension(%) 2.2 4.0 2.1 2.1 0 1.3
Missing(%) 24.5 41.6 31.3 34.0 65.4 45.8
Diabetes(%) 0 1.0 0.3 0 0 0.7
Missing(%) 19.0 39.6 29.0 31.9 65.4 43.9
Arthralgia(%) 0 1.0 0.3 0 3.8 0.2
Missing(%) 20.1 61.4 28.9 29.8 61.5 44.4
Birth weight < 
2500g(%)
4.3 2.0 2.6 0 0 1.8
Missing(%) 40.8 57.4 52.4 53.2 88.5 63.9
BMI>25 kg/m2(%) 48.4 32.7 38.3 51.1 34.6 36.1
Missing(%) 12.0 22.8 16.5 17.0 50.0 29.7
Nulliparous Multiparous
Lifestyle factors in first trimester
Paternal factors
Pregnancy-associated factors
Characteristics
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Nulliparous women had a higher risk to develop pregnancy-induced hypertension and pre-
eclampsia (crude odds ratio with 95% confidence interval, 2.56, 1.81 – 3.70 and 4.54, 2.56 
– 7.69, respectively). 
Risk factors for pregnancy induced hypertension 
Table 2 and 3 show the associations between risk factors and pregnancy-induced 
hypertension. An increased BMI, European ethnicity and a history of family hypertension 
were associated with pregnancy-induced hypertension in nulliparous women. Previous 
gestational hypertension and an increased BMI were associated with pregnancy-induced 
hypertension in multiparous women. Advanced maternal age, Surinamese ethnicity, 
maternal low birth weight, twin pregnancies, headache and paternal factors were neither 
associated with pregnancy-induced hypertension in nulliparous nor multiparous women. 
The consumption of alcoholics showed a trend to protect for development of pregnancy-
induced hypertension in the first pregnancy. We did not find any significant associations 
with regards to smoking, and drinking coffee or tea in early pregnancy. 
Risk factors for pre-eclampsia 
Table 4 and 5 show the associations between risk factors and pre-eclampsia. All potential 
risk factors for pre-eclampsia are summarized in figure 2. 
Figure 2. Multivariable analysis of potential significant risk factors for pre-eclampsia for 
nulliparous and multiparous women 
Results from multiple logistic regression . Values are odds ratios (95% Confidence Interval).  
Risk factors for pre-eclampsia are presented in black for nulliparous women and in white for multiparous women.
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Advanced maternal age, maternal low birth weight and twin pregnancy were associated 
with pre-eclampsia in nulliparous women after adjustments made for an increased BMI 
and hypertension. In addition, an increased BMI and chronic hypertension appeared to be 
independently associated with pre-eclampsia. Chronic hypertension and headache were 
associated with an increased risk for pre-eclampsia in multiparous women after 
adjustments for previous gestational hypertension. Moreover, previous pre-eclampsia and 
previous pregnancy-induced hypertension were associated with an increased risk of pre-
eclampsia. Women from Dutch or European ethnicity and those with a high education 
exhibit a lower risk to develop pre-eclampsia. Family history of hypertension, lifestyle 
factors and paternal factors were associated with pre-eclampsia in neither nulliparous nor 
multiparous women.  
Risk factors for pre-eclampsia or pregnancy-induced hypertension
Table 6 shows potential different risk factors for pre-eclampsia versus pregnancy-induced 
hypertension in the subgroup of women who developed a hypertensive disorder in  
pregnancy. Nulliparous women of Surinamese ethnicity, low maternal birth weight or 
complaints of headache in early pregnancy had a higher risk to develop a pre-eclampsia. 
Multiparous women with a high education were more prone to develop pregnancy-induced 
hypertension. 
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Table 2. Potential risk factors of pregnancy-induced hypertension for 
nulliparous women, n=3048. 
Results from simple and multiple logistic regression analyses. Data are odds ratios (95% Confidence Interval) 
ǂ Crude: unadjusted 
†Adjusted: adjusted for body mass >25kg/m2 and hypertensive disorders in family
#Adjusted for age>40, body mass>25, hypertensive disorders in family 
*P<0.05. 
Age > 40years 1.02 (0.99-1.05) 1.75 (0.22-14.2) 1.70 (0.21-13.6
BMI > 25kg/m2 2.73 (2.02-3.69)* 2.70 (1.93-3.78)* 2.64 (1.91-3.66)*
European ethnicity 1.74 (1.22-2.48)* 1.94 (1.28-2.94)* 1.94 (1.29-2.93)*
Surinamese ethnicity 1.02 (0.59-1.75) 0.85 (0.44-1.62) 0.92 (0.51-1.66)
High education 0.68 (0.50-0.93)* 0.77 (0.55-1.09) 0.79 (0.56-1.10)
Diabetes 0 0 0
Maternal birth weight 1.00 (0.55-1.84) 1.17 (0.62-2.18) 1.14 (0.61-2.11)
Family history
Hypertensive 
disorder in family
1.90 (1.35-2.69)* - 1.54 (1.11-2.14)*
Diabetes in family 1.57 (1.06-2.31)* 1.25 (0.82-1.91) 1.32 (0.88-1.98)
Lifestyle factors
Smoking 0.93 (0.65-1.33) 0.79 (0.53-1.18) 0.63 (0.34-1.15)
Alcohol 0.58 (0.34-0.98)* 0.67 (0.39-1.15) 0.65 (0.38-1.11)
Coffee 0.75 (0.55-1.03) 0.76 (0.54-1.07) 0.76 (0.54-1.06)
Tea 1.41 (0.73-2.70) 1.39 (0.69-2.79) 1.39 (0.71-2.72)
Twin pregnancy 0.86 (0.11-6.47) 0.73 (0.09-5.69) 0.74 (0.10-5.67)
Headache in first 
trimester
0.89 (0.63-1.27) 0.81 (0.55-1.20) 0.86 (0.59-1.25)
Paternal 
hypertension
0.93(0.33-2.58) 0.84 (0.26-2.78) 0.84 (0.26-2.75)
Diabetes 0 0
Arthralgia 0 0
Paternal birth weight 1.38 (0.65-2.94) 1.39 (0.57-3.37) 1.28 (0.53-3.06)
Hypertension family 1.19 (0.83-1.71) 1.13 (0.76-1.68) 1.16 (0.79-1.71)
BMI > 25kg/m2 1.44 (1.05-1.98)* 1.13 (0.79-1.62) 1.17 (0.82-1.65)
Adjusted† Adjusted#
Paternal related factors
Maternal related factor
Pregnancy-associated factors
Maternal comorbidity
Risk factor
Crudeǂ
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Table 3. Potential risk factors of pregnancy-induced hypertension for multiparous women, 
n=1901. 
Results from simple and multiple logistic regression analyses. Data are odds ratios (95% Confidence Interval)
ǂ Crude:unadjusted
†Adjusted: adjusted for PIH in a previous pregnancy
#Adjusted: adjusted for pre-eclampsia in a previous pregnancy 
^Adjusted for age>40, body mass>25, hypertensive disorders in family and PIH or pre-eclampsia in a previous pregnancy
*P<0.05. 
Risk factor
Crudeǂ Adjusted† Adjusted # Adjusted^
Maternal related factor
Age > 40years 0 0 0 0
BMI > 25kg/m2 3.15 (1.68-5.93)* 2.96 (1.48-5.93)* 3.52 (1.73-7.16)* 2.68 (1.32-5.42)*
European ethnicity 1.69 (0.90-3.19) 1.51 (0.75-3.02) 1.46 (0.73-2.92) 1.79 (0.86-3.71))
Surinamese ethnicity 0.24 (0.03-1.73) 0 0 0
High education 0.79 (0.42-1.48) 0.75 (0.38-1.49) 0.74 (0.37-1.50) 0.86 (0.41-1.79)
Previous pre-eclampsia 4.62 (1.34-15.9)* 0.84 (0.22-3.22) - 0.99 (0.19-5.11)
Previous pregnancy-
induced hypertension
10.0 (5.25-19.1)* - 9.43 (4.54-19.6)* 7.41 (3.24-17.0)*
Hypertensive disorder in 
pregnancy in history
9.55 (5.02-18.2)* - - 8.30 (4.16-16.5)*
Maternal comorbidity
Diabetes 0 0 0
Maternal birth weight 0.41 (0.06-3.02) 0.34 (0.05-2.57) 0.45 (0.06-3.36) 0.42 (0.05-3.22)
Family history
Hypertensive disorder in 
family
1.87 (0.95-3.66) 1.05 (0.50-2.19) 1.35 (0.66-2.78) 1.11 (0.56-2.20)
Diabetes in family 1.11 (0.51-2.44) 0.97 (0.41-2.27) 0.97 (0.40-2.36) 0.79 (0.32-1.99)
Twin pregnancy 2.15 (0.28-16.4) 3.27 (0.38-28.3) 2.87 (0.37-22.3) 3.45 (0.36-33.2)
Headache in first 
trimester
0.97 (0.50-1.89) 1.02 (0.50-2.06) 1.21 (0.59-2.45) 0.91 (0.45-1.86)
Paternal risk factors
Paternal hypertension 1.36 (0.18-10.4) 1.05 (0.12-8.92) 1.40 (0.17-11.2) 0.99 (0.11-8.70)
Diabetes 0 0 0 0
Arthralgia 0 0 0 0
Paternal birth weight 0 0 0 0
Hypertension family 0.87 (0.38-2.00) 0.98 (0.41-2.35) 1.17 (0.49-2.82) 1.03 (0.41-2.54)
BMI > 25kg/m2 1.51 (0.79-2.91) 1.47 (0.74-2.92) 1.25 (0.63-2.49) 1.14 (0.56-2.31)
Pregnancy-associated factors
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Table 4. Potential risk factors of pre-eclampsia for nulliparous women, n=2965. 
Results from simple and multiple logistic regression analyses. Data are odds ratios (95% Confidence Interval) 
ǂ Crude: unadjusted 
†Adjusted: adjusted for body mass index
#Adjusted: adjusted for body mass index and chronic hypertension 
^Adjusted for age>40, body mass>25, hypertensive disorders in family and chronic hypertension
*P<0.05. 
Risk factor
Crudeǂ Adjusted† Adjusted# Adjusted^
Maternal related factor
Age > 40 years 3.38 (0.77-14.8) 3.84 (0.86-17.1) 5.03 (1.09-23.3)* 4.27 (0.80-22.9)
BMI > 25kg/m2 2.84 (1.22-6.61)* - 2.57 (1.66-3.96)* 2.18 (1.40-3.41)*
European ethnicity 0.72 (0.48-1.09) 0.78 (0.51-1.17) 0.69 (0.45-1.06) 0.68 (0.44-1.06)
Surinamese ethnicity 2.21 (1.27-3.84)* 1.96 (1.12-3.43)* 1.94 (1.09-3.48)* 1.82 (0.97-3.40)*
High education 0.60 (0.39-0.92) 0.78 (0.51-1.18) 0.76 (0.50-1.17) 0.73 (0.47-1.15)
Maternal comorbidity
Diabetes 6.88 (1.44-32.8)* 5.21 (1.06-25.6)* 3.79 (0.66-21.7) 5.66 (1.01-31.9)*
Hypertension 13.9 (6.63-29.1)* 4.66 (1.80-12.0)* - 7.86 (3.35-18.4)*
Maternal birth weight 2.94 (1.69-5.11)* 3.01 (1.72-5.26)* 2.98 (1.67-5.31)* 2.61 (1.42-4.78)*
Family history
Hypertensive disorder 
in family
1.46 (0.91-2.33) 1.38 (0.86-2.21) 1.24 (0.76-2.02) 1.24 (0.79-1.93)
Diabetes in family 1.38 (0.77-2.44) 1.29 (0.76-2.20) 1.28 (0.73-2.24) 1.23 (0.70-2.18)
Twin pregnancy 5.13 (1.48-17.7)* 4.55 (1.29-16.0)* 5.13 (1.43-18.4)* 5.22 (1.46-18.7)*
Headache in first 
trimester
1.47 (0.96-2.25) 1.38 (0.90-2.11) 1.35 (0.87-2.10) 1.28 (0.81-2.03)
Paternal factors
Paternal hypertension 2.66 (0.93-7.62) 2.15 (0.75-6.15) 2.30 (0.79-6.71) 2.44 (0.81-7.41)
Diabetes 4.05 (0.51-32.2) 3.12 (0.38-25.3) 3.80 (0.46-31.1) 2.66 (0.25-28.0)
Arthralgia 4.97 (0.61-40.5) 3.57 (0.43-29.7) 4.43 (0.51-38.4) 6.69 (0.74-60.8)
Paternal birth weight 1.03 (0.24-4.35) 0.86 (0.20-3.64) 0.58 (0.08-4.34) 1.00 (0.23-4.38)
Hypertension family 1.15 (0.63-2.08) 1.08 (0.63-1.88) 1.15 (0.65-2.03) 1.11 (0.62-1.97)
BMI > 25kg/m2 0.79 (0.48-1.30) 0.72 (0.45-1.15) 0.72 (0.44-1.18) 0.75 (0.45-1.25)
Pregnancy-associated factors
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Table 5. Potential risk factors of pre-eclampsia (1.4%) for multiparous  
women, n=1880. 
Results from simple and multiple logistic regression analyses. Data are odds ratios (95% Confidence Interval).
ǂ Crude: unadjusted 
†Adjusted: adjusted for pre-eclampsia in a previous pregnancy
^Adjusted for age>40, body mass>25, hypertensive disorders in family and chronic hypertension and hypertensive disorder in previous pregnancy
*P<0.05. 
Risk factor
Crudeǂ Adjusted† Adjusted^
Maternal related factor
Age > 40years 2.37 (0.31-18.08) 4.55 (0.57-36.0) 3.43 (0.34-34.7)
BMI > 25kg/m2 2.67 (1.14-6.28)* 3.58 (1.24-10.3)* 2.74 (0.90-8.33)
European ethnicity 0.30 (0.11-0.77)* 0.25 (0.08-0.73)* 0.27 (0.09-0.85)*
Surinamese ethnicity 2.51 (0.84-7.57) 2.82 (0.88-9.00) 2.34 (0.62-8.77)
High education 0.23 (0.07-0.79)* 0.26 (0.07-0.93)* 0.28 (0.06-1.30)
Previous pre-eclampsia 11.6 (3.15-42.4)* 12.4 (3.31-46.0)* 0
Previous pregnancy-
induced hypertension
9.94 (3.64-27.2)* 10.1 *(3.31-30.6) 6.89 (1.97-24.1)*
Hypertensive disorder in 
pregnancy in history
12.2 (4.75-31.3)* - 7.51 (2.45-23.0)*
Maternal comorbidity
Diabetes 0 0 0
Hypertension 15.0 (4.00-55.9)* 9.54 (2.11-43.1)* 6.33 (1.31-30.5)*
Maternal birth weight 0.90 (0.11-6.88) 0.92 (0.12-7.13) 0.96 (0.12-7.87)
Family history
Hypertensive disorder in 
family
5.11 (1.10-23.7)* 4.18 (0.88-19.9) 1.49 (0.52-4.26)
Diabetes in family 2.22(0.76-6.56) 1.63(0.52-5.21) 1.78(0.58-5.44)
Twin pregnancy 4.03 (0.51-31.7) 8.20 (0.97-69.5) 7.01 (0.66-74.4)
Headache in first trimester 2.29 (0.96-5.98) 2.74 (1.02-7.33)* 1.54 (0.54-4.37)
Paternal related factors
Paternal hypertension 0 0
Diabetes 0 0
Arthralgia 32.1 (3.22-319)* 32.2 (3.18-325)* 10.0 (0.64-156)
Paternal birth weight 0 0
Hypertension family 0.26 (0.03-2.16) 0.30 (0.04-2.61) 0
BMI > 25 1.89 (0.57-6.31) 2.34 (0.60-9.19) 1.84 (0.40-8.41)
Pregnancy-associated factors
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Table 6. Potential risk factors for pre-eclampsia versus pregnancy-induced hypertension 
for nulliparous and multiparous.  
Results from simple logistic regression analyses. Data are odds ratios (95% Confidence Interval).
*P<0.05.
  
DISCUSSION 
An increased BMI was associated with development of pregnancy-induced hypertension 
and pre-eclampsia in nulliparous and multiparous women as described in tables 1-4. 
Maternal low birth weight was associated with an increased risk for pre-eclampsia in 
Nulliparous Multiparous 
Risk factor N=285 N=73
Maternal related factors
Age > 40years 3.70 (0.33-41.3) 0
BMI > 25kg/m2 0.98 (0.60-1.60) 0.90 (0.32-2.57)
European ethnicity 0.41 (0.24-0.71)* 0.20 (0.07-0.61)*
Surinamese ethnicity 2.17 (1.02-4.62)* 10.0 (1.05-95.7)*
High education 1.01 (0.61-1.67) 0.29 (0.07-1.14)
Previous pre-eclampsia - 2.50 (0.45-13.9)
Previous pregnancy-induced 
hypertension
- 1.14 (0.37-3.53)
Hypertensive disorder in 
pregnancy in history
- 1.28 (0.42-3.88)
Maternal comorbidity
Diabetes 0 0
Hypertension 2.20 (0.65-7.42)
Family history
Maternal birth weight 2.94 (1.32-6.50)* 2.06 (0.12-35.1)
Hypertensive disorder in family 0.77 (0.43-1.36) 2.74 (0.52-14.6)
Diabetes in familiy 0.93 (0.49-1.77) 1.82 (0.49-6.74)
Pregnancy-associated factors
Twin pregnancy 5.96 (0.61-58.3) 1.87 (0.11-32.0)
Headache in first trimester 1.65 (0.96-2.84)* 2.46 (0.80-7.54)
Paternal related factors
Paternal hypertension 2.46 (0.59-10.2) 0
Diabetes 0
Arthralgia 0 0
Paternal birth weight 0.62 (0.13-3.02)
Hypertension family 0.91 (0.48-1.74) 0.30 (0.03-2.87)
BMI > 25kg/m2 0.60 (0.35-1.04) 1.41 (0.37-5.39)
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nulliparous women. Previous hypertensive disorders were associated with pregnancy-
induced hypertension and pre-eclampsia in multiparous women. Headache in early 
pregnancy was associated with development of pre-eclampsia in multiparous women. 
Determination of risk factors for gestational hypertensive disorders is important to further 
unravel the pathophysiology and for risk selection to provide adequate antenatal care 
tailored to the individual. Modifiable risk factors known before conception include obesity 
and advanced maternal age. More healthy women before pregnancy will result in more 
healthy pregnancies and less maternal morbidity and mortality. 
 The findings of our study confirm the association between an increased BMI  and 
pregnancy-induced hypertension and pre-eclampsia14,15. With respect to the association of 
an increased BMI and pre-eclampsia, Athukorala et al. demonstrated an increased risk of 
pre-eclampsia amongst obese women defined by a BMI greater than 30kg/m2, but just a 
trend towards increasing risk in the overweight group versus a normal weight16. Another 
previous study described that an increased BMI is one of the strongest risk factors for pre-
eclampsia and Catov et al. described a linear association between an increasing BMI and 
pre-eclampsia117,18,19. The mechanisms explaining that an increased BMI predispose to 
pregnancy-induced hypertension and pre-eclampsia have not been well studied. An 
increased BMI is characterized by a systemic inflammatory response20. Several of the 
metabolic and inflammatory disorders that characterise an increased BMI have been 
documented in pregnant women21. An inflammatory response is amplified in obese 
individuals because of the pro-inflammatory output from adipose tissue and this may 
account for the increased susceptibility of obese pregnant women to fail the stress test of 
pregnancy, clinically manifested by pre-eclampsia. Other important mediators include 
oxidative stress, insulin resistance, reduced immune function, reduced endothelial 
dysfunction, other markers of dyslipidemia, or lifestyle factors such as poor prenatal diet 
and prenatal physical inactivity. Bodmar et al. described that pathways may also vary by 
ethnicity for development of pregnancy-induced hypertension or pre-eclampsia22. 
Maternal low birth weight associated with pre-eclampsia supports the hypothesis of 
fetal origin of an adult disease. There is evidence to link low birth weight with endothelial 
dysfunction in adults especially in hunger winter studies23. Low birth weight is associated 
with cardiovascular diseases in later life as well24. Maternal predisposition for 
cardiovascular disease might contribute to malplacentation and subsequent subclinical 
242 │ Chapter 2.1 
maternal endothelial dysfunction might predispose to the development of pre-eclampsia. 
With respect to pregnancy-induced hypertension, Rasmussen described in a population-
based study an association between maternal low birth weight and both pregnancy-induced 
hypertension or pre-eclampsia25. Wikstrom et al. showed an increased risk of developing 
cardiovascular disease after gestational hypertension26. The absolute risk for pregnancy-
induced hypertension (odds ratio 1.6 (95%CI 1.3-2.0)), however, was small compared to 
risks in women after severe gestational hypertensive disorders (odds ratio 2.8 (95%CI 2.3-
3.7)) or recurrent hypertensive disorders (odds ratio 2.8 (95%CI 2.0-3.9)). Secondly, 
maternal low birth weight and pre-eclampsia may share a genetic origin27, in view of the 
evidence of intergenerational recurrence and increased risk of recurrence in subsequent 
pregnancies of placental dysfunction related disorders25.
We demonstrated a strong association between previous gestational hypertension 
and pre-eclampsia, and the risk of pregnancy induced hypertension and pre-eclampsia in 
multiparous women up to a ten fold increased risk for pre-eclampsia. This supports the 
idea that the first pregnancy is a stress-test for later life: women who fail the test, i.e. 
develop hypertension during pregnancy are at increased risk for development of 
hypertensive diseases in a subsequent pregnancy and of cardiovascular events later in life
due to an unfavorable risk factor profile28,29.
European ethnicity was associated with an increased risk for pregnancy-induced 
hypertension in nulliparous women and a lower risk for pre-eclampsia in multiparous 
women. In addition,  Bouthoorn et al. demonstrated substantial differences in blood 
pressure levels and pregnancy hypertensive disorders in a multiethnic society30. These 
differenties could not be explained bij education or lifestyle. These results suggest different 
mechanisms in development of pregnancy-induced hypertension and pre-eclamspia. 
High education is suggested to reflect a protective effect for the development of pre-
eclampsia in multiparous women. Education has been the strongest and most consistent 
socioeconomic predictor of cardiovascular disease31. Because low socio-economic status is 
a marked risk factor for an increased BMI, metabolic syndrome, hypertension and 
cardiovascular disease32-34, socio-economic status is also likely to contribute to the 
prevalence of hypertensive disorders in pregnancy35,36.
Headache in early pregnancy appeared to be associated with pre-eclampsia in 
multiparous women. This association could not be explained by maternal age, migraine, 
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consuming of coffee or an increased BMI (results not shown). Migraine and pre-eclampsia 
may represent a common pathological link due to abnormal vascular reactivity, increased 
platelet agreeability, and high underlying cardiovascular risk profile37. A positive 
association between headaches and pregnancy-induced hypertension or pre-eclampsia was 
reported in 14 out of 16 studies38. Facchinetti et al. described in a prospective cohort study 
a three fold increased risk of gestational hypertensive disorders in case of migraine39.
The association of paternal arthralgia with pre-eclampsia might be coincidence. We 
only found two cases with men with arthralgia who fathered a pregnancy complicated by 
pre-eclampsia. However, others reported that men who had fathered a pre-eclamptic 
pregnancy in one woman had an increased risk of fathering a pre-eclamptic pregnancy in 
another woman40. Paternal genes could be passed to the fetus and increase the risk of pre-
eclampsia41,42. Both maternal and paternal contributions to fetal genes may have a role in 
defective placentation. Women with rheumatologic diseases are more likely to have pre-
eclampsia than women without rheumatologic disease (8.8% and 2.3% respectively)43.
Both nulliparous and multiparous women who develop pregnancy-induced 
hypertension partly share risk factors with women who develop pre-eclampsia. In women 
with an underlying predisposition such as chronic hypertension, an increased BMI, type II 
diabetes or metabolic syndrome a pregnancy may cause a maternal syndrome in a highly 
susceptible individual. The origins of the pre-eclampsia lie in events in very early 
pregnancy44. Ethnicity and maternal low birth weight may be a sign for such underlying 
predisposition44. This is in line with previous literature describing several phenotypes of 
pre-eclampsia as a result of different linking mechanisms between placental stage and the 
second stage of maternal systemic disease1. It is apparent that changes relevant to pre-
eclampsia can be detected in the first trimester, long before the failed vascular remodelling 
necessary to reduce placental perfusion is completed45. Furthermore, it is evident that 
linkage is not likely to be one factor but several, different for different women, resulting in 
several phenotypes of the disease. 
Methodological considerations 
The strength of the Generation R study is that it is a population-based cohort with a large 
number of women prospectively included. The study examines these women and their 
children from early pregnancy onwards. The diagnoses of gestational hypertensive 
disorders in the Generation R Study were verified. All women were living in a specific
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area, enabling to manually check all medical reports of women with hypertension disorders 
in pregnancy in systematic way12. However, a limitation of this study is that some data  
were collected using questionnaires. Although commonly used in epidemiological studies, 
self-reported information on complications in (previous) pregnancies, chronic diseases, 
disorders in the family and lifestyle determinants may have introduced some 
misclassifications11. However, some limitations should be addressed such as The 
Generation R‘ response rate of 61% implicating that selective participating may have 
influenced the observed associations46. There was some selection towards a relatively high 
educated, and healthier study population47. Secondly, even though we were able to control 
for a large number of potential confounders residual confounding is always reason of 
concern and should be taken into account. 
Conclusion 
Several easily accessible risk factors in early pregnancy for the development of subsequent 
pregnancy-induced hypertension or pre-eclampsia were identified. Some risk factors in 
early pregnancy seem to apply to both pregnancy-induced hypertension and pre-eclampsia 
whereas others differ between these two gestational complications, as well as  between 
nulliparous and multiparous women. This may point at differences in the pathophysiology 
of the two disorders. 
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ABSTRACT 
Objectives: To examine whether maternal socioeconomic status, as indicated by maternal 
educational level, is associated with pre-eclampsia, and if so, to what extent known risk 
factors for pre-eclampsia mediate the effect of educational level. 
Methods: In the Generation R Study, a population-based cohort study, we examined data 
of 3547 pregnant women. Odds ratios (OR) of pre-eclampsia for low, mid-low and mid-
high educational level compared to high educational level were calculated after adjustment 
for confounders and additional adjustment for a selection of potential mediators (family 
history, material factors, psychosocial factors, substance use, working conditions, pre-
existing medical conditions, maternal arthropometrics and blood pressure at enrollment) 
that individually caused more than 10% change in the OR for low education. 
Results: Adjusted for the confounding effects of age, gravidity and multiple pregnancy, 
women with low educational level were more likely to develop pre-eclampsia (OR 5.12; 
95% CI: 2.20,11.93) than women with high educational level. After additional adjustment 
for financial difficulties, smoking in pregnancy, working conditions, body mass index and 
blood pressure at enrollment, the OR 4.91; 95% CI: 1.93,12.52).  
Conclusions: Low maternal socioeconomic status is a strong risk factor for pre-eclampsia. 
Only a small part of this association can be explained by the mediating effects of 
established risk factors for pre-eclampsia. Further research is needed to disentangle the 
pathway from low socioeconomic status to pre-eclampsia. 
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INTRODUCTION 
Pre-eclampsia, marked by hypertension and proteinuria, is a leading cause of perinatal and 
maternal morbidity and mortality and complicates 5-7% of first pregnancies and 1-3% of 
all pregnancies 1-4. The exact pathogenesis is unknown, but it has been suggested that pre-
eclampsia may be an early adult manifestation of the metabolic syndrome5. This is based 
on observations that the metabolic abnormalities in pre-eclampsia resemble those in the 
metabolic syndome6 and that women with a history of pre-eclampsia have an increased risk 
for development of cardiovascular disease later in life7,8.
The known risk factors for pre-eclampsia are age above 35 years, nulliparity, 
history of pre-eclampsia in previous pregnancies, family history of pre-eclampsia, multiple 
pregnancy, pre-existing medical conditions such as diabetes, gestational diabetes, time 
between pregnancies, high body mass index and high blood pressure (BP) in early 
pregnancy9,10.  Psychosocial stressors and strenuous working conditions have also been 
associated with an increased risk for pre-eclampsia11,12. Surprisingly, smoking has been 
shown to reduce the risk for pre-eclampsia13; the underlying mechanism is unknown.  Low 
socioeconomic status is a marked risk factor for obesity, high BP, the metabolic syndrome 
and cardiovascular disease14-17, and may also be associated with an increased risk for pre-
eclampsia. However, only few studies of pre-eclampsia have evaluated its association with 
maternal socioeconomic status, and showed inconsistent results10, 18-23: some have found 
socioeconomic circumstances tob e negatively associated with pre-eclampsia18-20, others 
have found no association10, 21-23.
Within the framework of the Generation R Study, a large prenatally recruited birth 
cohort study with extensive assessments during pregnancy24, we examined the association 
between socioeconomic status and pre-eclampsia. We used maternal education as an 
indicator of socioeconomic status as it has been described as the most consistent 
socioeconomic predictor of cardiovascular disease risk factors25. The present study was 
restricted to an ethnic homogeneous population, as literature indicates that prevalence of 
pre-eclampsia and its risk factors26, as well as socioeconomic disparities in pre-eclampsia20
may differ by ethnic groups. 
We also evaluated whether a possible association can be explained by the 
mediating effect of known risk factors for pre-eclampsia, including family history of 
hypertensive complications in pregnancy, material factors, psychosocial factors, substance 
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use, working conditions, pre-existenting medical conditions, maternal anthropometrics and 
BP at enrollment. 
METHODS  
Design 
The present study was embedded in The Generation R Study, a population-based 
prospective cohort study from fetal life until young adulthood. The Generation R Study 
was designed to identify early environmental and genetic determinants of growth, 
development and health, and has been described previously in detail24-27. Briefly, the 
cohort includes 9778 mothers and their children (response rate 61%) of different ethnicities 
living in Rotterdam, the Netherlands27. Enrollment was aimed in early pregnancy, but was 
possible until birth of the child.  Assessments in pregnancy, including physical 
examinations, ultrasound assessments and questionnaires, were planned in early pregnancy 
(gestational age < 18 weeks), mid-pregnancy (gestational age 18-25 weeks) and late
pregnancy (gestational age  25 weeks). The study was conducted in accordance with the 
guidelines proposed in the World Medical Association Declaration of Helsinki and has 
been approved by the Medical Ethical Committee of the Erasmus MC, University Medical 
Centre Rotterdam. Written consent was obtained from all participants.
Study population  
All pregnant women who were resident in the study area at their delivery date from April 
2002 until January 2006 were invited to participate. Of the total of 9778 enrolled women, 
91% (n=8880) were enrolled in pregnancy27. Women with a Dutch ethnicity (n=1457, 
45.7%) comprised the largest ethnic subgroup and were selected for present analyses. A 
women was of Dutch ethnicity, when she reported that both her parents were born in the 
Netherlands28. Of the women who participated with more than one pregnancy in this study 
(8.3%), data on the second (n=332) or third pregnancy (n=5) were excluded from analyses 
to avoid clustering. We excluded women with missing information on their educational 
level (n=21), cases of induced abortions (n=14), fetal death before 20 weeks of gestation 
(n=7), women lost to follow-up (n=3), and women without information on of pre-
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eclampsia (n=72), gravidity (n=5), anthropometrics (n=17), or BP at enrollment (n=34), 
leaving 3547 women for analyses.  
Socioeconomic status 
The highest educational level achieved by mother was used as an indicator of maternal 
socioeconomic status. Maternal education was assessed by questionnaire at enrollment, 
according to the Dutch standard classification29, and was categorized into four educational 
levels: high (university or PhD degree), mid-high (higher vocational training), mid-low 
(more than 3 years general secondary school, intermediate vocational training or first year 
of higher vocational training), and low education (no education, primary school, lower 
vocational training or intermediate general school or 3 years or less general secondary 
school).  
Pre-eclampsia 
After each delivery, the present community midwife or obstetrician completed a delivery 
report. According to the Dutch standards of antenatal care, all women whose pregnancies 
are complicated by pre-eclampsia should deliver in a hospital under medical supervision of 
an obstetrician. The delivery reports of study participants who delivered under medical 
supervision were retrieved and screened by a trained medical record abstractor. Based on 
the documentation of any kind of hypertensive complications or fetal growth retardation on 
the delivery report, 398 women were suspected to have pre-eclampsia. To confirm 
presence of pre-eclampsia, the same abstractor conducted detailed reviews of hospital 
charts of these women. Pre-eclampsia was defined according to the criteria described by 
the International Society for the Study of Hypertension in Pregnancy (ISSHP): 
development of systolic BP at least 140 mmHg and/or diastolic BP at leat 90 mmHg after 
20 weeks of gestation in a previously normotensive woman and proteinuria (defined as two 
or more dipstick readings of 2+ or greater, one cathether sample reading of 1+ or greater, 
or a 24–hour urine collection containing at least 300 mg of protein)30. Neither women with 
eclampsia nor women with hemolysis, elevated liver enzyme and low platelet syndrome 
were defined as cases. 
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Potential confounders and mediators 
Information on all factors was collected during pregnancy. Categories are indicated in 
parentheses.  
Potential confounders  
The following risk factors were considered to potentially confound the effect of maternal 
education on pre-eclampsia. 
General characteristics. Maternal age was assessed at enrollment in one of the research 
centres and categorized into three groups (<30 years, 30-35 years, ≥35 years). Gravidity 
(primigravida, multigravida) was obtained by questionnaire. Presence of multiple  
pregnancy (singleton pregnancy, twin pregnancy) was determined by fetal ultrasound in 
early pregnancy. 
Potential mediators 
The known risk factors for pre-eclampsia may be in the pathway from socioeconomic 
status to pre-eclampsia were considered potential mediators. 
Family history. Information about history of gestational hypertension (no, yes, do not 
know) and pre-eclampsia (no, yes, do not know) in a first-degree relative was retrieved 
from questionnaire.
Material factors. Employment status (not employed, part-time employed, fulltime 
employed), and presence of financial difficulties in the preceding year (no, yes) were 
assessed by questionnaire. 
Psychosocial factors. Presence of long-lasting difficulties (score in tertiles) was measured 
by questionnaire with a 12 item-checklist covering financial problems, social deprivation,
neighbourhood problems and problems in relationships31. Maternal psychopathology was 
assessed by questionnaire using the Global Severity Index (score in tertiles) of the Brief 
Symptom Inventory32.
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Substance use. Smoking and alcohol consumption (never, before pregnancy, until 
pregnancy known, continued in pregnancy) were assessed by questionnaire.  
Working conditions during pregnancy.  Through the questionnaire in mid-pregnancy, 
participants were asked whether (yes, no) they had been exposed to the following working 
conditions in the preceding three months: prolonged sitting, prolonged working behind a 
monitor screen, these two were defined as sedentary working conditions, prolonged 
standing, prolonged walking, prolonged working in a warm environment, lifting or 
carrying loads of 5 kilograms or more, lifting or carrying loads of 25 kilograms or more, 
these were defined as physically demanding working conditions, and prolonged vehicle 
driving and nightshifts.  
Medical conditions at enrollment. Presence of pre-existent diabetes and raised cholesterol 
(no, yes, do not know) were assessed by questionnaire at enrollment. 
Anthropometrics at enrollment. Maternal anthropometrics were assessed in one of the 
research centres at enrollment. Height and weight were measured without shoes and heavy 
clothing. Body mass index (BMI) was calculated from height and weight (weight/height2)
and categorized into normal weight (<25 kg/m2), overweight (25-30 kg/m2), and obese 
(30 kg/m2) according to WHO standards. Systolic and diastolic blood pressure were 
measured using an Omron 907® Automated Blood Pressure Monitor (Omron Healthcare, 
Europe B.V. Hoofddorp, The Neteherlands). BMI and BP values were adjusted for 
gestational age at time of measurement.
Statistical analyses 
We assessed the frequency distributions of pre-eclampsia and risk factors for pre-
eclampsia according to educational level. To test the trend across educational level, chi-
square tests for trend were used for categorical factors and one-way analysis of variance 
for continuous factors.  
Multivariate logistic regression was used to calculate the odds ratios (OR) of pre-eclampsia 
and their 95% confidence intervals (CI) for levels of education, adjusted for the potential 
confounding effects of age, gravidity and multiple pregnancy, and additionally adjusted for 
potential mediators. The highest educational level was set as reference. Missing data on 
categorical factors were included in the analyses as a separate category. 
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The conceptual hierarchical framework 
To take into account the interrelations between maternal education and potential mediators, 
a conceptual hierarchical framework was developed35.  
(1) Hierachical levels of maternal education and potential mediators: 
(a) Hierarchical level 1: Maternal education 
(b) Hierarchical level 2: Family history of hypertensive disorders in pregnancy 
(c) Hierarchical level 3: Material and psychosocial factors 
(d) Hierarchical level 4a: Substance use and working conditions during pregnancy 
(e) Hierarchical level 4b: Medical conditions, anthrpometrics and bloed pressure 
at enrollment 
(2) Outcome: pre-eclampsia 
We hypothesized maternal education (as seen in listed above) to be the most distal factor 
that may directly or indirectly determine all proposed mediators. The next hierarchical 
level (hierarchical level 2) comprises family history, which is partly determined by 
socioeconomic status. Hierarchical level 3 included material and psychosocial factors, 
which are partly determined by maternal education. Hierarchical level 4 included 
substance use, working conditions during pregnancy, medical conditions,  anthropometrics 
and BP at enrollment, which are all partly determined by maternal education, psychosocial 
and material factors. As substance use and working conditions may affect BP36, 37,
hierarchical level 4 was divided into 2 sublevels: hierarchical level 4a (substance use and 
working conditions during pregnancy) and hierarchical level 4b (medical conditions and 
anthropometrics at enrollment). 
Hierarchical logistic models 
We started with  model 1, which represented the overall effect of maternal education. To 
evaluate the individual mediating effects of all potential mediators, these factors were 
added separately to model 1. For each adjustment, the percentage change in OR for the 
educational levels with an increased risk for pre-eclampsia was calculated (100x[ORmodel 1
- OR+mediator]/[ORmodel 1 – 1]). We defined factors that caused an attenuation of the OR as 
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mediator, and factors that caused an increase of the OR as suppressor in the association 
between maternal education and preeclampsia38.
Next, hierarchical logistic models were built. Starting with model 1, factors from the next 
hierarchical levels were added stepwise. Only those factors that individually produced at 
least 10 percent change39 in the OR for the educational level with the highest risk were 
included. Because BMI may affect pre-eclampsia risk through an increased BP40, BP was 
added to the logistic models in a separate step. 
All analyses were performed using Statistical Package of Social Sciences version 11.0 for 
Windows (SPSS Inc, Chicago, IL, USA).  
RESULTS  
Of the 3547 women in this study, mean age was 31.2 years (sd 4.6); 34.7% were younger 
than 30 years and 18.0% were 35 years or older. Of these women, 54.4% were 
primigravida. The median gestational age at enrollment was 13.8 weeks (90% range: 10.9 - 
21.9). The median gestational age at delivery was 40.1 weeks (90% range: 36.7 - 42.1); the 
newborns had a mean birth weight of 3471 grams (sd 563.4). 
Of all women, 17.6% were low educated and 31.5% were high educated (Table 1). Fifty-
one women (1.5%) developed pre-eclampsia; this percentage was 0.8%, 0.8%, 2.1% and 
2.9% for women with high, mid-high, mid-low and low education respectively (p for trend 
< 0.001, table 1).  
Age, employment status, family history of hypertension in pregnancy, alcohol 
consumption during pregnancy, sedentary working conditions, prolonged vehicle driving 
(p for trend < 0.001) and night shifts (p for trend < 0.05) were positively associated with 
level of education (see also table 1). Gravidity, family history of pre-eclampsia, financial 
difficulties, long lasting difficulties, psychopathology, smoking during pregnancy, 
physically demanding working conditions, BMI and BP (p for trend < 0.001) and pre-
existent diabetes (p for trend < 0.05), were negatively associated with the level of 
education (see also table 1). 
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Table 1 Distribution of pre-eclampsia and a selection of risk factors by maternal 
educational level (n = 3547)
Level of maternal education
Total
n=354
7
High
n=1118
(31.5%)
Mid-high
n=885
(25.0%)
Mid-low
n=918
(25.9%)
Low
n=626
(17.6%)
P
for 
trenda
Pre-eclampsia (%) 1.5 0.8 0.8 2.1 2.9 <0.001
General characteristics
Age
<30 years (%) 34.7 16.3 30.2 46.8 56.2
30-35 years (%) 47.3 61.6 49.8 38.9 30.7 <0.001
≥ 35 years (%) 18.0 22.1 20.0 14.3 13.1
Gravidity
Primigravidity 54.4 56.7 56.5 56.6 43.9 <0.001
Multiple pregnancy
Twin pregnancy 1.4 1.3 1.7 1.6 1.0 0.69
Material factors
Financial difficulties
Yes (%) 10.6 4.2 8.0 12.7 22.7 <0.001
Missing (%) 12.2 6.8 6.4 13.8 27.8
Substance use
Smoking
Never (%) 49.0 59.7 52.9 45.1 30.0
Before pregnancy (%) 19.4 20.2 21.1 19.1 15.8
Until pregnancy known (%) 8.1 7.5 9.1 9.0 6.4 <0.001
Continued in pregnancy (%) 17.1 5.2 10.3 20.7 42.5
Missing (%) 6.5 7.4 6.6 6.1 5.3
Working conditions
Prolonged sitting
Yes (%) 69.3 86.2 76.5 62.9 38.7 <0.001
Missing (%) 11.0 6.4 6.3 12.6 23.2
Prolonged working behind a monitor screen
Yes 60.6 82.0 62.9 53.5 29.4 <0.001
Missing (%) 11.1 6.6 6.6 12.6 23.0
Prolonged walking (%)
Yes (%) 41.1 30.1 44.3 47.1 47.4 <0.001
Missing (%) 11.0 6.7 6.1 12.5 23.2
Prolonged vehicle driving
Yes (%) 13.5 19.3 15.0 9.4 6.9 <0.001
Missing (%) 10.9 6.4 6.0 12.7 23.0
Anthropometrics and BP at enrollment
BMI b
Normal weight (%) 67.4 76.9 73.1 60.2 52.6
Overweight (%) 23.5 19.6 21.7 26.2 29.2 <0.001
Obese (%) 9.1 3.5 5.2 13.6 18.2
Systolic BP b in mmHg (mean, 
sd)
117.8 
(12.3)
116.1 
(11.3)
117.1 
(11.9)
119.6
(12.9)
119.4
(12.9) <0.001
Diastolic BP b in mmHg (mean, 
sd)
68.8 
(9.5)
68.0 
(8.7)
68.4
(9.3)
69.9
(10.0)
69.1
(10.3)
<0.001
BMI, body mass index; BP, blood pressure; SD, standard deviation. a P values are derived from x2 tests for trend across educational levels (categorical 
factors) and for (linear) trend component of one-way analysis of variance (continuous factors). b Values of body mass index, systolic and diastolic blood 
pressure at enrolment are adjusted for gestational age at enrolment. 
Compared to women with high education, women with low and mid-low education had an 
increased risk for pre-eclampsia after adjustment for age, gravidity and mutiple pregnancy 
(model 1, tables 2 and 3), with the highest risk in the lowest educational level (OR 5.12; 
95% CI: 2.20,11.93).  
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Table 3 Hierarchical logistic regression models fitted on pre-eclampsia (n=3547) 
Model 1 
OR (95% CI)
Model 2 
OR (95% CI)
Model 3 
OR (95% CI)
Model 4a 
OR (95% CI)
Model 4b 
OR (95% CI)
Maternal education
High (ref) 1.00 1.00 1.00 1.00 1.00
Mid-high 1.05 (0.39,2.84) 1.04 (0.38,2.81) 1.06 (0.39,2.89) 1.02 (0.37,2.80) 1.02 (0.37,2.80)
Mid-low 3.01 (1.34,6.81) 2.91 (1.28,6.60) 3.19 (1.39,2.89) 2.69 (1.15,6.27) 2.61,1.12,6.08)
Low 5.12 (2.20,11.93) 4.55 (1.90,10.89) 6.32 (2.53,15.74) 5.00 (1.97,12.68) 4.91 (1.93,12.52)
Material factors
Financial difficulties
No (ref) 1.00 1.00 1.00 1.00
Yes 1.26 (0.54,2.98) 1.58 (0.66,3.81) 1.46 (0.61,3.54) 1.52 (0.62,3.71)
Missing 1.60 (0.78,3.29) 1.60 (0.32,7.98) 1.40 (0.29,6.82) 1.37 (0.29,6.56)
Substance use
Smoking
Never (ref) 1.00 1.00 1.00
Before pregnancy 0.80 (0.37,1.72) 0.81 (0.38,1.76) 0.83 (0.38,1.81)
Until pregnancy known 1.37 (0.58,3.24) 1.44 (0.61,3.42) 1.60 (0.67,3.82)
Continued in pregnancy 0.37 (0.15,0.95) 0.40 (0.16,1.03) 0.45 (0.18,1.16)
Missing 1.21 (0.45,3.27) 1.26 (0.47,3.39) 1.26 (0.46,3.42)
Working conditions
Prolonged sitting
No (ref) 1.00 1.00 1.00
Yes 1.32 (0.46,3.78) 1.31 (0.45,3.82) 1.21 (0.41,3.58)
Missing* - - -
Prolonged working behind a monitor screen
No (ref) 1.00 1.00 1.00
Yes 2.13 (0.83,5.51 2.12 (0.81,5.53) 2.15 (0.81,5.70)
Missing* - - -
Prolonged walking
No (ref) 1.00 1.00 1.00
Yes 1.65 (0.87,3.13) 1.65 (0.87,3.12) 1.70 (0.90,3.23)
Missing* - - -
Prolonged vehicle driving
No (ref) 1.00 1.00 1.00
Yes     0.43 (0.13,1.43) 0.43 (0.13,1.42) 0.44 (0.13,1.44)
Missing*     - - -
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Table 3 continued 
Model 1 
OR (95% CI)
Model 2 
OR (95% CI)
Model 3 
OR (95% CI)
Model 4a 
OR (95% CI)
Model 4b 
OR (95% CI)
Anthropometrics and BP at enrollment
BMI     
Normal weight (ref)   1.00 1.00
Overweight     1.64 (0.86,3.12) 1.32 (0.68,2.58)
Obese     2.71 (1.29,5.68) 1.64 (0.72,3.74)
Systolic BP†     1.00 (0.97,1.02)
Diastolic BP†     1.05 (1.01,1.09)
BMI, body mass index; BP, blood pressure; CI, confidence interval; OR, odds ratio; ref, reference category.  
* Due to small or zero cells, results for these categories were invalid. As these effects were not of primary interest they are 
not presented.  
† Values of body mass index, systolic and diastolic blood pressure at enrolment are adjusted for gestational age at enrolment.  
Model 1: Maternal education, age, gravidity and multiple pregnancy.  
Model 2: Model 1 + financial difficulties.  
Model 3: Model 2 + smoking, prolonged sitting, prolonged working behind a monitor screen, prolonged walking, prolonged 
vehicle driving.  
Model 4a: Model 3 + body mass index at enrolment.  
Model 4b: Model 3 + body mass index, systolic and diastolic blood pressure at enrolment. 
Individual adjustment for financial difficulties, prolonged walking, prolonged 
vehicle driving, BMI, systolic and diastolic BP at enrollment attenuated the OR for low 
education by more than 10%, where as adjustment for smoking, prolonged sitting and 
prolonged working behind a monitor screen increased the OR for low education also by 
more than 10% (Table 2). These factors were included in the hierarchical logistic models. 
Financial difficulties, when added to model 1 (model 2, table 3), mediated 14% of the 
effect of low education (adjusted OR: 4.55; 95% CI:1.90,10.89). The addition of  smoking 
and the selected working conditions in model 3 resulted in an increase of the OR for low 
education (adjusted OR 6.32; 95% CI: 2.53,15.74), which was mostly due to the effect of 
smoking; women who continued smoking in pregnancy had a reduced risk for pre-
eclampsia (OR 0.37, 95% CI: 0.15, 0.95) compared to never smokers. 
In model 4a, BMI at enrollment was added, which mediated 25% of the effect of 
low education (adjusted OR: 5.00; 95% CI: 1.97,12.68). Adjusted for the other factors in 
this model, obesity was associated with an increased risk for pre-eclampsia (OR: 2.71; 
95% CI: 1.29,5.68). Additional adjustment for systolic and diastolic BP at enrollment in 
the final model (model 4b) resulted in further mediation, but not elimination, of the effect 
of low education (OR: 4.91; 95% CI: 1.93,12.52), and partial mediation of the effect of 
obesity. Diastolic BP at enrollment was significantly associated with pre-eclampsia risk in 
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this model (OR per mmHg increase: 1.05; 95% CI: 1.01,1.09). The effect of smoking was 
no longer significant due to additional adjustment for BMI and BP.
DISCUSSION  
The present study showed that low-educated pregnant women had a five-fold increased 
risk for pre-eclampsia compared with high-educated women. Although the effect of low 
education was in part mediated by financial difficulties, occupational exposure to 
prolonged walking, prolonged vehicle driving, and BMI and BP at enrollment, the 
association between education level and pre-eclampsia remained largely unexplained.  
Methodological considerations 
Present results were based on a population-based prospective cohort study in which a large 
number of women were enrolled early in pregnancy, and information on numerous 
potential confounders and mediaters was available. We used medical chart review and 
applied standard international criteria for a consistent pre-eclampsia definition.  
Socioeconomic status refers to the ‘social and economicfactors that influence what 
positions individuals or groups hold whitin the structure of society’42. It is a complex and
multifactor construct. The most frequently used indicators of socioeconomic status are 
educational level, income level and occupational class42,43. In this study, we used 
educational level as single indicator of maternal socioeconomic status. Education is an 
important determinant of employment and economic circumstances, and thus reflects 
material resources but also noneconomic social characteristics, such as general and health-
related knowledge which influences health behaviour, literacy, problem-solving skills and 
prestige43,44. It has been shown to be the strongest and most consistent socio economic 
predictor of cardiovascular disease risk factors25. Additionally, level of education as 
socioeconomic indicator can be applied to teenage and unemployed mothers, unlike for 
example occupational class. However, educational level does not entirely capture the 
material and financial aspects of socioeconomic status43,44.
Information on maternal education and many of the evaluated risk factors was derived 
from questionnaires, which may have induced some misclassification. Misclassification of 
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potential mediating risk factors may have contributed to the lack of explanation of the 
observed association between maternal education and pre-eclampsia. 
Comparison with other studies 
The incidence of pre-eclampsia in this cohort was 1.5%, which is lower than that reported 
in some other studies. A Danish birth cohort study1, for example, reported an incidence of 
3%. This may be due to regional differences in pre-eclampsia incidence, but may also be 
due to difference in case definition and data collection9. For our study, we conducted 
detailed analyses of hospital charts of all participants with suspected pre-eclampsia, with 
regard to the strict criteria of hypertension and proteinuria. In contrast, many studies were 
based on self-reported diagnoses of pre-eclampsia or hospital registries1. 
Our study supports others that found a comparable association between measures of 
socioeconomic status and pre-eclampsia18-20. Haelterman et al.18 found an OR of pre-
eclampsia of 2.3 (95% CI: 1.2,4.4) for women with primary education compared with 
women with education higher than primary school. The lower magnitude of effect 
compared with our results is probably due to the difference in the educational composition 
of the reference category. When we repeated our analyses, after categorizing maternal 
education into two levels similar to Haelterman et al.18, we found a comparable effect (OR: 
2.47, 95% CI: 0.86, 7.08). 
Our study challenged those studies10,21-23 that did not find an association between 
socioeconomic status and development of pre-eclampsia. This discrepancy may be 
attributable do differences in exposure definition or case definition. Lawlor et al.21 used 
occupation of the women’s partners as indicator of maternal socioeconomic status, which 
may influence risk for pre-eclampsia differently than maternal education. Parazzini et al.23
and Savitz and Zhang et al.22 not only included pre-eclampsia, but also pregnancy-induced 
hypertension without proteinuria in the outcome definition, leading to a more 
heterogeneous group.  
Mediating and suppressing mechanisms 
Part of the observed effect of low education on pre-eclampsia was mediated by higher rates 
of financial difficulties, occupational exposure to prolonged walking and obesity, higher 
BP levels at enrollment and lower rates of occupational exposure to prolonged vehicle 
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driving among low educated women. The effect of vehicle driving on pre-eclampsia has 
been poorly studied, but emotional stress, of which financial difficulties may be a source45
and occupational exposure to prolonged walking have been associated with an increased 
risk for pre-eclampsia12. Overactivation of the sympathetic nervous system may be 
involved in this association45,46.  However, the effects of these factors on pre-eclampsia 
were not statistically significant in our study, and further research is necessary to elucidate 
the underlying mechanism from low socioeconomic status through emotional and physical 
stress to pre-eclampsia. 
BMI at enrollement had the highest mediating effect. Obesity was a significant risk factor 
for pre-eclampsia, and in trun, more than half the effect of obesity was mediated through 
BP early in pregnancy. These findings are in line with current hypotheses on the 
underlying mechanism of how obesity leads to pre-eclampsia; it may act through raised 
triglyceride levels, increased systemic inflammation and increase in BP from early 
pregnancy9, 47. Even within the normal range of BP, the risk for pre-eclampsia is known to 
increase with increased BP in early pregnancy10.
In contrast, part of the effect of low education on pre-eclampsia was suppressed by lower 
rates of sedentary working conditions and higher rates of continued smoking in pregnancy 
among low-educated women. These factors partly masked the vulnerability of low-
educated women to develop pre-eclampsia. Although the increased risk for pre-eclampsia 
associated with sedentary working conditions was not significant in our study, our results 
were comparable with results of a recent study by Saftlas et al48. They suggest that women 
who spend a lot of their work time sitting have a higher risk for pre-eclampsia compared to 
women who spend less time sitting. Regular physical activity may reduce the risk for pre-
eclampsia. 
Smoking in pregnancy had the largest suppressing effect on the risk for pre-eclampsia in 
low-educated women. As described in previous studies13, we found continued smoking in 
pregnancy to be protective of pre-eclampsia. The underlying mechanism is unclear, but our 
findings suggest that the effect of smoking acts partly through changes in BP.  
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Conclusions and perspectives for future research 
We conclude that low socioeconomic status, as indicated by low level of education, is a 
strong risk factor for pre-eclampsia. Remarkably, this association remains largely 
unexplained, athough we included a wide range of known risk factors for pre-eclampsia in 
oru study. This implies that the established risk factors for pre-eclampsia included in this 
study do not fully capture the underlying pathway by which socioeconomic circumstances 
affect pre-eclampsia risk. Other potential determinants of pre-eclampsia that were not 
available for the current study, such as leisure time, physical activity, dietary factors, 
periodontal health, metabolic factors (e.g. cholesterol and fatty acid levels), parameters of 
endothelial function and factors related to vascular inflammation (e.g. C-reactive protein), 
currently unknown risk factors may also contribute to the explanation6,49-52.
As pre-eclampsia is considered an early adult predictor of cardiovascular disease, our 
findings extend the literature on socioeconomic inequalities in cardiovascular disease14 by 
demonstrating that low socioeconomic status is also associated with pre-eclampsia. The 
observed socioeconomic gap in pre-eclampsia may represent the emergence of 
socioeconomic inequalities in cardiovascular disease morbidity and mortality in women. 
Given the short and long-term adverse health consequences associated with pre-eclampsia, 
further research is needed to disentangle the pathway from low socioeconomic status to 
pre-eclampsia. Understanding this association may contribute to an earlier diagnosis and 
development of effective interventions and may reduce morbidity and mortality from this 
disease. 
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ABSTRACT 
We examined wheter maternal educational level as an indicator of socioeconomic status is 
associated with gestational hypertension. We also examined the extent to which the effect 
of education is mediated by maternal substance use (i.e., smoking, alcohol consumption 
and illegal drug use), pre-existing diabetes, anthropometrics (i.e., height and body mass 
index (BMI)), and blood pressure at enrollment.  
This was studied in 3262 Dutch pregnant women participating in the Generation R Study, 
a population-based cohort study. Level of maternal education was established by 
questionnaire at enrollment, and categorized into high, mid-high, mid-low and low. 
Diagnosis of gestational hypertension was retrieved from medical records using standard 
criteria. Odds ratios (OR) of gestational hypertension for educational levels were 
calculated, adjusted for potential confounders, and additionally adjusted for potential 
mediators.  
Adjusted for age and gravidity, women with mid-low (OR: 1.52; 95% CI: 1.02,2.27) 
andlow education (OR: 1.30; 95% CI: 0.80, 2,12) had a higher risk of gestational 
hypertension than women with high education . Additional adjustment for substance use, 
pre-existing diabetes, athropometrics and blood pressure at enrollement attenuated these 
ORs to 1.09 (95% CI: 0.70, 1.69) and 0.89 (95% CI: 0.50, 1.58) respectively. These 
attenuations were largely due to the effects of BMI and blood pressure at enrollment.  
Women with relatively low educational levels have a higher risk of gestational 
hypertension, which is largely due to higher BMI and blood pressure levels from early 
pregnancy. The higher risk of gestational hypertension in these women is probably caused 
by pre-existing hypertensive tendencies that manifested themselves during pregnancy.  
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INTRODUCTION 
Gestational hypertension is associated with perinatal morbidity, including preterm birth 
and foetal growth retardation1,2. It is characterized by de novo hypertension after the 
twentieth week of pregnancy without proteinuria, and complicates about 7–18% of first 
pregnancies and 4–9% of all pregnancies1–5. Although little is known about the 
pathophysiology of gestational hypertension, studies have shown that it is associated with 
features of the metabolic 
syndrome6 and with later development of essential hypertension and cardiovascular 
disease7,8. This suggests that these conditions may have similar pathological mechanisms. 
Known risk factors for gestational hypertension are high maternal age, twin pregnancy, 
pre-existing diabetes, obesity and high-normal blood pressure in early pregnancy2,9. In 
some studies, smoking during pregnancy has been associated with a lower risk of 
gestational hypertension10,11. Because low socioeconomic status is a marked risk factor for 
obesity, metabolic syndrome, hypertension and cardiovascular disease12–14, socioeconomic 
status is also likely to be associated with gestational hypertension. As early as the 1950s, 
researchers described associations between measures of socioeconomic status and 
hypertension during pregnancy15–19. However, most earlier studies focused primarily on 
pre-eclampsia, which is characterized by hypertension and proteinuria, and which is 
thought to have a different aetiology than gestational hypertension20. The results of these 
studies also conflict. For example, in 1955 Nelson studied maternal social class as 
measured by the husband’s occupation in relation to the incidence of pre-eclampsia, and 
found no association17. In contrast, Davies et al.15, and, more recently, Haelterman et al.16
found that, relative to women with a higher educational level, those with a low educational 
level had a higher risk of pre-eclampsia. We found only two studies that evaluated 
socioeconomic status in relation to isolated gestational hypertension18,19. Surprisingly, 
these found no associations, but this may have been due to the study design or to the 
chosen measures of socioeconomic status. For example, while these two studies used 
occupation of the woman’s partner18 and the woman’s area of residence19 as measures of 
socioeconomic status, such measures may not reflect all aspects of a pregnant woman’s 
individual socioeconomic circumstances. Given the adverse health consequences for the 
offspring of mothers with gestational hypertension, it is important for clinical practice and 
for public health policy to know whether socioeconomically disadvantaged women run a 
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higher risk of gestational hypertension20. Studying the association between socioeconomic 
status and gestational hypertension might also improve our insight into the causes of 
socioeconomic inequalities in women’s cardiovascular health. Working within the 
framework of the Generation R Study, a large birth-cohort study recruited prenatally21, we 
studied the association between maternal educational level as an indicator of maternal 
socioeconomic status and gestational hypertension. We also examined whether such an 
association can be explained by the mediating effects of substance use (that is smoking, 
alcohol consumption and illegal drug use), pre-existing diabetes, and maternal 
anthropometrics and blood pressure at enrolment. We used level of maternal education as 
it has been found to be the strongest and most consistent socioeconomic predictor of 
cardiovascular health22. As the literature indicates that socioeconomic disparities in 
hypertensive complications of pregnancy may differ between ethnic groups, the present 
study was restricted to an ethnically homogeneous population23. 
MATERIAL AND METHODS 
The Generation R Study  
The present study was embedded within the Generation R Study, a population-based 
prospective cohort study from foetal life until young adulthood. The Generation R Study 
has previously been described in detail21,24. Briefly, the cohort includes 
9778 (response rate 61%) mothers and children of various ethnicities living in Rotterdam, 
the Netherlands24. Although enrolment ideally took place in early pregnancy, it was 
possible until the birth of the child. All children were born between April 2002 and 
January 2006. Assessments during pregnancy included physical examinations, ultrasound 
assessments and questionnaires, and took place in early pregnancy (gestational age <18 
weeks), mid-pregnancy (gestational age 18–25 weeks) and late pregnancy (gestational age 
≥25 weeks). The study was conducted in accordance with the guidelines proposed in the 
World Medical Association Declaration of Helsinki, and has been approved by the Medical 
Ethical Committee at the Erasmus MC, University Medical Centre Rotterdam (Erasmus 
MC). Written consent was obtained from all participating parents. 
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Study population  
Of the 9778 women, 91% (n=8880) were enrolled during pregnancy24. Women of Dutch 
ethnicity (n=4057) comprised the largest ethnic subgroup, and were selected for the 
analyses described below. Awoman was classified as Dutch if she reported that both her 
parents had been born in the Netherlands25. Of the women who participated in this study 
with more than one pregnancy (8.3%), data on the second (n=332) or third pregnancy 
(n=5) were excluded from analyses to avoid clustering. Women who had been included 
after 25 weeks of gestation (n=77) were also excluded, because we were mainly interested 
in the effects of maternal anthropometrics and blood pressure early in pregnancy. To 
restrict the study to adult pregnant women, women younger than 20 years of age (n=63) 
were excluded. We also excluded twin pregnancies (n=51), cases of induced abortion, 
foetal deaths before 20 weeks of gestation and women lost to follow-up (n=23), and 
women lacking information on their educational level (n=20), diagnosis of gestational 
hypertension (n=65), gravidity (n=5), anthropometrics (n=17) or blood pressure at 
enrolment (n=29). Finally, as this study focused on de novo and isolated hypertension in 
pregnancy, we excluded women with pre-existing hypertension and those who developed 
pre-eclampsia, eclampsia or haemolysis, elevated liver enzyme and low platelet syndrome 
(n=108). This left 3262 women for analysis. 
Educational level  
On the basis of a questionnaire used at enrolment, we established the highest education 
achieved by each mother. This was categorized into four levels: (1) high (university 
degree), (2) mid-high (higher vocational training), (3) mid-low (more than 3 years general 
secondary school, intermediate vocational training or first year of higher vocational 
training) and (4) low (no education, primary school, lower vocational training, 
intermediate general school or 3 years or less at general secondary school) 26.
Gestational hypertension  
After each participant had given birth, the attending community midwife or obstetrician 
completed a delivery report. The reports on those participants who had given birth under 
the medical supervision of an obstetrician were selected and screened by a trained medical-
record abstractor. On the basis of documentation on the delivery report of any kind of 
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hypertensive complication or foetal growth retardation, 398 women were suspected of 
having gestational hypertension. To confirm the presence of gestational hypertension, the 
same abstractor conducted detailed reviews of these women’s hospital charts. Gestational 
hypertension was defined according to the criteria described by the International Society 
for the Study of Hypertension in Pregnancy27: development of systolic blood pressure 
≥140mmHg and/or diastolic blood pressure ≥90mmHg without proteinuria after 20 weeks 
of gestation in previous normotensive women. 
Potential mediators and confounders  
Level of maternal education cannot directly affect the risk of gestational hypertension, but 
is likely to act through more proximal risk factors, so-called mediators28. We considered 
the following factors to be potential mediators in the pathway between maternal education 
and gestational hypertension: factors involving substance use, that is smoking, alcohol 
consumption and illegal drug use; preexisting diabetes; maternal anthropometrics and 
blood pressure at enrolment (Figure 1). Categories are indicated below in parentheses. 
Substance use 
Smoking, alcohol consumption and illegal drug use, including marijuana, hashish, cocaine, 
heroin and ecstasy (never, before conception, until pregnancy was known, continued in 
pregnancy) were established using questionnaires in early, mid and late pregnancy. 
Pre-existing diabetes 
Presence of pre-existing diabetes (no, yes, unknown) was established by questionnaire at 
enrolment. Because we could not assume that women who answered ‘no’ to this question 
had actually been tested for diabetes, we recoded ‘no’ into ‘unknown’.
Anthropometrics and blood pressure at enrolment 
Maternal anthropometrics and blood pressure were measured at enrolment in one of the 
research centres. Height and weight were measured without shoes and heavy clothing, and 
body mass index (BMI) was calculated from height and weight (weight/height2). BMI was 
categorized according to WHO standards into normal weight (<25kgm2), overweight (25–
30kg/m2) and obese (≥30kg/m2). Systolic and diastolic blood pressure were measured 
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using an Omron 907 Automated Blood Pressure Monitor (OMRON Healthcare Europe 
BV, Hoofddorp, the Netherlands) 29. Gestational age at enrolment varied from 5.1 to 24.9 
weeks, and was correlated with level of education. We therefore adjusted BMI and blood 
pressure values for gestational age at time of measurement. First, we performed a separate 
linear regression analysis with gestational age at time of enrolment as predictor and 
BMI/blood pressure as outcome. Next, per woman, we added the difference between the 
fitted BMI/blood pressure value at the individual’s gestational age at enrolment and the 
actual BMI/blood pressure observation to the fitted value at the population median 
gestational age at enrolment (14 weeks). All models were adjusted for age and gravidity, 
treating them as potential confounders, because the effects of these factors in the 
association between maternal education and gestational hypertension were not of primary 
interest in this study, and as they cannot be considered indisputable mediators (Figure 1). 
Maternal age was assessed at enrolment in one of the research centres and categorized into 
four groups (20–25, 25–30, 30–35 and ≥35 years). Gravidity (first pregnancy, ≥second 
pregnancy) was obtained through questionnaires at enrolment in the study. 
Statistical analyses  
We assessed the frequency distribution of potential confounders and mediators according 
to educational level. Chi-squared tests for trend were used for categorical factors, and 
Spearman’s correlation coefficients were used for continuous factors. Multivariate logistic 
regression was used to calculate the odds ratios (OR) of gestational hypertension and their 
95% confidence intervals (CI) for levels of education after adjustment for the potential 
confounders (model 1), and after additional adjustment for potential mediators. The 
highest educational level was set as reference. Missing data on categorical factors were 
included as separate categories. First, to evaluate the individual mediating effects of all 
potential mediators, these factors were added separately to model 1. For each adjustment, 
we calculated the percentage change in OR for the educational levels with a higher risk of 
gestational hypertension compared to the reference (100x{(ORmodel1 - OR+mediator) }/{ 
(ORmodel - 1}). When the OR attenuated to lower than 1, the change was set at 100%. 
Factors that caused an attenuation of the OR were defined as mediators in the association 
between maternal education and gestational hypertension30. In the subsequent analyses, 
hierarchical logistic models31 were built for two reasons: (1) to evaluate the mediating 
effects of substance use, pre-existing diabetes, anthropometrics and blood pressure at 
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enrolment in the association between maternal education and gestational hypertension and 
(2) their own effects on gestational hypertension, taking due account of the conceptual 
hierarchical relationships between these factors. We hypothesized that, as an indicator of 
socioeconomic status, maternal education was the factor most distal to gestational 
hypertension that might influence risk of gestational hypertension through substance use, 
pre-existing diabetes, anthropometrics and blood pressure at enrolment. In turn, substance 
use might influence gestational hypertension risk directly, or indirectly through diabetes32
or changes in anthropometrics33. Finally, we hypothesized that pre-existing diabetes, height 
and BMI at enrolment might influence gestational hypertension risk directly, or indirectly 
through blood pressure changes.9 For the logistic hierarchical models, we started with 
model 1, then added smoking, alcohol consumption and illegal drug use (model 2). To this 
model, we then added pre-existent diabetes, height and BMI at enrolment (model 3). In the 
final model (model 4), additional adjustment was made for systolic and diastolic blood 
pressure at enrolment. All analyses were performed using the Statistical Package of Social 
Sciences version 11.0 for Windows (SPSS Inc., Chicago, IL, USA). 
RESULTS 
Of the 3262 women in the study, mean age was 31.3 years (s.d. 4.3), 8.9% were between 
20 and 25 years old, 17.6% were 35 years or older and 53.6% were primigravida. The 
median gestational age at enrolment was 13.6 weeks (90% range: 10.9, 21.2). Participants 
gave birth at a median gestational age of 40.3 weeks (90% range: 37.1, 42.1); their children 
had a mean birth weight of 3492g (s.d. 547.9). 
Of all women, 16.3% had a low educational level and 32.6% had a high 
educational level (Table 1). Gestational hypertension developed in 180 women (5.5%); the 
respective percentages for women with high, mid-high, mid-low and low education were 
5.1, 4.4, 7.2 and 5.6% (w2: 6.77; degrees of freedom: 3; P-value: 0.08).  
Age, alcohol consumption in pregnancy and height were positively associated with 
level of education (P for trend <0.001). Gravidity, smoking and illegal drug use during 
pregnancy, BMI, systolic and diastolic blood pressure at enrolment were negatively 
associated with level of education (P for trend <0.05). Women with a mid-low educational 
level had the highest systolic and diastolic blood pressure values at enrolment (Table 1).
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Table 1 Distribution of general characteristics, substance use, pre-existing diabetes, 
anthropometrics and blood pressure at enrollment in the total study population and by 
educational level 
Level of maternal education
Total
n=3262
High 
n=1063 
(32.6%)
Mid-high 
n=843 
(25.8%)
Mid-low 
n=823 
(25.2%)
Low n=533 
(16.3%) P for trend*
General characteristics
Age, in years mean (s.d.) 31.3 (4.3) 32.9 (3.2) 31.9 (3.8) 30.0 (4.5) 29.2 (5.0) <0.001
Age, categorical
20–25 years (%) 8.9 0.1 3.3 15.9 24.2
25–30 years (%) 25.1 16.2 27.5 31.2 29.6 <0.001
30–35 years (%) 48.4 62.1 49.3 39.9 33.2
≥35 years (%) 17.6 21.6 19.9 13.0 13.0
Gravidity
53.6 56.4 56.1 55.3 41.3 <0.001
First pregnancy (%)
Parity
64.6 64.9 67.9 67.1 55.0 0.004
Nulliparous (%)
Substance use
Smoking
Never (%) 49.4 59.7 52.9 45.8 29.1
Before conception (%) 19.4 20.1 21.1 19.1 15.8
Until pregnancy was known 
(%) 8.3 7.7 8.9 9.5 6.5 <0.001
Continued in pregnancy (%) 16.4 5.1 10.3 19.9 43.3
Missing (%) 6.5 7.4 6.8 5.7 5.3
Alcohol consumption
Never (%) 13.1 3.4 9.9 17.8 30.0
Before conception (%) 19.0 13.9 15.9 23.6 27.0
Until pregnancy was known 
(%) 15.2 13.0 16.1 17.9 14.1 <0.001
Continued in pregnancy (%) 49.4 67.3 54.8 36.2 25.7
Missing (%) 3.3 2.4 3.3 4.5 3.2
Illegal drug use
Never (%) 86.7 90.5 86.7 85.0 81.8
Before conception (%) 4.4 1.8 5.0 5.8 6.7
Until pregnancy was known 
(%) 2.1 0.6 1.8 1.7 6.2 <0.001
Continued in pregnancy (%) 0.8 0.1 0.3 1.3 1.9
Missing (%) 6.0 7.0 6.2 6.2 3.4
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Table 1 Continued 
Total
n=3262
High 
n=1063 
(32.6%)
Mid-high 
n=843 
(25.8%)
Mid-low 
n=823 
(25.2%)
Low n=533 
(16.3%) P for trend*
Pre-existing diabetes
Unknown (%) 92.4 91.6 92.1 92.4 94.7
Yes (%) 0.2 0.1 0 0.4 0.4 0.097
Missing (%) 7.4 8.3 7.9 7.2 4.9
Anthropometrics and BP at enrolment
Height, in cm mean (s.d.) 170.7 (6.4) 171.4 (6.0) 171.3 (6.3) 170.6 (6.5) 168.9 (6.7) <0.001
BMI†, in kgm~2 mean (s.d.) 24.2 (4.0) 23.3 (3.1) 23.5 (3.3) 24.9 (4.5) 25.7 (5.0) <0.001
BMI†, categorical
Normal weight (%) 68.2 77.6 73.8 60.8 52.4
Overweight (%) 23.3 18.8 21.9 26.1 29.8 <0.001
Obese (%) 8.5 3.6 4.3 13.1 17.8
SBP†, in mmHg mean (s.d.) 117.4 (11.9) 116.0 (11.2) 116.3 (9.1) 119.1 (12.5) 118.6 (12.3) <0.001
DBP†, in mmHg mean (s.d.) 68.5 (9.2) 68.0 (8.6) 68.3 (9.1) 69.4 (9.8) 68.5 (9.5) 0.017
Abbreviations: BMI, body mass index; BP, blood pressure; DBP, diastolic blood pressure; SBP, systolic blood pressure.  
*P-values are for w2-test for trend (categorical factors) or Spearman’s correlation coefficient (continuous factors).  
†Values of BMI and SBP and DBP at enrolment are adjusted for gestational age at enrolment. 
Compared with women with high education, those with a mid-low and low education had a 
higher risk of gestational hypertension after adjustment for age and gravidity; those with a 
mid-low education had the highest risk (OR: 1.52; 95% CI: 1.02, 2.27; model 1; Tables 2 
and 3). The OR for women with a low educational level did not reach statistical 
significance (OR: 1.30; 95% CI: 0.80, 2.12).  
Individual adjustment for each potential mediator resulted in +2 to -71% changes 
in the OR for midlow education and +10 to1-100% change in the OR for low education 
(Table 2). The largest attenuations were caused by BMI, systolic and diastolic blood 
pressure at enrolment.  
Table 3 presents the hierarchical logistic models fitted on gestational hypertension. 
Part of the effect of a mid-low and low educational level on gestational hypertension was 
mediated by substance use. When added to model 1, substance use, in particular alcohol 
consumption, attenuated the ORs by 21 and 63% to 1.39 (95% CI: 0.92, 2.11) and 1.11 
(95% CI: 0.64, 1.92), respectively (model 2). Although alcohol consumption tended to 
reduce the risk of gestational hypertension in this model, this effect was not significant. In 
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contrast, smoking before conception was associated with a higher risk of gestational 
hypertension than never smoking was (OR: 1.68; 95% CI: 1.14, 2.46).  
Pre-existing diabetes, height and BMI at enrolment further mediated more than 
half the effect of mid-low education (OR: 1.12; 95% CI: 0.73, 1.71; model 3) and all of the 
remaining effect of low education (OR: 0.83; 95%: 0.48, 1.44). This mediation was due 
mainly to BMI at enrolment. After adjustment for the other factors in model 3, overweight 
(OR: 2.43; 95% CI: 1.70, 3.46) and obesity (OR: 5.15; 95% CI: 3.34, 7.95) were 
significant risk factors for gestational hypertension. Systolic and diastolic blood pressure at 
enrolment, when added in model 4, further mediated the effect of mid-low education with 
25% (in relation to model 3) to an OR of 1.09 (95% CI: 0.70, 1.69). This final OR for mid-
low education corresponded with a total attenuation of 83% relative to model 1.  
Additionally, blood pressure mediated half the effect of overweight (OR: 1.70; 
95% CI: 1.17, 2.45) and 72% of the effect of obesity (OR: 2.13; 95% CI: 1.31, 3.47) on 
gestational hypertension risk. Adjusted for all other factors in model 4, the risk of 
gestational hypertension increased with increasing systolic (OR per mmHg increase: 1.02; 
95% CI: 1.00, 1.04) and diastolic blood pressure (OR per mmHg increase: 1.07; 95% CI: 
1.04, 1.09). The effect of smoking hardly changed after adjustment for BMI and blood 
pressure at enrolment. 
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Table 3 Hierarchical logistic regression models fitted on gestational hypertension 
Model 1
OR (95% CI)
Model 2 
OR (95% CI)
Model 3 
OR (95% CI)
Model 3 
OR (95% CI)
Maternal education
High (reference) 1.00 1.00 1.00 1.00
Mid-high 0.87 (0.56,1.34) 0.83 (0.54,1.29) 0.81 (0.52,1.25) 0.79 (0.50,1.24)
Mid-low 1.52 (1.02,2.27) 1.39 (0.92,2.11) 1.12 (0.73,1.71) 1.09 (0.70,1.69)
Low 1.30 (0.80,2.12) 1.11 (0.64,1.92) 0.83 (0.48,1.44) 0.89 (0.50,1.58)
Substance use
Smoking
Never (reference) 1.00 1.00 1.00
Before conception 1.68 (1.14,2.46) 1.63 (1.10,2.40) 1.70(1.14,2.53
Unti l pregnancy was known 1.20 (0.67,2.16) 1.20 (0.66,2.16) 1.41 (0.77,2.58)
Continued in pregnancy 1.28 (0.79,2.09) 1.21 (0.74,1.97) 1.35 (0.81,2.24)
Missing 1.41 (0.48,4.11) 1.53 (0.48,4.85) 1.58 (0.46,5.48)
Alcohol consumption
Never (reference) 1.00 1.00 1.00
Before conception 0.89 (0.53,1.49) 1.01 (0.59,1.70) 1.02 (0.601.76)
Unti l pregnancy was known 0.85 (0.49,1.48) 1.00 (0.56,1.76) 1.07 (0.501.91)
Continued in pregnancy 0.68 (0.41,1.13) 0.86 (0.52,1.45) 0.97 (0.57,1.64)
Missing 0.50 (0.15,1.70) 0.59 (0.17,2.08) 0.71 (0.202.54)
Illegal drug use
Never (reference) 1.00 1.00 1.00
Before conception 1.11 (0.56,2.20) 1.36 (0.68,2.72) 1.39 (0.68,2.81)
Unti l pregnancy was known 0.48 (0.11,2.01) 0.59 (0.14,2.52) 0.67 (0.16,2.91)
Continued in pregnancy 0.66 (0.09,5.06) 0.59 (0.07,4.68) 0.68 (0.08,5.47)
Missing 1.13 (0.37,3.47) 1.45 (0.39,5.43) 1.54 (0.37,6.35)
Pre-existing diabetes
Unknown (reference) 1.00 1.00
Yes 1.49 (0.16,14.13) 1.27 (0.13,12.67)
Missing 0.69 (0.20, 2.34) 0.60 (0.17,2.19)
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Table 3 Continued 
Model 1
OR (95% CI)
Model 2 
OR (95% CI)
Model 3 
OR (95% CI)
Model 3 
OR (95% CI)
Anthropometrics and BP at enrolment
Height 1.01 (0.99,1.04) 1.00 (0.98,1.03)
BMI
Normal weight (reference) 1.00 1.00
Overweight 2.43 (1.70,3.46) 1.70 (1.17,2.45)
Obese 5.15 (3.34,7.95) 2.13 (1.31,3.47)
SBP 1.02 (1.00,1.04)
DBP 1.07 (1.04,1.09)
Abbreviations: BMI, body mass index; CI, confidence interval; DBP, diastolic blood pressure; SBP, systolic blood pressure. 
Model 1: Adjusted for age and gravidity 
Model 2: Model 1 + smoking, alcohol consumption and illegal drug use 
Model 3: Model 2 + pre-existing diabetes, height and BMI at enrolment 
Model 4: Model 3 + SBP and DBP at enrolment (full mode) 
DISCUSSION 
This study showed that women with relatively low levels of education had a higher risk of 
gestational hypertension than women with a high level. This higher risk was explained by 
unequal distributions of known risk factors for gestational hypertension across educational 
levels, particularly by the higher rates of overweight and obesity and the relatively high 
blood pressure levels at enrolment found in lower educated women. 
Methodological considerations  
The main strength of this study lies in its population-based prospective design, in which a 
large number of women were enrolled early in pregnancy. The detailed information 
available on known risk factors for gestational hypertension enabled us to explain much of 
the association we observed between maternal education and gestational hypertension. 
Furthermore, the use of a conceptual hierarchical framework afforded insight into the 
interrelationships between maternal education and mediators, and their combined effects 
on gestational hypertension. An additional strength was the use of medical chart review 
and applied standard international criteria for a consistent definition of gestational 
hypertension. Although other measures of socioeconomic status exist, such as income level 
and occupational class34; for our study we selected maternal educational level as a main 
indicator of socioeconomic status. We did this for two reasons: (1) not only does 
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educational level partly reflect material resources because it structures occupation and 
income, it also reflects non-economic social characteristics, such as general and health-
related knowledge, literacy, problemsolving skills and prestige35,36 and (2) educational 
level has also been shown to be the strongest and most consistent socioeconomic predictor 
of cardiovascular health22. To various extents, our results may have been influenced by the 
following limitations. First, the response rate among pregnant Dutch women in the 
Generation R Study was relatively high (68%)37, but there was some selection towards a 
relatively high educated and healthier study population24. Second, review of delivery 
reports and hospital charts was restricted to women who had been referred for delivery 
under medical care. However, in Dutch practice, community midwives often remain 
responsible for the care of women with a diastolic blood pressure between 90 and 
100mmHg, provided that proteinuria does not develop. In the event of a diastolic blood 
pressure between 95 and 100mmHg, they are required to consult an obstetrician. All 
women with gestational hypertension with a diastolic blood pressure over 100mmHg 
should receive antenatal care and give birth in the hospital under the supervision of an 
obstetrician. Our study may therefore have missed mild cases of gestational hypertension 
with a diastolic blood pressure up to 100mmHg. Third, in all logistic models, we adjusted 
for gravidity, to take account of the protective effect of a previous pregnancy, including 
those that ended in spontaneous abortions. Although a woman’s risk of gestational 
hypertension is highest during her first pregnancy, the literature indicates that a change of 
partner between pregnancies may cause the risk to revert towards the same level as a 
primigravida38. Unfortunately, in this study we had no information on change of partners 
between pregnancies. Finally, our study may have been vulnerable to misclassification, 
particularly with regard to substance-use factors, which were measured using 
questionnaires. Similarly, in accordance with the Dutch Standard Classification25, we 
assigned a Dutch ethnicity to a participant if both her parents had been born in the 
Netherlands. However, when identifying immigrant descent in Dutch residents, this 
classification goes no further than the second generation. The number of third-generation 
immigrants is nonetheless likely to have been very small and not to have affected our 
conclusions. 
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Comparison with other studies  
Socioeconomic differences in blood pressure and prevalence of hypertension have been 
consistently reported among the general, adult population14,39. 
According to a review by Colhoun et al.39 most studies performed in developed countries 
associate indicators of low socioeconomic status with higher blood pressures; these 
associations are stronger in women than in men, and are largely explained by 
socioeconomic differences in BMI.  
Hypertension during pregnancy, particularly pre-eclampsia, has also been 
associated with level of education as a measure of socioeconomic status15,16. However, two 
studies that evaluated the association between indicators of socioeconomic status and 
isolated gestational hypertension18,19 did not find an association. Although this contrasts 
with our own findings, the discrepancy in both cases is probably due to differences in 
study design or in exposure definition. One study18 depended on retrospective data and had 
to deal with a large amount of missing data. The same study also primarily used 
occupation of the women’s partners as an indicator of maternal socioeconomic status - 
which, because it reflects other aspects of socioeconomic status, may therefore influence 
risk of gestational hypertension differently than maternal education does. The second 
study19 examined an area-based measure of socioeconomic status in relation to occurrence 
of gestational hypertension. However, an area-based measure of socioeconomic status is 
unlikely to fully capture health risks that are associated with socioeconomic status at an 
individual level. 
Educational level and risk of gestational hypertension  
Relative to women with a high educational level, those with a low educational level and 
those with a mid-low educational level had, respectively, a 30 and 52% higher risk of 
gestational hypertension. The finding that the highest risk was not found in women with 
the lowest educational level somewhat weakens the evidence for a firm conclusion that 
maternal education level is negatively associated with gestational hypertension risk. 
However, this finding was probably attributed to chance; women with low education 
comprised the smallest subgroup, and the difference in gestational hypertension incidence 
between mid-low and low-educated women was not statistically significant (7.2 versus 
5.6%; chi-squared: 1.25; degrees of freedom: 1; P-value: 0.263).  
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Another hypothetical explanation for this finding is that women with a low 
education received better medical care, due for example to their coverage under social 
medicine schemes. However, this is unlikely: in the Netherlands, obligatory health 
insurance ensures equal primary prenatal care for everyone.  
Referral bias is a third possible explanation. As previously discussed, mild cases of 
gestational hypertension were not necessarily referred to an obstetrician. If women with a 
low education with gestational hypertension were more likely to remain under a midwife’s 
care, these cases may have been selectively missed in our study.  
The last possible explanation is the selection bias that would have resulted if low-
educated women who did not participate in this study had a higher risk of gestational 
hypertension than low-educated women who did participate. However, among the 
participants we found a clear linear trend across educational levels in a variety of other 
factors, such as smoking, alcohol consumption and BMI. This makes selection bias less 
likely. 
Mediating mechanisms  
Most of the higher risk of gestational hypertension in women with mid-low and low 
education was mediated by relatively high rates of overweight and obesity at enrolment in 
these subgroups. Although obesity is an important risk factor for gestational 
hypertension, the underlying biological mechanism is not completely clear. A recent study 
suggested that obesity mostly increases the risk of gestational hypertension through higher 
blood pressure levels9. Our results indeed suggest that at least half the effect of overweight 
and obesity acts through relative increases in blood pressure early in pregnancy. In women 
with a mid-low education, relatively high blood pressure levels at enrolment further 
contributed independently of BMI to the explanation of their increased risk of developing 
gestational hypertension.  
Blood pressure in early pregnancy has been shown to be positively associated with 
the risk of gestational hypertension, even when it is within the normal range9. Normal 
pregnancy is characterized by haemodynamic changes, which cause a steady decrease in 
blood pressure in the first half of pregnancy, followed by a rise in blood pressure in the 
second half until delivery40. It is plausible that the higher the blood pressure is at the start 
of pregnancy, the higher the blood pressure will be when haemodynamic demands increase 
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in the second half of pregnancy, and the sooner blood pressure will cross the threshold 
level of hypertension.  
The higher risk of gestational hypertension in women with mid-low and low 
education was explained to a lesser extent by lower rates of alcohol consumption before 
and during pregnancy. This was due to a trend shown in our data towards a protective 
effect on gestational hypertension of alcohol consumption, which seemed to act through 
changes in BMI and blood pressure. Moderate alcohol consumption is known to lower 
blood pressure and to reduce the risk of development of essential hypertension in the non-
pregnant population41. It is unknown whether moderate alcohol consumption during 
pregnancy has a similar effect on gestational hypertension.  
Maternal smoking and illegal drug use did not contribute an explanation of the 
effects of a mid-low and low educational level. Remarkably, we observed that smoking 
before conception and during pregnancy tended to increase the risk of gestational 
hypertension, significantly so for smoking before conception. This is in contrast with many 
other studies which reported that women who smoke during pregnancy have a lower risk 
of gestational hypertension than women who have never smoked11. However, with regard 
to the effect of smoking before conception, studies have shown conflicting results. Zhang 
et al.42 found that past smoking was associated with a lower risk of gestational 
hypertension, whereas a more recent study by England et al.10 showed that women who 
smoked before pregnancy did not have a lower risk.  
In non-pregnant women, cessation of smoking has been associated with a higher 
risk of hypertension than continued smoking or never smoking,43 a finding that appears to 
support our results. Further study is needed to confirm a similar association between 
cessation of smoking and gestational hypertension. 
Implications and conclusions  
It has been postulated that gestational hypertension is a ‘sign of latent hypertension 
unmasked by pregnancy’44. The present study supports this hypothesis. The educational 
subgroups with the highest risk of gestational hypertension had the highest blood pressure 
values at enrolment, and their increased risk of gestational hypertension was almost 
entirely explained by factors that are also associated with essential hypertension45. These 
2Maternal educational level and gestational hypertension │ 93 
findings suggest that the relatively high risk of gestational hypertension in women with 
relatively low levels of education may reflect pre-existing hypertensive tendencies that are 
disclosed by the physiological stress of pregnancy.  
We conclude that a relatively low educational level is associated with a higher risk 
of gestational hypertension. The educational inequalities observed in gestational 
hypertension may represent an early manifestation of the socioeconomic differences in 
morbidity and mortality from cardiovascular disease in women13. Strategies to reduce 
educational inequalities in gestational hypertension should be aimed primarily at reducing 
the burden of overweight and obesity in lower socioeconomic groups. 
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ABSTRACT
Objective  
To validate the accuracy of a previously published clinical prediction model for the 
identification of women who develop hypertension before 36 weeks gestation in an  
independent population sample. 
Methods  
The prediction model includes three easy to measure variables: systolic blood pressure, 
diastolic blood pressure and weight. The performance of this prediction model was studied 
in 988 healthy nulliparous women recruited from 7 midwifery practices in Rotterdam, The 
Netherlands. We assessed its discrimination and calibration and calculated sensitivity, 
specificity and negative predictive value for different risk categories.
Results  
58 of 988 women (5.9%) developed hypertension before 36 weeks of gestation. The AUC 
of the prediction model was 0.73 compared to 0.78 in the original study. Of the women 
with a very low score (13.4% of the population), none developed hypertension before 36 
weeks of gestation. In those with a high score (12.8% of the population) the risk was 
15.9%. 
Conclusion  
This validation study confirms the predictive ability of the model, which may be of use to 
reduce the number of frequent antenatal visits in healthy nulliparous women.
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INTRODUCTION 
Hypertension is one of the most common complications of pregnancy and is a major cause
of maternal and perinatal morbidity and mortality, in particular when hypertension is 
combined with proteinuria (pre-eclampsia).1 Because gestational hypertension can shortly 
progress to pre-eclampsia, de novo hypertension occurring after mid-gestation in a 
nullipara always requires intensified antenatal surveillance, and often more interventions, 
such as antihypertensive medication, hospital admission and, finally, induction of labor.  
Although there is no effective prevention strategy and the only cure is by delivery, 
identification of women at a high risk of developing hypertension already early in 
pregnancy is important. These women might benefit from intensified antenatal surveillance 
and timely diagnosis, improving pregnancy outcome. On the other hand, identifying 
women at very low risk of the disease may offer a possibility to reduce the number of 
antenatal visits in this group. Results from at least ten randomized trials suggest that in 
healthy nullipara, reduction of  the number of antenatal visits to as few as four to eight 
could be implemented without any increase in adverse maternal and perinatal outcomes2.
The organisation of antenatal care could be much more efficient, targeting health care 
strategies to those women who might really benefit. 
In healthy normotensive nulliparous women adequate risk classification of 
hypertensive diseases has proven to be very difficult. Recent studies focus mainly on 
combinations of biomarkers to predict a high risk of developing pre-eclampsia3,4. Although 
some show promising results, prediction models should preferably be based on parameters 
that are widely available and obtained at no or minimal cost. In a previous study, we 
developed and internally validated a model for prediction of hypertension in pregnancy 
before 36 weeks of gestation using simple clinical variables routinely obtained at the first 
antenatal visit, namely systolic blood pressure, diastolic blood pressure and weight5. The 
model accurately identified those women at very low risk of developing hypertension 
before 36 weeks gestation, as well as those at high risk. Its predictive accuracy was 
confirmed by an area under the receiver operating characteristic (ROC) curve of 0.78. 
Geographical validation showed that the model was stable across populations in two 
different cities in The Netherlands. 
Although the prediction model was internally and geographically validated in the 
derivation study, it has not been externally validated in a separate sample. Specifically, the 
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model was derived from data that was collected between 1990 and 1994, raising concerns 
about the model performance in contemporary populations. In this study, we investigated 
the accuracy of the prediction model in a subpopulation of the Generation R study, a 
recent, independent population-based cohort.  
METHODS 
Study population 
The Generation R study is a population-based prospective cohort study to investigate early 
environment and genetic determinants of growth, development and health in fetal life, 
childhood and adulthood. The study is conducted in Rotterdam, the second largest city in 
the Netherlands. Rationale and details of the Generation R study have been previously 
published6. In total 9778 pregnant women with a delivery date between April 2002 and 
January 2006 were enrolled at their routine ultrasound examination in pregnancy after 
written consent was obtained. For this validation study only healthy, nulliparous women 
with a singleton pregnancy, who entered antenatal care at a midwife practicebefore 16 
weeks of gestation were included (n=1038). This is the only group for which all necessary 
data were available.The women had an expected date of delivery between April 2002 and 
December 2006 and had their forst control of blood pressure before 16 weeks of 
gestational age. Gestational age was determined from the best estimate according to 
menstrual history or ultrasound measurement early in pregnancy. Blood pressure was 
measured by auscultatory sphygmomanometry. Only women who were normotensive 
(blood pressure <140/90 mmHg) at booking were included in our analysis (n = 988).  
Hypertension before 36 weeks of pregnancy was defined as SBP ≥140 mmHg and/or DBP 
≥ 90 mmHg measured twice with an interval of at least 6 hours, based on blood pressure 
measurements from midwives during regular routine antenatal visits.
Statistical analyses 
The published prediction model uses SBP, DBP, and maternal weight for calculating the 
risk of hypertension (see Appendix)5. Missing values in the validation set on these 
variables (2.9%) were imputed with single regression techniques7-9.  
To quantify external validity of the prediction model, we assessed its 
discrimination and calibration. Discrimination is the ability of the model to discriminate 
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between patients with and without hypertension, and is quantified by the area under the 
receiver operating characteristic curve (AUC). An AUC ranges from 0.5 (no 
discrimination; same as flipping a coin) to 1.0 (perfect discrimination). Calibration refers 
to the agreement between the predicted probabilities and observed frequencies of 
hypertension.  
To further explore predictive ability, all patients were assigned to 1 of 4 risk 
categories (very low risk, low risk, moderate risk and high risk), based on the score chart 
derived from the previous published prediction model (see Appendix). For the thresholds, 
we calculated corresponding sensitivity, specificity and negative predictive value.  
 The data were analyzed using the statistical software package SPSS for Windows 
(version 17.0, SPSS Inc., Chicago, Illinois, USA) and R (version 2.7.0, http://www.r-
project.org/). 
RESULTS 
There were 988 participants who were normotensive at booking. Measurements were 
performed at 12.0 ± 1.8 weeks of pregnancy, compared to 12.2 ± 2.1 weeks in the 
derivation study.  
Maternal characteristics and pregnancy outcome are given in Table 1. There were 
more women of Non-Caucasian ethnic origin in the validation sample (64% vs 76%). In 
the validation study 5.9% (N=58) of the women developed hypertension in pregnancy 
before 36 weeks of gestation, compared to 6.0% in the original study.
The area under the curve of the model was 0.73 (95% CI 0.67-0.80), compared 
0.78 (95% CI 0.75-0.82) in the original study. The calibration plot is depicted in Figure 1.
This figure shows that the mean predicted probability to develop hypertension before 36 
weeks of gestation equals the mean observed proportion of women who did develop 
hypertension, up till a predicted probability of 18%. After this percentage, the predicted 
risks are too high. 
After applying the score chart, 132 out of 988 women were categorized as having a 
very low risk (Table 2). None of these women developed hypertension before 36 weeks of 
gestation. Application of the model using this threshold could thus reduce the number 
women needing frequent antenatal visits by 13% (compared to 19% in the original study), 
with a sensitivity of 100%, and a corresponding specificity of 14%. By increasing the 
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threshold of less frequent antenatal visits specificity increases, but at the cost of lower 
sensitivity (missing women who do develop hypertension before 36 weeks of gestation).  
In the high risk category 16% of the women developed hypertension, compared to 23% in 
the original study. 
Figure 1 Calibration plot of observed and predicted probability of developing 
hypertension after applying the prediction model to the Generation R data.
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Table 1 Maternal characteristics and pregnancy outcome  
in the validation and derivation study. 
Data expressed as mean±SD or numbers(%). SBP; systolic blood pressure, DBP;diastolic blood  
pressure. 
Definition gestational hypertension according to definition of ISSHP.
Validation study 
(N=988)
Derivation study 
(N=2334)
Characteristics
  Age (years) 28.0± 5.2 27.6 ± 4.7
  Weight (kg) 67.9 ± 12.3 65.2 ± 10.9
  Height (cm) 168.4 ± 7.4 167.7 ± 7.0
  Caucasian, N  (%) 628 (63.6) 1768 (75.7)
  SBP (mmHg) 114.0 ± 9.7 113.3 ± 12.6
  DBP (mmHg) 67.0 ± 7.4 70.1 ± 8.2
Pregnancy Outcome
  Gestational age at 
  delivery 39.9 ± 1.9 39.6 ± 2.9
  Birth weight (gram) 3339.4 ± 564.1 3279.0 ± 635.3
  Hypertension before 36  
  weeks gestation, N  (%)
58 (5.9) 141 (6.0)
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Table 2 Classification in risk categories in the validation and derivation study. 
Women Women 
SE(%) SP(%) NPV(%)
Women
needing less 
frequent 
visits 
developing HT without HT 
N (%) N (%) N (%)
Validation study (N=988)
Very low risk (N=132) 0 (0.0) 132 (100.0) 100.0 14.2 100.0 132 (13.4)
Low risk (N=445) 15 (3.4) 430 (96.6) 74.1 60.4 97.4 577 (58.4)
Moderate risk (N=285) 23 (8.1) 262 (91.9) 34.5 88.6 95.6 862 (87.2)
High risk (N=126) 20 (15.9) 106 (84.1)
Derivation study (N=2334)
Very low risk (N=438)             2 (0.5) 436 (99.5) 98.6 19.9 99.5 438 (18.8)
Low risk (N=982) 27 (2.7) 955 (97.3) 79.4 63.4 98.0 1420 (60.8)
Moderate risk (N=599)          40 (6.7) 559 (93.3) 51.1 88.9 96.6 2019 (86.5)
High risk (N=315)          72 (22.9) 243 (77.1)
HT: hypertension; SE: sensitivity; SP: specificity; NPV: negative predictive value 
Very Low risk = Sum score ≤4.5; Low risk = Sum score 5-6; Moderate risk = Sum score 6.5-7; High risk = Sum score ≥7.5. See score chart in Appendix. 
DISCUSSION 
In this study we validated a previously derived prediction model for hypertension before 
36 weeks gestation in healthy nulliparous women by using recent data (2002-2006) of a 
separate sample of women receiving routine prenatal care in a primary health care setting. 
The data of this independent cohort confirm adequate predictive ability of the model and 
support its potential use to classify women into subgroups at very low, low, moderate and 
high risk for developing hypertension. Although the model performed more accurately in 
the data from which it was derived (AUC = .78) compared to the validation data (AUC = 
.73), this difference was not statistically significant. The calibration plot showed that after 
a predicted probability of 18%, the predicted risks were too high. This is not clinically 
relevant however; a predicted risk of 18% is high enough to classify a women as having a 
high risk anyway. More important is that low risks were adequately predicted, to classify 
women correctly as having a very low or low risk.     
Previous studies have also attempted to predict development of hypertensive 
disorders in pregnancy. Results of a large systematic review in 2004, conducted by the 
WHO failed to identify clinically useful “single” screening tests to predict the development 
of preeclampsia10. In 2008, authors of another systematic review concluded that no test, 
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nor combinations of tests had emerged with high enough sensitivity and specificity to be of 
clinical use11. The importance of continuing research to identify useful markers was 
stressed. The authors of a recent literature review concluded that specific angiogenic, 
antiangiogenic and proteomic markers are the most promising biomarkers of pre-
eclampsia12.  In a recent case-control study, a consistent discriminatory metabolite 
signature in early pregnancy plasma was discovered, consisting of a combination of 14 
metabolomic biomarkers3. These kind of studies offer insight into disease pathogenesis and 
generate hope that ultimately the screening test for pre-eclampsia will be developed. In the 
development of our model we specifically focused on commonly available clinical 
variables, easy to use in routine antenatal care in midwifery practices. After risk 
classification based on our model, validated screening tests based on biomarkers may help 
classify risk further. The cost-effectiveness of using these more expensive tests in all, or a 
selection of women needs further study. 
Some aspects of our study need to be addressed to appreciate the results. First, a 
validation sample should include preferably a 100 events to detect substantial changes in 
accuracy with 80% power, e.g. a 0.1 change in c-statistic13. In our validation sample, 58 
women developed hypertension before 36 weeks of gestation. This affects the precision of 
our estimates. Second, in the derivation study, blood pressure was measured by an 
automated device (BOSO). Based on the validation results of the BOSO equipment, 
measurements on average are slightly higher than what a standard mercury device would 
have measured. BOSO on average overestimates diastolic pressure by 1 mmHg and 
systolic pressure by 2 mmHg, as compared to standard auscultatory mercury 
sphygmomanometry by trained observers14. In the validation sample, blood pressure was 
measured routinely by auscultatory shygmomanometry. The model however performed 
adequately despite this different method. Third, the validation sample included less 
Caucasian women. Although our model does not include ethnicity as a predictor and 
performed well in the validation sample, we recognise the importance of ethnicity in the 
risk of developing hypertensive disorders.  
A strength of the present study is that the subgroup of the Generation R population 
that received routine health care in multiple midwifery practices provided recent data, 
ideally suited for external validation of the prediction model. Furthermore, our model is 
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very easy to use in clinical practice because it uses predictive variables that are obtained as 
part of routine care.   
The clinical implications of our study are that risk of hypertension before 36 weeks 
of gestation can be established early in pregnancy and patient management tailored to risk 
levels. The model could serve as a tool to identify women who might require intensified 
surveillance in pregnancy, in the future maybe after further screening based on biomarkers, 
while the antenatal visits in very low or low risk women might potentially be reduced. This 
would obviously have implications in terms of more efficient utilisation of health-care 
resources. It is unknown whether such strategies based on this prediction model would be 
of benefit; this should be the focus of future research.  
In summary, a clinical prediction model consisting of three variables easily 
available to midwives, demonstrated adequate performance for classifying women 
according to their risk of developing hypertension before 36 weeks of gestation.  
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Appendix 
Prediction model for the development of hypertension before  
36 weeks gestation5. 
SBP: systolic blood pressure; DBP: diastolic blood pressure; ROC: receiver operating characteristic  
*Systolic blood pressure categorized per 5 mmHg: <80 
(category 1); 80-84 (2); 85-89 (3); 90-94 (4); 95-99 (5); 100-104 (6); 105-109 (7); 110-114 (8); 115-119   
(9); 120-124 (10); 125-129  (11); 130-134 (12); ≥135 (13).
Diastolic blood pressure  categorized per 5 mmHg: <50 (category 1); 50-54 (2); 55-59 (3); 60-64  
(4); 65-69 (5); 70-74 (6); 75-79 (7); 80-84 (8); ≥85 (9). 
Variable
Regression 
Coefficient **
Odds ratio 95%  CI
Systolic blood pressure 
(category)*
   0.33 1.39 1.26-1.53
Diastolic blood pressure 
(category)*
   0.29 1.34 1.19-1.51
Weight (kg)    0.02 1.02 1.01-1.03
Intercept   -9.25
Area under the ROC 
curve***
   0.78 0.75-0.82
Formula to calculate the risk of hypertension:
1 / (1+exp-(intercept + 0.334 x category SBP + 0.291 x category DBP + 0.023 x weight))
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Score chart for the risk of developing hypertension before 36 weeks of gestation5.  
Predictor Score
Systolic blood pressure (mmHg) …
< 85 0.5
85-89 1
90-99 1.5
100-104 2
105-114 2.5
115-119 3
120-129 3.5
≥ 130 4
Diastolic blood pressure (mmHg) …
< 55 0.5
55-64 1
65-74 1.5
75-79 2
≥ 80 2.5
Weight (kg) …
< 55 1
55-79 1.5
80-99 2
≥100 2.5
…
-------+
Total sum score …
2
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ABSTRACT 
Objective:  
In this study, we assessed the validity of maternally, self-reported history of preeclampsia.  
Study Design and Setting: 
This study was embedded in the Generation R Study, a population-based prospective 
cohort study. Data were obtained from prenatal questionnaires and one questionnaire 2
months postpartum from the mother. All women who delivered in hospital and returned a 2 
month postpartum questionnaire (n=4330) were selected.  
Results: 
Of the 4330 women, 76 out of 152 (50 %) women who self reported preeclampsia 
appeared not to have had the disease according to the definition (International Society for 
the Study of Hypertension in Pregnancy). From the women who self reported not to have 
experienced preeclampsia, 11 out of 4178 (0.3%) had suffered from  preeclampsia. 
Sensitivity and specificity were 0.87 and 0.98, respectively. Higher maternal educational
level and parity were associated with a better self reported diagnosis of preeclampsia.  
Conclusion: 
The validity of maternal-recall self-reported preeclampsia is moderate. The reduced self-
reported preeclampsia might suggest a lack of patient-doctor communication. Therefore, 
doctors have to pay attention to make sure that women understand the nature of 
preeclampsia.  
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INTRODUCTION 
Pre-eclampsia is still a major cause of fetal and maternal morbidity and mortality1,2. Its 
pathogenesis is unknown, and as a consequence, rational therapy is lacking. In clinical 
management, it is important to act on known risk factors at antenatal booking. Recently, 
Milne et al. developed a community guideline, which provided an evidence based risk 
assessment as a framework for appropriate care for the best outcome for the mothers and 
their babies3. This guideline provides a risk assessment for individual care using known 
risk factors for pre-eclampsia. The authors recommend referral before 20 weeks’ gestation 
if women have risk factors, including a history of pre-eclampsia and chronic hypertension. 
These risk factors have mainly been determined by epidemiologic studies through subjects' 
self-report by means of personal interviews or mailed questionnaires. Besides using pre-
eclampsia as a risk factor for subsequent pregnancies, recent reports in epidemiologic 
studies have suggested an association of pre-eclampsia as a risk factor for cardiovascular 
disease in later life4. This implies a necessity for adequate information on the correct 
diagnosis of pre-eclampsia. In this study, we assessed the agreement of a self-reported 
history of pre-eclampsia with the information on diagnostic criteria for pre-eclampsia in 
medical files. 
Study Design and Setting 
This study was embedded in the Generation R Study, a population-based prospective 
cohort study from fetal life until young adulthood. The Generation R Study examines early 
environmental and genetic determinants of growth, development, and health in fetal life, 
childhood and adulthood5,6. Briefly, the cohort includes 9778 women, of whom 8880 were 
enrolled during pregnancy, of different ethnicities living in Rotterdam, The Netherlands. 
Enrollment was aimed in early pregnancy but possible until birth of the child. Women and 
their partners were enrolled in the study at their first routine ultrasound examination in 
pregnancy after written consent was obtained. Data from three different questionnaires 
during pregnancy, data about the delivery, and data from a questionnaire 2 months post 
partum were analyzed. All children were born between April 2002 and January 2006. The 
Medical Ethical Committee of the Erasmus Medical Centre, Rotterdam, has approved the 
study.  
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Medical charts and maternal outcome 
Women within the Generation R Study, who delivered in hospital and had chronic 
hypertension or were reported to have experienced pregnancy-induced-hypertension (
140/90 mmHg) or hypertension related complications (pre-eclampsia, proteinuria, 
eclampsia and/ or HELLP syndrome (haemolysis, elevated liver enzymes, and low 
platelets)) were selected from hospital registries. Their individual medical records were 
subsequently studied. Pregnancy-induced-hypertension, pre-eclampsia and eclampsia were 
defined according to the International Society for the Study of Hypertension in Pregnancy 
(ISSHP) criteria7 and according to those of the American College of Obstetricians and 
Gynaecologists (ACOG)8. HELLP syndrome was defined as thrombocytes <100x109/l, and 
both ASAT (aspartate aminotransferase) and ALAT (alanine aminotransferase) >70 U/l 
and LDH (lactate dehydrogenase) > 600 U/L. Severe pre-eclampsia was defined according 
to the criteria described by Sibai9.
Self-reporting of complications of pregnancy
Information on the index pregnancy was obtained from the questionnaire for the mother, 2 
months postpartum. Pre-eclampsia was asked for as being hypertension in combination 
with  proteinuria (no, yes or don’t know). Pre-eclampsia was explained in a lay term 
(translated in Dutch as “zwangerschapsvergiftiging”) as a high blood pressure in 
combination with loss of proteins in urine. Women who answered don’t know were 
classified as missing (n=37, 0.8%).
Covariates 
Information about maternal characteristics (age, parity (≥ 1), ethnicity, education, netto 
income per household (> Є 2200), chronic hypertension), family diseases (chronic 
hypertension, pregnancy-induced hypertension or pre-eclampsia) and quality of language 
was obtained from the prenatal questionnaire in early pregnancy at enrolment. The highest 
educational level achieved by the mother was categorized into three educational levels: 
high (high school or university), mid (secondary school) and low (no education or primary 
school). Quality of language was asked for as how well are you able to speak, read and 
write your language (not at all, a little, reasonable, quite well, very well). Information 
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about satisfaction of prenatal care was obtained from the prenatal questionnaire in the third 
trimester. 
Population for analysis 
In total 8880 women were enrolled in pregnancy in the Generation R Study. Of these 
women, 6897 participated in the postnatal phase of the study. Data of women who did not 
continue the study were excluded. Women who had missing information on pregnancy 
outcome (1.2%, n=77) were excluded from present study. Some women had contributed 
with more than one pregnancy in the Generation R Study. In total, 468 pregnancies (6.9%) 
were a second pregnancy, and four pregnancies (0.05%) were a third pregnancy within the 
study. Data on only the first ongoing pregnancy were used for analysis to avoid clustering. 
The response for the cohort of this questionnaire was 82%10. A subgroup of the study 
population did not receive or return the questionnaire 2 month postpartum (30%, n = 
1938). As we started to distribute the questionnaire at the postnatal age of 2 months in a 
later stage of the study, not all women received this questionnaire (9%). This group of 
women did not differ from the others and language problems were no issue. A second 
group was not sent a questionnaire, because no postnatal consent was given (6%). Sixty 
three women who did not answer specific question about pre-eclampsia (0.8%, n=63) were 
classified as missing. Four (6.3%) of them had had pre-eclampsia, according to their 
medical record. The results of thirty-seven women (0.3%) who answered ‘do not know’, 
were classified as missing. Therefore, 4330 subjects remained for further analyses.
Data analysis 
We treated the diagnosis pre-eclampsia according to the medical record as “gold standard” 
(i.e., true pre-eclampsia; true no pre-eclampsia, defined by the ISSHP criteria) and 
calculated sensitivity (percent true pre-eclampsia reported as pre-eclampsia), specificity 
(percent true no pre-eclampsia reported as no pre-eclampsia), positive predictive value 
(PPV; percent of reported as pre-eclampsia that is true pre-eclampsia), negative predictive 
value (NPV; percent of reported as no pre-eclampsia that is true no pre-eclampsia)11. Both 
the definition of the ISSHP and ACOG were used to calculate sensitivity and specificity. 
Furthermore, calculations were made for the diagnosis severe pre-eclampsia according to 
Sibai9. The associations of specific determinants and validity were assessed using logistic 
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regression analysis. A new variable for validity was computed, categorized as yes (self-
reported diagnosis and the diagnosis from medical record are similar) and no (self-reported 
diagnosis and the diagnosis from medical record are dissimilar). All regression analyses 
were adjusted for age, parity and ethnicity. The analyses were adjusted for age and parity, 
because older women or women with more pregnancies could be more experienced with 
complications and, therefore, could be confounding variables. Different ethnicity could 
have an effect on education, by different language or culture. 
The Statistical Package of Social Sciences version 12.0 for Windows (SPSS Inc, Chicago, 
IL, USA) was used for all statistical analyses. 
Results 
Table 1 shows the characteristics of the women who received and returned a questionnaire 
versus who were not sent a questionnaire or the questionnaire was not returned. As no data 
were available from women to whom no questionnaire was sent and from women to whom 
one was sent  but who did not return, they are described as one group in the manuscript. In 
the group who returned a questionnaire, we found less pre-eclampsia, more first 
pregnancies, older women, higher educated, more Dutch ethnicity, and a higher income. 
Figure 1 and table 2 present the data from the questionnaire and the medical records. Of 
the 4330 women 4178 (96.5%) answered that they had not experienced pre-eclampsia, and 
152 (3.5%) answered that they had experienced pre-eclampsia (table 2). In total, 152 
women who answered to have suffered from pre-eclampsia, had, according to their 
records, suffered in 43 cases from hypertension without proteinuria and in 5 cases from 
HELLP syndrome without proteinuria (ISSHP criteria). Table 3 shows sensitivity, 
specificity, PPV and NPV calculated for the different definitions of pre-eclampsia. Similar 
results were found for sensitivity and specificity using ACOG criteria. However, using the 
definition of severe pre-eclampsia of Sibai9, a sensitivity of 0.92 could be calculated. Table 
4 shows the crude and adjusted odd ratios for potential risk factors and a correct diagnosis 
of self-reported pre-eclampsia.
Multiparity was associated with the correct self-reported diagnosis of pre-eclampsia (odds 
ratio with 95% confidence interval, 1.39, 1.00 – 1.94). For ethnicity, no associations could 
be found. Higher maternal education level was associated with the correct self-reported 
diagnosis of pre-eclampsia or its absence (primary school (odds ratio with 95% confidence  
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Table 1. Characteristics of women who were returned a questionnaire versus not sent or 
not returned.  
Received Not sent or not returned
N = 4330 N = 1918
Characteristics
Pre-eclampsia (in %) 2.1 2.8*
Age (mean in year) 30.6 28.6*
Parity ≥1 (in %) 35.8. 43.2*
Missing 2.7 7.0
Ethnicity (in %)
Dutch and other European 63.1 39.5*
Surinamese 6.0 10.8*
Turkish 7.5 12.9*
Moroccan 3.8 9.8*
Antillean 2.2 2.8
Cape Verdian 2.6 6.1*
Other 9.0 7.9
Missing 7.5 16.6*
Education (in %) 
Low 3.2 9.2*
Mid 31.7 43.2*
High 55.0 27.6*
Missing 10.1 20.0
Income per household (in %)
Less 45.8 77.6*
High 54.2 22.4*
Missing
Quality of language
Speaking low 4.1 9.4*
Speaking high 85.2 71.9*
Missing 10.7 18.7
Reading bad 3.8 8.5*
Reading well 85.2 71.6*
Missing 11.0 19.9
Writing bad 5.0 10.0*
Writing well 84.0 70.0*
Missing 11.1 20.0
* p < 0.05 
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Figure 1 Data about self-reporting of pre-eclampsia, obtained from the questionnaire 
compared to the medical records (PIH = pregnancy induced hypertension, HELLP = 
hemolysis, elevated liverenzymes and low platelets, PPROM = preterm premature 
rupture of the outer membranes. Total n=4330.
Questionnaire: pre-eclampsia  YES (N=152)
Medical Records: hypertensive 
complications, N=124
Pre-eclampsia 76
HELLP 5
Chronic hypertension 43
or pregnancy-induced hypertension
Medical records: no hypertensive 
complications, N=28
Uncomplicated 9
Incorrect diagnose hypertension 
or pre-eclampsia 4
Post date pregnancy 1
Blood loss 2e trimester 1
Caesarean section before 1
Intrauterine growth restriction 1
Breech presentation 1
Complication during delivery 
Fetal stress 3
PPROM 2
Meconium 5
Questionnaire: preeclampsia : NO (N = 4178)
Medical record 
Preeclampsia 11
HELLP 2
Chronic hypertension 160
or PIH
Medical Record:  no preeclampsia       
N = 4167
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interval, 0.39, 0.18 – 0.84), secondary school (0.70, 0.51 – 0.96), and high education (1.63, 
1.19 – 2.24) (trend analysis for education P < 0.05)).  
Income per household was not associated with the validity of the diagnosis. Chronic 
hypertension and pre-eclampsia in a preceding pregnancy were inversely associated with 
the correct self-reported diagnosis of pre-eclampsia or its absence (odds ratio with 95% 
confidence, 0.05, 0.03 – 0.10 and 0.17, 0.06 – 0.47, respectively). 
No association was found between quality of language of the women and the validity of 
the self-reported diagnosis. An association between the validity of the diagnosis of pre-
eclampsia and satisfaction of prenatal care asked for in the last trimester of pregnancy was 
not found (odds ratio with 95% confidence interval 1.00, 0.77 – 1.32).  
Table 2 Data about self-reporting of pre-eclampsia, obtained  
from the questionnaire compared to the medical records. 
Table 3. Accuracy of maternal recall of the diagnosis pre-eclampsia,  
using different definitions for pre-eclampsia. 
Medical record Preeclampsia No preeclampsia Total
Self-reported
Pre-eclampsia 76 76 152
No pre-eclampsia 11 4167 4178
Total 87 4243 4330
Pre-eclampsia 
according to 
ISSHP criteria
Pre-eclampsia 
according to 
ACOG criteria
Severe pre-
eclampsia
Sensitivity (%) 87 84 92
Specifity (%) 98 98
Positive predictive value 
(%)
50 57
Negative predictive value 
(%)
99 99 99
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Table 4 Risk factors for a correct diagnosis of pre-eclampsia,  
odds ratios with 95% confidence are shown. 
CONCLUSION 
Personal interviews and self-reported questionnaires are commonly used for risk
assessment in pregnancy or later life and in epidemiologic studies as a sole source of 
exposure information. Our study showed that the validity of maternal self-reported pre-
eclampsia is moderate.  
An explanation for the reduced maternal self-reported pre-eclampsia is that our study has 
not tested the validity of maternal recall of what they wre told by medical professionals but 
Risk factor
Crude OR Adjusted OR
Age >35 years 0.78 (0.55 – 1.11) 0.70 (0.48 – 1.02)
Parity>1 1.39 (1.01 – 1.90) 1.39 (1.00 – 1.94)
Ethnicity
   European 0.82 (0.59 – 1.13) 0.83 (0.49 – 1.41)
   Surinamese 0.70 (0.42 – 1.17) 0.62 (0.31 – 1.25)
   Turkish 1.79 (0.83 – 3.84) 1.64 (0.63 – 4.27)
   Marroccan 1.56 (0.63 – 3.85) 1.25 (0.45 – 3.49)
   Cape verdian 2.72 (0.67 – 11.1) 2.17 (0.49 – 9.60)
   Antillian 0.89 (0.36 – 2.21) 0.75 (0.27- 2.10)
   Other 1.15 (0.68 – 1.94) 1.34 (0.48 – 3.77)
Education
   Primary 0.59 (0.41 – 1.15) 0.39 (0.18 – 0.84)
   Secondary 0.79 (0.58 – 1.06) 0.70 (0.51 – 0.96)
  Tertiary 1.38 (1.03 – 1.85) 1.63 (1.19 – 2.24)
Quality of language
   Speaking 0.96 (0.47 – 1.99) 0.74 (0.33 – 1.70)
   Reading 1.01 (0.46 – 2.18) 0.82 (0.34 – 1.96)
   Writing 1.19 (0.58 – 2.46) 1.00 (0.45 – 2.23)
Income > Є2200 0.99 (0.75 – 1.31) 1.23 (0.90 – 1.70)
Satisfaction of prenatal care 1.04 (0.80 – 1.35) 1.00 (0.77 – 1.32)
Chronic hypertension 0.06 (0.03 – 0.11) 0.05 (0.03 – 0.10)
Previous PE 0.17 (0.06 – 0.46) 0.17 (0.06 – 0.47)
Family history of PE 0.53 (0.27 – 1.03) 0.54 (0.28 – 1.06)
Family history of PIH 0.57 (0.38 – 0.84) 0.57 (0.38 – 0.85)
Family history of chronic 
hypertension
0.50 (0.37 – 0.67) 0.52 (0.38 – 0.71)
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rather the agreement of their recall with the diagnostic cirteria for pre-eclampsia. 
Therefore, these results might suggest an inaccurate use of the definition of pre-eclampsia 
in the communication between doctor and the patient. Actually, the agreement between 
pre-eclampsia according to the criteria and pre-eclampsia according to the questionnaire is 
reduced. 
We found that parity, low maternal education, chronic hypertension, and pre-eclampsia in 
a preceding pregnancy were associated with the validity of self-reported pre-eclampsia. 
Quality of language of the woman herself and ethnicity did not seem to influence the 
validity of maternal self-reported pre-eclampsia. This again suggests that maternal 
knowledge gaps on the characteristics of the disease pre-eclampsia might be  responsible 
for the inadequate understanding of information. In contrast to the expectation that chronic 
hypertension  and/or pre-eclampsia in a preceding pregnancy were positively associated 
with the correct diagnosis because of their knowledge, we found that both factors were 
found more often in women with the incorrect recall. This may imply a similar problem in 
patient-doctor communication as described earlier. The low number of women with pre-
eclampsia in a preceding pregnancy could also explain this finding.  
In a study by Yawn et al., pre-eclampsia defined from medical records and mother's report 
10-15 year after delivery had high levels of negative agreement (agreement that the event 
did not occur) but had low level of positive agreement (51.6%)12. In our study, we found a 
higher sensitivity (87% and 84%) of mothers’ self-report of pre-eclampsia using the ISSHP 
and ACOG definition, as described earlier (66%), but the same high specificity (99%)13. In 
addition, Sou et al. described that the symptoms of pre-eclampsia, such as proteinuria, are 
recalled worse than the diagnosis itself13. Recently, Klemmensen showed that the 
information on the diagnosis pre-eclampsia either being recorded in a registry or obtained 
by detailed interview by telephone had acceptable validity (sensitivity: 71% and 73%, 
respectively, and kappa: 0.74 and 0.64, respectively)14. As in this study, written 
questionnaires were used, and results cannot be compared with those of our study. 
The validity of maternal data, in general, obtained by questionnaire, varies. Self-reported 
information on having had an infant delivered by caesarean section, maternal diabetes 
before pregnancy, smoking habits, and having had amniocentesis have a high level of 
agreement12,13,15. These items, however, are easy to define, asked by direct questions and 
actual events at one or more points in time13. The moderate recall of pre-eclampsia might 
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reflect a lack of patient-physician communication rather than a time gap bias, because the 
questionnaire in our study was sent 2 months post partum.  
Diehl et al. recently demonstrated an 80% sensitivity and 96% specificity in verifying a 
history of pre-eclampsia, with a PPV of 51%16. This study tested the accuracy of a 
questionnaire used to screen a history of pre-eclampsia 24.5 years after the index 
pregnancies in 144 women who had a pregnancy complicated by pre-eclampsia, eclampsia, 
or a toxaemia, and in 158 women who had had a normotensive pregnancy. They conclude 
that their validated questionnaire may be a useful tool in identifying women with a 
previous history of pre-eclampsia. Our results indicate that inadequate maternal recall of 
pre-eclampsia may lead to substantial bias in studies on estimates of potential associations 
of complications in subsequent pregnancies and maternal cardiovascular disease in later 
life. However, withsuch a high specifity, it is unlikely that women without a history of pre-
eclampsia would self-report positive history.Therefore, for studies considering associations 
between pre-eclampsia and future cardiovascular disease, the currently reported 
sensitivities and specificities of maternal recall are sufficient to use self-reported pre-
eclampsia. 
It is of clinical interest that PPV of maternal recall increased from 50% to 82% by 
including all hypertensive complications in our study. Different studies showed an 
increased risk of pre-eclampsia in a subsequent pregnancy if a pregnancy is complicated by 
a hypertensive complication, including pre-eclampsia, HELLP syndrome, and chronic 
hypertesnion3,17.
Harlow and Brown demonstrated a diversity of diagnoses of pre-eclampsia as a result of 
using different definitions of this condition18. As comparison of results among studies is 
fundamental to the correct elucidation of knowledge about pre-eclampsia, standardization 
of the classification and diagnostic criteria of the hypertensive disorders of pregnancy 
should be a priority17.
We used the definition according to the ISSHP because of its international agreement and 
ability to compare different studies in the literature. A definition that includes even more 
women with pre-eclampsia, using the ACOG criteria, revealed similar sensitivity and 
specificity. The sensitivity using the definition for severe pre-eclampsia (according to the 
Sibai criteria) was higher, as expected. Women who have been severely ill during 
pregnancy may experienced more detailed and repeated patient-physician communication. 
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Women with severe pre-eclampsia are more likely to have complications of pregnancy, 
including preterm delivery and caesarean section.  
This study has a number of strengths. Firstly, the data collection in the Generation R Study 
are very detailed, which implies that we were able to study covariates. Secondly, all data 
were abstracted in a methodologically consistent manner from the medical records. 
However, several limitations to our report need to be discussed as well. Firstly, the medical 
record was assumed to be complete and correct, which might not be always the case. 
Secondly, not all data were available from the questionnaires. Third, a subgroup had not 
been sent a questionnaire postpartum.  
To assess possible bias introduced by this, data in both groups were compared for the 
presence of pregnancy complications. In the group that had been sent and returned a 
questionnaire, less women had had pre-eclampsia, and women were more frequently 
nulliparous, older, and higher educated. Furthermore, women were more often of Dutch 
native origin and had higher incomes. In the analyzed group, parity and education were 
shown to be associated with the validity. This means that the effect of education and parity 
on the validity of self-reported pre-eclampsia may have been stronger than that suggested 
in this study. 
In conclusion, our study found that the validity of maternally self-reported pre-eclampsia is 
moderate. A clear diagnosis based on the criteria of hypertension and proteinuria, which is 
clear for the doctor and the patient, is essential for the management of a subsequent 
pregnancy, preconception care, and possible prevention of cardiovascular disease in later 
life. For studies studying associations between pre-eclampsia and future cardiovascular 
disease, the currently reported sensitivities and specifities of maternal recall are sufficient 
to use self-reported pre-eclampsia.  
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ABSTRACT 
Background  
Haemostasis is a complex balance of activating and inhibitory pathways resulting in 
coagulation and lysis. Normal pregnancy is associated with hypercoagulation that is even 
more profound in complicated pregnancies. 
Objective  
To study the role of the plasminogen-activator system in complicated pregnancy with 
regard to haemostasis, it is essential to have reference values of components of this system 
during uneventful pregnancy. In this study we investigated the concentrations of six 
different components of the plasminogen-activator system preconceptionally, during and 
after uncomplicated pregnancies. 
Material and methods  
Tissue-type and urokinase-type plasminogen activator (tPA and uPA), plasminogen 
inhibitor type-1 and -2 (PAI-1 and-2), and the complexes between tPA and PAI-1, and 
between uPA and PAI-1 (tPA-PAI-1, uPA-PAI-1) were measured by ELISAs in blood 
obtained preconceptionally, at 6, 10, 20, 32 weeks of gestation, and 6 weeks after delivery 
in uncomplicated pregnancies (n=41; all six parameters n=22). 
Results  
tPA and uPA concentrations decreased in the first 10 weeks of pregnancy and 
subsequently increased in the third trimester. PAI-1 concentrations increased in the third 
trimester and PAI-2 concentrations increased throughout pregnancy (preconception versus 
32 weeks of gestation; 38.73 versus 102.23ng/ml, and 0.024 versus 151.06ng/ml, 
respectively). tPA-PAI-1 and uPA-PAI-1 complex concentrations decreased in the first 
trimester, followed by an increase in the third trimester. The concentrations of all 
components returned to the preconception values 6 weeks after delivery. 
Conclusion  
This study provides longitudinal data on activating and inhibitory components of the 
plasminogen-activator system during pregnancy. Insight in the longitudinal changes in 
these concentrations may be of help in the understanding of the thrombotic tendency in 
pregnancy complications such as pre-eclampsia. 
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INTRODUCTION 
Haemostasis is regulated by a complex system of activating and inhibitory pathways. 
Vascular endothelial cells, circulating platelets and plasma proteins play a central role in 
this system. The fibrinolytic components, tissue-type plasminogen activator (tPA) and 
urokinase-type plasminogen activator (uPA) promote the conversion of plasminogen to 
plasmin, which is responsible for fibrin degradation. Plasminogenactivatorinhibitor-
type1(PAI-1) is a potent inhibitor of tPA and uPA. Vascular endothelial cells are primarily 
responsible for tPA synthesis and secretion into the blood. Furthermore, vascular smooth 
muscle cells, platelets and the liver also produce PAI-1. Plasminogen activator inhibitor-
type 2 (PAI-2) is mainly 
produced by trophoblasts and is reported to play an important role in counteracting uPA 
during pregnancy1. An excess of inhibitors of fibrinolysis could lead to thrombosis. 
Endothelial cells present a confluent, non-thrombogenic surface to which platelets 
do not adhere. However, when insults to endothelial cells expose the subendothelium, 
platelets rapidly cover these areas and initiate the formation of a haemostatic plug2. The 
viability of these plugs is related to the balance between endogenous fibrinolytic 
components and inhibitors of fibrinolysis.  
Uncomplicated pregnancy is associated with a reduction 
of fibrinolytic activity3 and an increase of PAI-14concentrations in blood, contributing to a 
state of hypercoagulation. Reduced fibrinolytic activity is even more profound in 
pregnancies complicated by abnormal placentation as in the case of pre-eclampsia, 
abruption 
placenta and intrauterine growth restriction5.  
In order to gain insight in the possible involvement of abnormal fibrinolytic 
activity in the pathophysiology of major complications of pregnancy in the future, we 
studied the concentrations of plasminogen activators and inhibitors and the complexes 
between these components in blood from women with uneventful pregnancy throughout 
gestation. 
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Material and methods 
Patients 
Between 1987 and 1990, 41 women were selected by strict criteria from a larger cohort 
described previously6-8. These exclusion criteria included risk factors of adverse 
pregnancy outcomes, first-degree relatives with a genetic disorder known to cause major 
congenital malformations and treatment for infectious, metabolic, endocrine or malignant 
diseases. Women were recruited before conception. All selected women were Caucasian, 
nulliparous and had a singleton and uncomplicated pregnancy. The study was a multi-
centred cohort study. The Medical Ethical Committee of the Radboud University 
Nijmegen Medical 
Centre, The Netherlands, approved the protocol. After informed consent a researchnurse 
visited the participants at home to obtain a medical history and to collect blood samples 
(P0). The research nurse revisited the women if they were not pregnant within 6 months 
after first blood sample collection for obtaining a new preconceptional blood sample. 
Pregnancy was confirmed by a monoclonal antibody-based pregnancy test on the 17th day 
of conception and menstrual history. One or two transvaginal ultrasonographic 
examinations before the 8th week of gestation were performed in order to ascertain the 
duration of pregnancy. Subsequent blood sampling took place at weeks 6 (P1), 10 (P2), 20 
(P3) and 32 (P4) of gestation as 
well as at 6 weeks after delivery (P5). Of all women included in the study (n = 41), from 
22 women the complete set of six samples from preconception till 6 weeks after delivery 
were available for analysis. In the remaining samples of 19 women one or more of the 
longitudinal 
samples were missing. 
Methods 
From all women blood was drawn from a brachial vein in sterile tubes containing EDTA. 
Within 1 h of collection, blood was centrifuged at 1500 x g for 10 min, and plasma was 
stored at -30 °C until assayed. Plasma concentrations of tPA, uPA, PAI-1, PAI-2, tPA-
PAI-1 complex and uPA-PAI-1 complex were assayed with enzyme-linked immu-
nosorbent assay procedures as described before9,10. The samples were analyzed in 2002. 
We performed the 
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measurements in duplicate.  
In each run, an international reference sample developed by the Department of 
Chemical Endocrinology (the Quality Assurance Center for the Receptor and Biomarker 
Group of the European Organisation for Research and Treatment of Cancer) was run to 
check between-assay variability and to monitor overall performance. Therefore, 
lyophilized control preparations were used. For tPA thewithin-run coefficient of variability 
(CV) and between-run CVare found to be 3.3% and 10.7%, respectively, and for uPA these 
values amount to 4.0% and 9.2%, respectively. For PAI-1 the within-run CV and between-
run CV are found to be 2.0% and 6.2%, respectively, and for PAI-2 5.3% and 11.2%, 
respectively. Within-run and between-run CVs for uPA-PAI-1 are 4.2% and 11.6%, and 
for tPA-PAI PAI-1-1 complex 5.9% and 12.9%, respectively.  
Hematocrit and creatinine were also measured.  
Statistical analysis 
Friedman test with repeated measurements was used to analyse differences between the 
different time points of each component of the plasminogen-activator system since the data 
appear to be non-parametric. Simple linear regression analysis was used to determine 
associations between the concentrations of each component of the plasminogen-activator 
system and hematocrit and creatinine at each specific time point. Simple linear regression 
analysis was also used to determine associations between the concentrations of each 
component of the plasminogen-activator system and maternal body mass index and 
smoking habits. 
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Fig. 1. Data are shown as median concentrations with 5th–95th percentile of tPA and uPA, their inhibitors, PAI-1 and PAI-2, and the complexes  
tPA-PAI-1 and uPA-PAI-1 inplasmaof41women.TheX-axis represents time of bloodsampling, preconceptional(P0), week6(P1), week10(P2), 
week20(P3), week32(P4) and 6 weeks after delivery (P5). 
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RESULTS 
Demographic and clinical data of all participants 
The mean maternal age at 6 weeks of gestation was 29.7 ± 0.51 (S.D.) years. The 
gestational age at delivery ranged between 37 and 42 weeks. The mean birth weight was 
3377 ± 61 (S.D.) grams (range 2700–4200 g). 
Laboratory data 
Plasma concentrations of tPA and uPA, their inhibitors, PAI-1 and PAI-2, as well as the 
complexes tPA-PAI-1 and uPA-PAI-1in blood obtained before, during and after pregnancy 
are shown in the Fig. 1A–F. The 22 women with all six samples throughout pregnancy 
available are shown in Fig. 2A–F (for all parameters p < 0.01 using Friedman test). The 
median concentrations of tPA and uPA significantly decreased in the first trimester 
(preconception versus 10 weeks of gestation; 2.45 versus 1.66 ng/ml, and 0.68 versus 0.52 
ng/ml, respectively, Fig. 1A and B). This was followed by a gradual increase towards term 
(preconception versus 32 weeks of gestation, tPA: 2.45 versus 2.75 ng/ml, and uPA: 0.68 
versus 0.98 ng/ml, respectively). PAI-1 concentrations increased in the third trimester and 
PAI-2 concentrations increased throughout pregnancy (preconception versus 32 weeks of 
gestation; 38.73 versus 102.23 ng/ml, and 0.024 versus 151.06 ng/ml, respectively, Fig. 1C 
and D). In particular, blood concentrations of PAI-2 were very low during the first 
trimester and dramatically increased in the second half of pregnancy. The tPA-PAI-1 and 
the uPA-PAI-1 complex concentrations showed a decrease in the first half of pregnancy 
(preconception versus 10 weeks of gestation; 6.58 versus 4.74 ng/ml, and 0.21 versus 
0.086 ng/ml, respectively, Fig.1E and F)and then gradually increased to preconception 
concentrations towards term. The plasma concentrations of all six components of the 
plasminogen-activator system 6 weeks after pregnancy were similar to those before 
conception. 
No correlations were found between the concentrations of the components of the 
plasminogen-activator system and hematocrit or creatinine at the various time points (R2
between 0 and 0.342), suggesting that the concentrations of these factors were not 
influenced by hemodilution. No correlations were found between the concentrations of the 
components of the plasminogen-activator system and body mass index or smoking at the 
various time points (R2 between 0 and 0.342). 
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Fig. 2. Data shown are median concentrations with 5th–95th percentile of tPA and uPA, their inhibitors, PAI-1 and  
PAI-2, and the complexes tPA-PAI-1 and uPA-PAI-1inplasmaof22womencollectedlongitudinal.TheX- axis represents 
 time of bloodsampling, preconceptional(P0), week6(P1), week10(P2) ,week 20 (P3), week 32 (P4) and 6 weeks after  
delivery (P5). 
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Discussion 
We observed profound changes in the concentrations of components of the plasminogen-
activator system in blood of women with uneventful pregnancy indicating the presence 
of a delicate balance between activators and inhibitors of fibrinolysis during pregnancy. 
All components of the plasminogen-activator system returned to preconceptional 
concentrations after pregnancy indicating that all changes are induced by pregnancy. It is 
suggested that these transient changes are explained by hormonal influences11.  
In conjunction with our finding is the study of Koh et al. which described similar 
changes of haemostasis in normal pregnancy during gestational periods, labour and after 
placental separation and reported similar concentrations of a portion of the fibrinolytic 
components (tPA, uPA, PAI-1 and PAI-2)12. The primary fibrinolytic components, tPA 
and uPA were transiently decreased during the first and second trimester of pregnancy, 
while in the third trimester the concentrations of uPA were significantly increased 
compared to preconceptional concentrations.The decrease in the concentrations of these 
fibrinolytic components cannot be explained by hemodilution during pregnancy, since we 
found no association between the concentrations of these factors and the hematocrit.  
The concentration of particularly that of PAI-2, increased substantially during 
pregnancy, which is in line with earlier observations13,14. The undetectable concentrations 
of PAI-2 in the first trimester indicate that this compound is produced by the trophoblastic 
cells that proliferate during pregnancy leading to higher synthesis and release into the 
bloodstream. These inhibitors form stable complexes with the endogenous thrombolytic 
entities uPA and tPA in a one-to-one fashion. Interestingly, the patterns of the uPA-PAI-1 
and tPA-PAI-1 complex concentrations as observed throughout pregnancy, strongly 
resemble those of uPA and tPA concentrations, respectively. This despite the 
concentrations of the two inhibitors increased profoundly during pregnancy. This indicates 
that the formation of the complexes in blood of pregnant woman strongly depends on the 
concentrations of uPA and tPA in blood, which indeed are much lower than those of their 
inhibitors. The decrease 
in uPA and tPA concentrations and in the levels of their complexes with PAI-1 suggest a 
decreased synthesis or an increased turnover rate of uPA and tPA during pregnancy.  
It has to be noted, however, that we only measured tPA and uPA complexed to 
PAI-1 and not the complexes of these two compounds with PAI-2. As the concentrations 
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of PAI-2 are sharply increased during pregnancy, it is likely that the free tPA and uPA will 
be predominantly complexed byPAI-2 and not by PAI-1. Our complex ELISA does not 
detect these complexes. Consequently, the concentrations of tPA-PAI-1 and uPA-PAI-1 in 
blood would decrease during pregnancy, which is in line with our observations. Following 
this line of reasoning the decreased concentrations of the uPA-PAI-1 and tPA-PAI-1
complexes would not necessarily implicate a decreased synthesis of tPA and uPA.  
An alternative explanation for the decrease in tPA and uPA concentrations in first 
10 weeks of gestation might be found in the detection efficiency of the complexes in the 
ELISAs. The tPA and the uPA ELISAs detect free as well as complexed tPA and uPA, 
albeit that the complexedforms are most probably less efficiently detected because of 
hindrance of antibody binding sites by the inhibitors. Therefore, the 
concentrations of total tPA and uPA immunoreactivity (i.e. free and complex components) 
detected by ELISA may decrease in blood, while the tPA and uPA production is not 
affected or even might be slightly increased.  
Although we cannot conclude whether the decrease in plasma uPA and tPA 
concentrations observed is due to decrease synthesis,increased turnover,or enhanced 
complex (with PAI-2) formation, it is reasonable to assume that the concentrations of free 
tPA and free uPA, which are the biologically active forms, are decreased in blood during 
the first 10 weeks of pregnancy. This is in line with the observations of Van Wersch et al. 
who reporteda decrease of tPA concentration during pregnancy, whereas all the other 
investigated fibrinolytic parameters (PAI, plasminogen, a2-plasmin and D -dimer) showed 
a progressive increase15. The reduced fibrinolytic potential of the plasminogen-activator 
system in early pregnancy may result in degradation and proteolysis of the decidua to 
secure adequate trophoblast invasion. This process may also play a role to dissolve the 
trophoblastic plugs at the end of the first trimester in order to establish adequate 
perfusion16.  
The increased uPA concentrations in blood observed in week 32 of pregnancy 
suggests an increased synthesis at this phase of pregnancy. Other authors previously 
reported a relatively slight increase of tPA during normal pregnancy compared with the 
rise in PAI-1 [12,17]. Belo et al. reported that the rise in PAI-1 concentration was higher 
than that of tPA which may explain the reduced fibrinolytic potential during pregnancy17.
Moreover, they reported an additional significant rise in the levels of D -dimers, assayed as 
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fibrin degradation products, which can explain the compensated state of low-grade 
intravascular coagulation, showing that the fibrinolytic system remains functionally active. 
Choi and Pai18 reported that PAI-1 levels were strongly associated with tPA as well as D -
dimer levels, suggesting that fibrinolysis protects the pregnant woman from 
hypercoagulation. Interestingly, Kruithof et al. 13 measured by a radioiodinated fibrin plate 
assay the overall fibrinolytic activity in plasma during pregnancy and showed that despite 
large variations in the levels of tPA, uPA, PAI-1 and PAI-2 concentrations, the fibrinolytic 
activity did not change.  
It should be noted, that the EDTA plasma is stored for a long period before 
analysis. Although, we did not test the stability of the proteins during this period of 
storage, the department of Chemical Endocrinology the Quality Assurance reference 
laboratory for biomarkers within the European Organisation for Research and Treatment of 
Cancer has a longstanding experience with uPA and PAI-1 measurements. Within their 
Quality Assurance studies reference preparations of pooled materials are used and 
appeared to be very stable for more than 8 years. Nilsson et al. recently described only 
marginally higher values of the tPA/PAI-1 complex after long storage of 8–11 years19.
Since we collected and stored all the samples in the same way, we expect a similar effect 
on the protein concentrations.  
Endothelial dysfunction, and subsequently changes in haemostasis, is considered a 
key factor in the aetiology of pre-eclampsia. To understand the involvement of the 
plasminogen-activator system in pregnancy-related-complications, particularly of pre-
eclampsia and intrauterine growth restriction20,14, it is necessary to describe the changes of 
components of the plasminogen-activator system during normal pregnancy. To our 
knowledge this is the first study describing six components of the fibrinolytic systems 
longitudinally from the preconceptional period onwards, throughout pregnancy up to 6 
weeks after pregnancy. The present study offers the opportunity to gain further insight in 
coagulation in normal pregnancy and is conditional to study complicated pregnancies with 
a thrombotic tendency, such as pre-eclampsia, in the future. 
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ABSTRACT 
Objective  
The imbalance of angiogenic factors (soluble fms-like tyrosine kinase 1 (sFlt1), placental 
growth factor (PlGF)) and fibrinolytic factors (plasminogen activator inhibitor-2 (PAI-2)) 
might affect placentation in early pregnancy. 
Methods  
We studied the associations of maternal sFlt1, PlGF and PAI-2 concentrations in the first 
trimester (<18 weeks), and sFlt1 and PlGF concentrations in the second trimester (18-25 
weeks) with placental function and adverse pregnancy outcomes. This study was 
embedded in a population-based prospective cohort study. Data were used from 7519 
women. Biomarkers concentrations were divided in deciles and evaluated in multivariable 
linear and logistic regression models. 
Results  
First trimester high sFlt1 was associated with a 5.2% lower uterine artery index in second 
trimester and a 1.6% higher birth weight (55 grams, CI95% 15 - 95). Neither in the first, 
nor in the second trimester were sFlt1 concentrations significantly associated with pre-
eclampsia. First trimester low PlGF was associated with  a 6.1% higher uterine artery 
index and a 3.4% lower birth weight (-115 grams, CI95% -157 - -74). First trimester low 
PlGF was associated with fetal growth restriction (OR 2.62, CI95% 1.68 - 4.08) and pre-
eclampsia (OR 2.46, CI95% 1.49 - 4.08). First trimester low PAI-2 was associated with a 
1.9% higher uterine artery index and a 2.7% lower birth weight (-94 grams, CI95% -136 - -
51). First trimester low PAI-2 was associated with a higher risk of fetal growth restriction 
(OR 2.22, CI 95% 1.39 - 3.55).  
Conclusion  
First half of pregnancy concentrations of sFlt1, PlGF and PAI-2 are associated with 
uteroplacental vascular resistance, placental weight and birth weight. Moreover, first 
trimester PlGF and PAI-2 are associated with an increased risk of adverse pregnancy 
outcomes. 
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INTRODUCTION
First trimester abnormal placentation may result in adverse pregnancy outcomes including 
preterm birth, fetal growth restriction and pre-eclampsia1,2. In placenta development and 
functioning growth factors including vascular endothelial growth factor (VEGF) and 
placental growth factor (PlGF) play a key role in the remodelling process of the maternal 
endothelium in the spiral arteries. Both VEGF and PlGF bind to soluble fms-like tyrosine 
kinase 1 (sFlt1), a splice variant of the VEGF receptor 1 and primarily localized to the 
syncytiotrophoblasts3,4. sFlt1 reduces free circulating levels of the proangiogenic factors, 
VEGF and PlGF, and thereby blunts the beneficial effects of these factors. 
A second important cascade in placental development and functioning is the 
fibrinolytic system. Fibrinolysis is activated by conversion of plasminogen to plasmin 
which is responsible for fibrin degradation. Uncomplicated pregnancy is associated with a 
reduction of fibrinolytic activity contributing to a state of 
hypercoagulation5. Reduced fibrinolytic activity is even more profound in pregnancies 
complicated by abnormal placentation as in the case of pre-eclampsia  and intrauterine 
fetal growth restriction6. Plasmin depends on a balance between plasminogen activators 
and plasminogen activator inhibitors (PAI). PAI-2 is produced by the trophoblast. It 
increases with gestational age until term in plasma of pregnant women with uncomplicated 
pregnancies and declines to undetectable levels 6 weeks after delivery7,8. A decreased 
production of PAI-2 is thought to be a result of impaired placental function9. 
Previously, an association between higher sFlt1 and lower PlGF circulating blood 
concentrations in women with pre-eclampsia was described10. Similarly (anti-) angiogenic 
profiles have been described in women with pregnancies complicated by fetal growth 
restriction11. The pathogenesis of pre-eclampsia is described as abnormal placenta 
development. The first (placental) stage of the disease might result in a failure in 
trophoblastinvasion. Episodes of placental hypoxia result in oxidative stress and release of 
various components into the maternal circulation. The second stage of the systemic 
maternal disease is associated with exaggerated endothelial activation and a generalised 
hyperinflammatory state compared to normal pregnancy1. We hypothesized that high sFlt1, 
low PlGF and low PAI-2 concentrations in blood act as a sign of the first placental stage, 
resulting in the second stage of systemic maternal disease or placental related diseases, 
including preterm birth, fetal growth restriction and pre-eclampsia. We therefore 
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investigated the associations of sFlt1, PlGF and low PAI-2 concentrations in first and 
second trimester of pregnancy with the uterine artery resistance index in second trimester, 
placental weight and birth weight. Secondly, we studied the associations of these factors 
with the risks for complications including preterm birth, fetal growth restriction and pre-
eclampsia.  
MATERIALS AND METHODS 
Study design 
This study was embedded in the Generation R Study, a population-based prospective 
cohort study from fetal life until young adulthood in the city of Rotterdam, the 
Netherlands12. The Generation R Study examines early environment and genetic 
determinants of growth, development and health in fetal life, childhood and adulthood. 
Enrolment was aimed in the first trimester, but possible until birth of the child. Women 
were enrolled in the study at their routine ultrasound examination in pregnancy after 
written consent was obtained. Assessments in pregnancy, including anthropometrics and 
questionnaires were planned in first, second and third trimester. All children were born 
between April 2002 and January 2006. Of all eligible children in the study area, 61% 
participated at birth in the study. The Medical Ethical Committee of the Erasmus Medical 
Centre, Rotterdam, approved the study.  
Blood sFlt1, PlGF and PAI-2 concentrations 
Maternal non-fasting venous blood samples were drawn in first trimester (weeks in median 
with 90% range, 13.4, 10.5 - 17.2)) and second trimester (weeks in median with 90% 
range, 20.4, 18.8 - 22.9).  Details of processing procedures have been described 
previously13. Blood samples were stored at -80°C. Plasma sFlt1 and PlGF concentrations 
were analyzed by the department of Clinical Chemistry of the Erasmus Medical Centre. 
sFlt1 and PlGF concentrations were analyzed using an  immunoelectrochemoluminence 
assay on the Architect System (Abbott Diagnostics B.V., Hoofddorp, the Netherlands). 
The between-run coefficients of variation for plasma sFlt-1 were 2.8 % at 5.5 ng/ml and 
2.3% at 34.0 ng/ml.  The coefficients for plasma PlGF were 4.7 % at 24 pg/ml, and 3.8% at 
113 pg/ml. Plasma PAI-2 concentrations, analyzed by the Department of Laboratory 
Medicine of the Radboud University Nijmegen Medical Centre, were determined by
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ELISA with the same experimental setup as described previously14,15. For calibration, 
recombinant PAI-2 generously provided by Biotech Australia (Roseville, Australia) was 
used. The analytical sensitivity, defined as the amount of PAI-2 giving a signal in the 
ELISA greater than two standard deviations above blank values, was 11 pg/ml, whereas 
the functional sensitivity was 32 pg/ml. For estimation of the accuracy of the method a 
reference preparation was used in each microtiter plate. The mean PAI-2 concentration in 
this preparation was 88.4 ng/ml, while the intra-assay variation, the between-plates 
variation and the inter-assay variation amounted to  3.4%, 2.9%  and 8.4%, respectively.
Maternal and fetal complications in pregnancy 
Maternal and child outcomes including hypertensive disorders in pregnancy (pregnancy-
induced hypertension and pre-eclampsia), gestational age at birth, birth weight and 
placental weight were obtained from medical records, completed by community midwives 
and obstetricians. The occurrence of hypertension and hypertension-related complications 
(including pre-eclampsia, proteinuria, eclampsia, and/or HELLP syndrome (hemolysis, 
elevated liver enzymes, and low platelets)) were cross-validated using hospital registries16.
Pre-eclampsia was defined after completion of the pregnancy according to the International 
Society for the Study of Hypertension in Pregnancy criteria17. Pre-eclampsia was defined 
as a de novo hypertension (an absolute blood pressure ≥140/90 mmHg) after the 20th
gestational week with concurrent proteinuria (≥ 0.3grams in a 24-hour urine specimen or ≥ 
2 + [1 g/l] on a voided specimen, or ≥ 1+ [0.3 g/l] on a catheterised specimen). 
Superimposed pre-eclampsia was defined as a chronic hypertension (an absolute blood 
pressure ≥140/90 mmHg preconceptionally or before the 20th week of pregnancy) and 
new-onset proteinuria. Early-onset pre-eclampsia was defined as pre-eclampsia with a 
delivery before a gestational age of 34 weeks18. Pre-eclampsia was diagnosed in 167 
women (2.2%) and superimposed pre-eclampsia in 25 women (0.3%). Early-onset pre-
eclampsia was diagnosed in 23 women (0.3%). Preterm birth was defined as a delivery 
started spontaneously before a gestational age of 37 weeks. Fetal growth restriction was 
defined a sex specific gestational age adjusted birth weight below 2.3th percentile of the 
study cohort.  
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Uteroplacental vascular resistance measurements 
Ultrasound examination to assess uterine artery resistance index (UtA-RI) was performed 
in mid-pregnancy (20.5 weeks in median with 90% range, 19.4 – 22.1). For each 
measurement three consecutive uniform waveforms were recorded by pulsed Doppler 
ultrasound and the mean was used for further analyses19. Doppler measurements were 
available in 54% of the women. The latter was because Doppler measurements could only 
be performed within one of the research centres. Characteristics of these women did not 
differ from those without a Doppler measurement.
Covariables 
Information on maternal characteristics was obtained directly in one of the research centres 
or by a self-administered questionnaire at enrolment. In this questionnaire ethnic 
background was extracted from information from country of birth of the woman herself 
and her parents and classified as follows: European and non-European. Education (highest 
completed educational level of the mother) was categorized into three levels: low (no 
education or primary school), mid (secondary school) and high (college or university). 
Maternal comorbidity was defined as a mother having a chronic disorder, including 
chronic hypertension, chronic heart disease, diabetes, hypercholesterolemia, thyreoid 
disease and systemic lupus erythematosus. Maternal smoking and alcohol consumption 
habits were assessed by repeatedly applied questionnaires in pregnancy20,21. Maternal 
height and weight were measured at enrolment. Body mass index (BMI) was calculated as 
weight per height squared (kg/m2).
Study population 
Of the total of 8880 mothers who were enrolled during pregnancy, 76% (n = 6748) were 
enrolled before a gestational age of 18 weeks (first trimester)12. Blood samples from 95% 
of these mothers (n = 6398)  were collected before 18 weeks. Before a gestational age of 
25 weeks 93% (n = 8241) mothers were enrolled. Blood samples between 18 and 25 weeks 
(second trimester) were collected in 92% (n = 7616) of the women. With respect to 
mothers with multiple pregnancies in the Generation R Study, we only included the first 
pregnancy to avoid clustering. Women with a stillbirth were also excluded. Consequently 
the present analysis was limited to singleton birth, delivered at a gestational age of more 
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than 22 weeks. sFlt1, PlGF and/or PAI-2 were analyzed in the remaining 7519 women who 
had at least one measurement of sFlt1 or PlGF in <18 weeks or between 18-25 weeks 
gestation (Figure 1). 
Statistical analysis 
Power calculations in the Generation R Study are based on 7000 subjects in the whole 
cohort. For a normally distributed continuous outcome it is possible to detect with a type I 
error of 5% and a type II error of 20% (power 80%) a difference of 0.11 SD in the whole 
cohort if 10% of all subjects has the relevant exposure. For dichotomous outcomes with 
the same type I and II errors, it is possible to detect a relative risk of 1.39 in the whole 
cohort if 10% of all subjects has the relevant exposure and the one year incidence of the 
outcome of interest is 10%. Rates of most dichotomous environmental and genetic 
exposures in the Generation R Study are expected to vary generally between 10 and 20%12.
Standard deviation scores (SDS) were created for each biomarker. A linear regression 
model was used to assess the associations of the maternal characteristics with the 
biomarker. To enable comparisons of the effect estimates between biomarkers and risk 
factors, we analyze our results as change per standard deviation score. These scores enable 
adjustment for gestational age (GA) avoiding the inclusion of non-linear functions of GA 
in models. Our approach for developing reference models for constructing SDS was based 
on the LMS model of Cole and Green22, as implemented in the GAMLSS software of 
Rigby and Stasinopoulos23, and previously applied and reported by us24. Subsequently, all 
factors associated with the biomarkers (P<0.05) were included in the multivariable model 
to assess the associations between the biomarkers and,  placental function and adverse 
pregnancy outcomes. We assessed individual changes in sFlt1 en PlGF (delta sFlt and delta
PlGF, n = 4849 and 4868, respectively) and we assessed sFlt1-PlGF ratios (first trimester 
and second trimester, n = 5495 and n = 6768 respectively). Since sFlt1 and PlGF 
concentrations were not normally distributed (evaluated in a histogram), we applied a
logarithmic transformation for these analyses. To assess the associations of biomarkers 
concentrations, deltas and ratios, with maternal and fetal outcomes, we created deciles of 
each biomarker, the delta and ratio.
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Figure 1 Flow chart of Study participants
Prenatally included mothers (n = 8880)
Plasma samples collected < 18weeks
sFlt1 (n = 6023), PlGF (n = 6035), PAI-2 (n = 5072) 
Plasma samples collected 18-25weeks 
sFlt1 (n = 7372), PlGF (n = 7374)
At least one measurement of sFlt1, PlGF < 18 weeks or 18-
25 weeks (n = 8101)
First singleton birth > 22weeks (n = 7519)
Excluded, due to twin 
pregnancies, more than one 
live birth in the GR Study (n 
= 582)
Missing data on sFlt1, PlGF, 
PAI-2
Plasma samples collected < 18weeks   (n = 6398)
Plasma samples collected 18-25weeks (n = 7616)
Not included
< 18 weeks (n = 2132)  
< 25 weeks (n =  639) 
Included < 18weeks (n = 6748)
Included < 25weeks (n = 8241)
Missing data on plasma samples 
<18 weeks    (n = 350) 
18-25 weeks (n = 625)
Adverse outcome
Preterm birth (n = 359)
Fetal growth restriction (n = 270)
Pre-eclampsia (n = 192)
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Furthermore, because high sFlt1 and low PlGF or PAI-2 concentration may 
represent potential risk factors for adverse outcomes, we additionally used for sFlt1 the 
tenth deciles and for PlGF and PAI-2 the first deciles as cut-off values. For sFlt1 in first 
trimester, concentrations ≤9.83ng/ml and >9.83ng/ml and in second trimester, 
concentrations ≤11.12ng/ml and >11.12ng/ml were considered as low (reference) and as 
high (tenth deciles), respectively. For PlGF in first trimester, concentrations ≤21.30pg/ml
and >21.30pg/ml, and in second trimester, concentrations ≤108.09pg/ml and >108.09pg/ml 
were considered as low (first deciles) and as high (reference), respectively. For PAI-2 in 
first trimester, concentrations ≤23.61ng/ml and ≥23.61ng/ml were considered as low (first 
deciles) and as high (reference), respectively. A multivariable linear regression model was 
used to assess the associations between sFlt1, PlGF and PAI-2 concentrations, and 
placental vascular resistance, placental weight and birth weight. Likewise, multivariable 
logistic regression models were used to study the associations between sFlt1, PlGF and 
PAI-2 and preterm birth, fetal growth restriction and pre-eclampsia. The consideration of 
confounding variables was based on literature25-29. These possible confounding factors 
included maternal age, BMI, parity, maternal ethnicity, maternal education, smoking, the 
use of alcohol and folic acid use as well as gender of the newborn. In the multivariable 
models missing data were completed using multiple imputation (missing: maternal 
ethnicity 7%, maternal education 14%, maternal comorbidity 12%, parity 1%, BMI 1%, 
smoking 13%, alcohol use 13% and folic acid use 25%). Data were imputed according to 
the Markov Chain Monte Carlo method assuming no monotone missing pattern. Five 
imputed data sets were created. Subsequently, multiple regression analyses were 
performed on each imputated dataset and thereafter combined to one pooled estimate30-32.
Since there were no major differences in the observed results between analyses with 
imputed missing data or complete cases only, only results including imputed data are 
presented. 
RESULTS 
Characteristics 
Baseline characteristics are depicted in table 1. Maternal age, BMI, multiparity, European 
ethnicity, smoking and the male sex of the baby were associated with lower sFlt1 
concentrations (P<0.05).  
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Table 1 Characteristics of participants 
Values are mean (sd), median (90% range) or percentages (%). 
Total Normal Preterm birth Intrauterine growth 
restriction
Pre-eclampsia
N = 7519 n = 6782 n = 359 n = 270 n = 192
Gestational age in weeks 
at intake, median  
(90% range)
14.4 (10.9 – 21.8) 14.2 (11.6 -  20.5) 14.8 (11.6 - 20.8) 14.4 (11.4 - 20.8) 14.4 (11.5 - 20.6)
Age in years mean (sd) 29.5 (5.2) 29.6 (5.2) 29.1 (5.6) 29.2 (5.7) 29.3 (5.4)
Age (%)
<25 1605 (21.3) 1388 (21.0) 87 (24.2) 71 (26.3) 39 (20.3)
25-34 4856 (64.6) 4292 (64.8) 228 (63.5) 158 (58.5) 126 (65.6)
≥35 1058 (14.1) 944 (14.3) 44 (12.3) 41 (15.2) 27 (14.1)
Ethnicity (%)
European 3990 (53.1) 3568 (53.9) 173 (48.2) 119 (44.1) 90 (46.9)
Non-European 2993 (39.8) 2598 (39.2) 153 (42.6) 129 (47.8) 87 (45.3)
Missing 536 (7.1) 458 (6.9) 33 (9.2) 22 (8.1) 15 (7.8)
Education level (%)
Primary or no school 397 (5.3) 356 (5.4) 19 (5.3) 13 (4.8) 12 (6.3)
Secondary 2916 (38.8) 2511 (37.9) 162 (45.1) 125 (46.3) 87 (45.3)
University or college 3177 (42.3) 2866 (43.3) 118 (32.9) 90 (33.3) 68 (35.4)
Missing 1029 (13.7) 891 (13.5) 60 (16.7) 42 (15.6) 25 (13.0)
Comorbidity (%)
No 6232 (82.9) 5532 (83.5) 275 (76.6) 219 (81.1) 139 (72.4)
Yes 359 (4.8) 280 (4.2) 34 (9.5) 16 (5.9) 35 (18.2)
Missing 928 (12.3) 812 (12.3) 50 (13.9) 35 (13.0) 18 (9.4)
Parity (%)
Primiparity 4402 (58.5) 3797 (57.3) 245 (68.2) 192 (71.1) 151 (78.6)
Multiparity 3038 (40.4) 2767 (41.8) 110 (30.6) 77 28.5) 40 (20.8)
Missing 79 (1.1) 60 (0.9) 4 (1.1) 1 (0.4) 1 (0.5)
Body mass index in kg/m2 
in median (90% range)
23.8 (19.3 - 33.7) 23.9 (20.2 - 30.8) 24.2 (19.9 - 31.6) 22.7 (19.2 - 29.2) 25.6 (20.1 - 35.7)
Body mass index (%)
<20 676 (9.0) 576 (8.7) 38 (10.6) 42 (15.6) 16 (8.3)
20-24.9 3870 (51.5) 3442 (52.0) 159 (44.3) 147 (54.4) 66 (34.4)
25-29.9 1978 (26.3) 1745 (26.3) 112 (31.2) 55 (20.4) 63 (32.8)
≥30 939 (12.5) 812 (12.3) 47 (13.1) 23 (8.5) 45 (23.4)
Missing 56 (0.7) 49 (0.7) 3 (0.8) 3 (1.1) 2 (1.0)
Smoking (%)
No 4802 (63.9) 4278 (64.6) 204 (56.8) 140 (51.9) 122 (63.5)
Until pregnancy known 569 (7.6) 503 (7.6) 25 (7.0) 18 (6.7) 19 (9.9)
Continued 1147 (15.3) 975 (14.7) 71 (19.8) 73 (27.0) 25 (13.0)
Missing 1001 (13.3) 868 (13.1) 59 (16.4) 39 (14.4) 26 (13.5)
Alcohol (%)
No 3250 (43.2) 2851 (43.0) 156 (43.5) 117 (43.3) 94 (49.0)
Until pregnancy known 907 (12.1) 782 (11.8) 52 (14.5) 36 (13.3) 26 (13.5)
Continued 2400 (31.9) 2153 (32.5) 97 (27.0) 80 (29.6) 50 (26.0)
Missing 962 (12.8) 838 (12.7) 54 (15.0) 37 (13.7) 22 (11.5)
O utcome of pregnancy
Characteristic
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Table 1 Continued 
Maternal age, BMI and the use of alcohol were associated with lower PlGF concentrations 
(P<0.05). Multiparity, low education, non-European ethnicity, smoking and no use of folic 
acid supplements were associated with higher PlGF concentrations (P<0.05). BMI, 
multiparity, smoking and the male sex of the baby were associated with lower PAI-2
concentrations (P<0.05). 
Uterine artery resistance index, placental weight and birth weight 
Placental weight and birth weight were significantly correlated (r=0.63, P=0.01). 
High sFlt1 concentrations in both the first (>9.83ng/ml) and second trimester (>11.1ng/ml) 
were associated with a lower uterine artery resistance index in second trimester (5.2% and 
3.1%, respectively), an increased placental weight (5.8% and 4.5%, respectively) and an 
increased birth weight (1.6% and 3.1%, respectively). Women with low first trimester and 
second trimester PIGF concentrations (<21.3pg/ml and <108pg/ml, respectively) had an 
increased uterine artery resistance index in second trimester (6.1% and 3.9%, respectively), 
a decreased placental weight (4.6% and 5.4%, respectively) and a decreased birth weight 
(3.4% and 4.1%, respectively). Lastly women with low concentrations of PAI-2
Characteristic Total Normal Preterm birth Intrauterine  growth restriction
Pre-eclampsia
Folic acid supplements (%)
No 1634 (21.7) 1413 (21.3) 88 (24.5) 76 (28.1) 43 (22.4)
Yes 3989 (53.1) 3556 (53.7) 175 (48.8) 112 (45.2) 102 (53.1)
Missing 1896 (25.2) 1655 (25.0) 96 (26.7) 72 (26.7) 47 (24.5)
Infant sex (%)
Male 3790 (50.4) 3332 (50.3) 185 (51.5) 142 (52.6) 93 (48.4)
Female 3729 (49.6) 3292 (49.7) 174 (48.5) 128 (47.4) 99 (51.6)
UtA-RI 
mean (sd) 0.54 (0.09) 0.54 (0.09) 0.59 (0.10) 0.58 (0.10) 0.60 (0.12)
Missing 3485 (46.3) 3005 (45.5) 196 (55.0) 133 (49.2) 98 (51.0)
Birth weight in grams
mean (sd)
Missing 46 (0.7) 8 (0.1) 12 (3.3) 0 3 (1.6)
Placental  weight in grams
mean (sd)
Missing 2065 (27.5) 1740 (26.4) 103 (28.7) 60 (22.2) 42 (21.9)
Gestational  age  at birth in 
weeks median (90% range)
39.8 (36.9 - 42.1) 40.3 (38.4 - 41.7) 35.4 (30.4 - 36.7) 39.7 (37.0 - 41.4) 38.3 (32.9 - 40.9)
Missing 0 0 0 0 0
O utcome of pregnancy
647 (140) 510 (150) 464 (118) 575 (164)
3402 (562)
634 (144)
3502 (465) 2330 (645) 2390 (397) 2776 (544)
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(≤23.61ng/ml) in the first trimester had and increased uterine artery resistance index in 
second trimester (1.9%), a decreased placental weight (3.6%) and a decreased birth weight 
(2.7%). Data are shown in table 2  
Adverse pregnancy outcomes 
In table 3 the concentrations of sFlt, PlGF and PAI-2, the delta’s of sFlt1 and PlGF 
between the first and second trimester, and the ratio’s of sFlt1 and PlGF in first and second 
trimester are presented. Table 4 shows the results of the associations between the 
biomarkers and adverse pregnancy outcomes. A high delta sFlt1 (difference between first 
and second trimester concentration, >0.096ng/ml) was associated with an almost two fold 
increased risk of preterm birth (OR 1.86, CI 95% 1.27, 2.74). A trend, though not 
significant, towards a lower risk of fetal growth resistriction was observed for high second 
trimester sFlt1 (>11.12ng/ml) concentrations (OR 0.62, CI95% 0.38, 1.02). First and 
second trimester sFlt1 concentrations were not associated with the occurrence of 
subsequent pre-eclampsia. Low PlGF (≤108.1pg/ml) concentrations in second trimester 
were associated with a two to almost 4 times increased risk of preterm birth (OR 1.64, 
CI95% 1.16, 2.31), fetal growth restriction (OR 2.55, CI95% 2.55, 4.10)  and pre-
eclampsia (OR 3.71, CI95% 2.55, 5.40). In addition, low PlGF (≤108.1pg/ml) 
concentrations in second trimester were considerably associated with early-onset pre-
eclampsia with an almost 12 times increased risk (OR 11.9, CI 95% 4.20 – 33.3). 
Likewise, the delta of PlGF between first and second trimester was associated with a 
substantially increased risk of early-onset pre-eclampsia (OR 9.35, CI 95% 3.12, 28.0). 
Lastly, low first trimester PAI-2 (≤23.6ng/ml) was associated with higher risk of fetal 
growth restriction (OR 2.22, CI 95% 1.39, 3.55).
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Table 2 Associations between sFlt1, PlGF and PAI 2, and uteroplacental vascular 
resistance, placental weight and birth weight. 
Results of multiple linear regression analyses. Values are means with standard deviation scores (sd) and regression coefficients (95% Confidence 
Interval). The regression coefficients reflect the difference in weight in grams for birth weight compared to the biomarkers concentrations: sFlt1, PlGF 
and PAI-2 in the first or second trimester, their ratios and deltas.  
UtA-RI mid = Uterine artery resistance index measured in second trimester. 
# Adjusted for gestational age of sampling/ ultrasound measurement, maternal age, ethnicity, education, comorbidity, body mass index, parity, smoking, 
use of alcohol, use of folic acid supplements. 
₣ Adjusted for gestational age of sampling, gestational age at birth, maternal age, ethnicity, education, comorbidity, body mass index, parity, smoking, 
use of alcohol, use of folic acid supplements and gender. 
*P<0.05 
Table 3 Concentrations of biomarkers, delta’s between second and first trimester and 
ratio’s of sFlt and PlGF. 
Results are shown in median (90 % range)
*P<0.05 
UtA-RI mid Adjusted # Placental weight Adjusted ₣ Birth weight Adjusted ₣
sFlt1 < 18wk
≤9.83ng/ml 0.54 (0.089) 0 (reference) 630 ± 145 0 (reference) 3407 ± 567 0 (reference)
>9.83ng/ml 0.51 (0.082) -0.028 (0.039, '-0.017)* 661 ± 145 36.8 (22.0, 51.1)* 3425 ± 550 55.1 (15.1, 95.2)*
≤ 11.12ng/ml 0.54 (0.090) 0 (reference) 634 ± 146 0 (reference) 3410 ± 557 0 (reference)
>11.12ng/ml 0.52 (0.088) -0.017 (-0.027, -0.008)* 646 ± 154 28.8 (15.2, 42.5)* 3363 ± 615 48.2 (12.2, 84.1)*
Delta sFlt1
≤0.096ng/ml 0.54 (0.088) 0 (reference) 637 ± 145 0 (reference) 3429 ± 556 0 (reference)
>0.096ng/ml 0.54 (0.094) 0.00 (-0.010, 0.011) 616 ± 159 -9.9 (-25.5, 5.6) 3267 ± 646 -61.6 (-103.7, -19.4)*
PlGF < 18wk
≤21.29pg/ml 0.57 (0.096) 0.033 (0.022, 0.044)* 599 ± 136 -29.5 (-44.7, -14.3)* 3272 ± 639 -115.3 (-156.8, -74.0)*
>21.29pg/ml 0.54 (0.088) 0 (reference) 637 ± 146 0 (reference) 3420 ± 554 0 (reference)
≤108.09pg/ml 0.56 (0.099) 0.021 (0.010, 0.032)* 606 ± 147 -34.4 (-47.8, -20.8)* 3258 ± 694 -139.5 (-175.2, -103.8)*
>108.09pg/ml 0.54 (0.088) 0 (reference) 638 ± 146 0 (reference) 3421 ± 545 0 (reference)
Delta PlGF
≤46.4pg/ml 0.54 (0.085) 0.00 (-0.011, 0.011) 618 ± 156 -17.7 (-33.4, -14.3)* 3265 ± 703 -85.3 (-126.4, -44.3)*
>46.4pg/ml 0.54 (0.089) 0 (reference) 636 ± 146 0 (reference) 3424 ± 556 0 (reference)
≤0.00015 0.54 (0.088) 0 (reference) 631 ± 146 0 (reference) 3407 ± 563 0 (reference)
>0.00015 0.54 (0.095) 0.003 (-0.007, 0.014) 648 ± 146 22.6 (7.8, 37.3)* 3313 ± 588 34.4 (-4.86, 73.6)
≤0.000027 0.54(0.089) 0 (reference) 634 ± 145 0 (reference) 3412 ± 550 0 (reference)
>0.000027 0.54 (0.098) -0.002 (-0.011, 0.008) 643 ± 163 22.6 (9.2, 36.0)* 3349 ± 656 19.2 (-16.4, 54.6)
PAI 2
≤23.61ng/ml 0.55 (0.090) 0.010 (0.001, 0.18)* 623 ± 146 -22.8 (-38.5, -7.0)* 3385 ± 585 -93.6 (-136.1, -51.2)*
>23.61ng/ml 0.54 (0.88) 0 (reference) 634 ± 146 0 (reference) 3408 ± 563 0 (reference)
PlGF 18-25wk
sFlt1/PlGF <18wk
sFlt1/PlGF 18-25wk
Biomarker Mean (sd) 
sFlt1 18-25wk
Mean (sd) in grams Mean (sd) in grams
Biomarkers Normal Preterm birth Fetal growth restriction Pre-eclampsia
n = 7117 n = 359 n = 270 n = 192
sFlt < 18wk (ng/ml) 5.14, 2.75 - 9.90 4.67, 2.58 - 9.38 4.18, 2.26 - 8.99* 4.94, 2.45 - 9.82
sFlt 18 - 25 wk (ng/ml) 5.03, 2.31 - 11.3 5.16, 2.35 - 12.6 4.46, 2.00 - 11.2* 5.20, 2.37 - 12.3
Delta sFlt (ng/ml) -0.032, -0.35 - 0.43 0.04, -0.30 - 0.68* 0.036, -0.30 - 0.42 0.011, -0.27 - 0.48*
PlGF < 18wk (pg/ml) 43.5, 21.9 – 120 39.0, 17.7 - 120 38.3, 17.7 - 109 36.3, 17.4 – 111.6
PlGF 18 - 25wk (pg/ml) 203, 111 – 415 199, 10.2 - 440 196, 71.7 - 424 149, 64.8 – 341*
Delta PlGF (pg/ml) 21.4, 10.1 - 47.2 20.9, 5.12 - 44.2 20.5, 5.46 - 50.6 14.7, 4.69 - 35.5*
sFlt/PlGF <18wk 0.00012, 0.00004 - 0.00028 0.00012, 0.00003 - 0.00034* 0.00010, 0.00003 - 0.00030 0.00012, 0.000033 -0.00041*
sFlt/PlGF 18-25wk 0.000025, 0.000009 - 0.000063 0.000025, 0.000009 - 0.000096* 0.000023, 0.000008 - 0.000084* 0.000031, 0.000011 - 0.00013*
PAI 2 (ng/ml) 39.8, 23.7 - 63.5 38.8, 24.4 - 68.9 38.8, 20.2 - 58.4 39.8, 23.7 - 65.6
Pregnancy outcome
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Table 4 Associations between sFlt1, PlGF and PAI 2 and adverse pregnancy outcomes.
Results from simple and multiple logistic regression. Values are odds ratios (95% Confidence Interval).
# Adjusted for gestational age of sampling, maternal age, ethnicity, education, comorbidity, body mass index, parity, smoking, use of alcohol, use of folic 
acid supplements and gender. 
*P<0.05. 
Preterm birth Fetal growth restriction Pre-eclampsia
Biomarkers %  Adjusted# %  Adjusted# %  Adjusted#
sFlt1 < 18wk
≤9.83ng/ml 4.7 1 (reference) 3.5 0 (reference) 2.6 1 (reference)
>9.83ng/ml 4.0 0.76 (0.46, 1.26) 3.2 0.79 (0.47, 1.35) 2.7 0.97 (0.94, 0.99)
sFlt1 18-25wk
≤ 11.12ng/ml 4.6 1 (reference) 3.8 1 (reference) 2.5 1 (reference)
>11.12ng/ml 6.4 1.21 (0.84, 1.74) 3.4 0.62 (0.38, 1.02) 2.7 0.92 (0.53, 1.60)
Delta sFlt1
≤0.096ng/ml 4.1 1 (reference) 3.7 1 (reference) 2.6 1 (reference)
>0.096ng/ml 8.1 1.86 (1.27, 2.74)* 3.1 1.14 (0.70, 1.85) 2.7 0.96 (0.51, 1.78)
PlGF < 18wk
≤21.29pg/ml 6.6 1.39 (0.90, 2.15) 6.2 2.62 (1.68, 4.08)* 5.1 2.46 (1.49, 4.08)*
>21.29pg/ml 4.4 1 (reference) 3.2 1 (reference) 2.4 1 (reference)
PlGF 18-25wk
≤108.09pg/ml 7.1 1.64 (1.16, 2.31)* 7.6 3.61 (2.55, 4.10)* 7.0 3.71 (2,55, 5.40)*
>108.09pg/ml 4.5 1 (reference) 3.3 1 (reference) 1 (reference)
Delta PlGF
≤46.4pg/ml 4.2 1.63 (1.09, 2.44)* 8.2 1.46 (0.93, 2.30) 6.7 1.96 (1.21, 3.18)*
>46.4pg/ml 6.8 1 (reference) 3.2 1 (reference) 2.2 1 (reference)
sFlt1/PlGF <18wk
≤0.00015 4.6 1 (reference) 3.4 1 (reference) 2.4 1 (reference)
>0.00015 5.3 1.11 (0.72, 1.74) 4.0 0.92 (0.55, 1.55) 5.2 2.14 (1.32, 3.47)*
sFlt1/PlGF 18-25wk
≤0.000027 4.4 1 (reference) 3.6 1 (reference) 2.3 1 (reference)
>0.000027 7.5 1.70 (1.14, 2.54)* 5.2 1.15 (0.76, 1.74) 4.7 1.30 (0.80, 2.11)
PAI 2
≤23.61ng/ml 3.8 0.60 (0.34, 1.06) 5.4 2.22 (1.39, 3.55)* 2.6 1.03 (0.54, 1.95)
>23.61ng/ml 4.6 1 (reference) 3.4 1 (reference) 2.7 1 (reference)
Pregnancy outcome
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DISCUSSION 
In this large observational study we show strong associations between angiogenic, 
placental growth and fibrinolytic factors, and placental development and function with 
subsequent risks for significant pregnancy outcomes.  
sFlt1 
High sFlt1 concentrations were associated with lower placental vascular resistance, with 
subsequently higher placental weight and birth weight. Secondly, a high delta of sFlt1 
between first and second trimester was associated with a decreased risk of preterm births. 
These results are in line with earlier studies showing increased sFlt1 concentrations in twin 
pregnancies compared to singletons, suggesting a positive association between trofoblastic 
mass and sFlt1 concentrations. Each trophoblast does not seem to be programmed to 
produce more of the anti-angiogenic protein sFlt1, however more sFlt1 is produced 
because of a greater number of trophoblastic cells. From this we hypothesize that in 
women with higher sFlt1 blood concentrations these elevations might be due to a greater 
amount of trophoblastic mass. 
With respect to preterm birth, Smith et al. described a high sFlt1 in the first 
trimester associated with a decreased risk of preterm births34. Previously expression of 
VEGF has been demonstrated in human myometrium and VEGF peaks have been 
associated with cervical ripening in rats. High sFlt1 could result in a decreased VEGF 
expression and hence protect for a preterm birth.  
Previously, increased sFlt1 concentrations were associated with pre-eclampsia, but 
only up to 5 weeks before onset of pre-eclampsia10. Other studies, however, presented
elevated sFlt1 in first and second trimester as a risk factor for pre-eclampsia35. In contrast 
to this, Kusanovic and Smith showed no association between first trimester sFlt-1 and pre-
eclampsia34,36. Previous studies showing an association between a high sFlt1 and pre-
eclampsia were relatively small and did not always adjust for the gestational age at time of 
sampling. We, like other larger studies, were also unable to confirm a positive association 
between sFlt-concentrations in early pregnancy and pre-eclampsia36.
The up-regulation of sFlt1 release has been described as a result of a hypoxic 
environment. sFlt1 is highly expressed in the first trimester and it seems plausible that low 
first trimester reflects low angiogenic activity and thereby impaired placental development. 
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One consequence of the placental impairment may be fetoplacental hypoxia followed by a 
strong subsequent angiogenic activity. High concentrations of sFlt1 may be a marker of 
this activity37. High sFlt1 concentrations appearing later in pregnancy, lead to endothelial 
dysfunction and mediate a pre-eclampsia38. In the presence of a placenta with an 
appropriate size for gestational age, predisposing cardiovascular and metabolic syndrome-
like disorders might also set off a cascade of placental oxidative stress, resulting in late 
onset pre-eclampsia39. Finally, sFlt1 is mainly produced by placenta, although other 
sources have been described as well such as peripheral blood monocytes and vascular 
endothelial cells40. 
PlGF 
Low PlGF was associated with a higher uteroplacental vascular resistance in mid-
pregnancy, a lower placental weight and birth weight, and considerable high risks for 
preterm births, fetal growth restriction and pre-eclampsia. The significant associations 
between low first trimester concentrations and high uteroplacental vascular resistance in 
mid-pregnancy may indicate early placental insufficiency. Specific binding of sFlt1 to 
PlGF has been suggested as explanation of decreased PlGF in pregnancies with adverse 
outcomes. However, in our study the sFlt1-PlGF ratio was not associated with placental 
weight and birth weight, suggesting another underlying mechanism41. Our first to second 
trimester delta of PlGF concentrations showed an association with a low placental weight 
and birth weight. It has been suggested that remodelling of the spiral arteries probably 
begins in late first trimester after which it is completed by 18-20 weeks of gestation42,43.
This may imply that the second trimester placental development is also important in 
relation to adverse pregnancy outcome. 
With respect to pre-eclampsia, a decrease of PlGF concentrations nine to eleven 
weeks before the development of pre-eclampsia with a considerable decrease five weeks 
before the actual onset, has been described10. We demonstrated strong associations 
between low PlGF concentrations in the first and second trimester and a low delta of PlGF 
and the risk of (early-onset) pre-eclampsia up to 10%. An explanation for development of 
pre-eclampsia would be a primary unknown trigger resulting in an abnormal placentation 
with a decreased release of PlGF, starting in early and second trimester, and with less 
effect on the sFlt1 concentration in first and second trimester. Furthermore, placental 
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insufficiency with low PlGF concentrations in early pregnancy is even more profound in 
early-onset pre-eclampsia.  
PAI-2 
The associations between PAI-2 and birth weight are in agreement with earlier studies44,45.
Because villous cells are the source of PAI-2, its concentrations may reflect trophoblastic 
mass and therefore explain the association with birth weight. The association between 
PAI-2 concentrations and the risk for preterm birth has not been described before. Only 
one study assessed the association between PAI-2 and preterm birth through an association 
with PAI-2 polymorphism46. In accordance with our results, Estelles et al. showed that low 
placental expression of PAI-2 was shown to be associated with fetal growth restriction44.
Finally, low PAI-2 concentrations in third trimester have been associated with pre-
eclampsia9. However, it is uncertain whether the altered concentrations of PAI-2 precede 
the clinical onset. Clausen et al. reported increased PAI-2 concentrations at 18 weeks in 
women who developed pre-eclampsia47. As in our study, Akolekar et al. found no 
association between PAI-2 concentrations in the first trimester and pre-eclampsia9. 
Methodological issues  
This was a large population-based prospective cohort study with an extensive data 
collection. Though participation rates for were relatively high and the ethnic distribution 
differs only moderately from that of the eligible population in the study area, The 
Generation R Study is characterized by a rather highly educated and healthy study 
population compared to available city data12. In cohort studies missing data analysis is 
always a critical issue. We attempted to deal with this by using multiple imputation for 
missing covariables. However, with repect to some outcomes, such as here placental 
weight complete information was missing in almost 27% of the women. Characteristics of 
these women did not differ from those with a known placental weight. For this reason, we 
do not expect that this has signifcantly influenced our results. Though we are aware that 
bias can not be fully excluded. 
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Conclusion 
First trimester sFlt1 concentrations do not seem to be a valuable predictor for adverse 
pregnancy outcomes. Lower PlGF concentrations, however, are associated with increased 
risks of preterm birth, fetal growth restriction and pre-eclampsia. Lower PAI-2
concentrations in the first trimester are associated with a higher risk of fetal growth 
restriction, but not pre-eclampsia. 
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ABSTRACT 
Introduction. Although the aetiology of pre-eclampsia is unknown, there is substantial 
evidence that it finds its roots in abnormal placentation. Prerequisites for successful 
placentation include trophoblast invasion, degradation and remodelling of the uterine 
decidual extracellular matrix, and apoptosis without thrombosis. We tested this hypothesis 
by analyzing the effect of functional polymorphisms in the genes coding for MMP9, 
MMP3 and annexin A5 on the risk of pre-eclampsia using a case-control design. 
Materials and Methods. In 163 women with pre-eclampsia and 163 controls we studied 
the association with polymorphisms in the MMP9 (–1562 C/T), MMP3 (–1612 5A/6A) 
and annexin A5 (–1 C/T) genes using logistic regression analysis.
Results. A lower prevalence of the rare T-allele of the MMP9 (–1562 C/T) polymorphism 
in women with pre-eclampsia was found (odds ratio 0.48, 95% confidence interval 0.25 –
0.90). The distribution of the MMP3 (–1612 5A/6A) and annexin A5 (–1 C/T) gene 
polymorphisms were similar in cases and controls.
Conclusion. Our results suggest that the MMP9-1562T allele is associated with a reduced 
risk of pre-eclampsia and therefore may protect against maladaptation of the spiral arteries 
and decreased decidual degradation. The elevated MMP9 concentrations reported to be 
associated with the –1562T allele might be essential for the development of an adeqaute 
maternal-fetal interface early in pregnancy by facilitating trophoblast apoptosis and 
degradation.
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INTRODUCTION 
Pre-eclampsia is a multiorgan disorder of pregnancy characterized by hypertension and 
proteinuria. Although its aetiology is unknown, there is substantial evidence that pre-
eclampsia finds its roots in abnormal placentation1. Early placentation is determined by 
genes inherited from both parents and maternal environmental factors2. Placentation 
involves trophoblast invasion and angiogenesis and its success is dependent on vascular-,
and endothelial cell function3. In normal early pregnancy, trophoblast invasion is 
characterized by cytotrophoblast migration invading the decidua and replacing the 
endothelium of decidual and myometrial vessels4. Prerequisite for successful trophoblast 
invasion is degradation and remodelling of the uterine decidual extracellular matrix. 
Matrix metalloproteinases (MMP’s) play a crucial role in restructuring the extracellular 
matrix by activating the secretion of gelatinases, collegenases and proteolytic enzymes5,6.
Several members of this enzyme family are present at the foetal- maternal interface. 
Cytotrophoblast MMP9 activity has been shown to be increased in human placental tissue7.
A second matrix metalloproteinase important for placenta development is matrix 
metalloproteinase 3. MMP3 is produced by first trimester decidual cells and 
cytotrophoblast cells8. MMP3 activates MMP9 and MMP2 and is implicated in connective 
tissue destruction and associated with endothelial cell dysfunction. The inability to produce 
sufficient matrix metalloproteinases may be an early manifestation of abnormal 
placentation such as in pre-eclampsia9.  
Apoptosis has also been implicated to play a role in the failure of extravillous 
trophoblast invasion observed in placentas from women with pregnancies complicated by 
pre-eclampsia10. Programmed apoptosis is regulated through annexin A5, which is 
expressed in syncytotrophoblasts and endothelial cells. Placentas of patients with pre-
eclampsia and the antiphospholid syndrome demonstrate diminished annexin A5 coverage 
on the placental villi. Annexin A5 is a strong anticoagulant protein due to the shielding of 
negatively charged phospholipids. Exposure of negatively charged phospholipids 
accelerates coagulation11. 
Given the strictly regulated and co-ordinated actions of matrix metalloproteinases, 
apoptosis and coagulation on normal placentation we studied the effect of functional 
polymorphisms in the genes coding for MMP9 (–1562 C/T), MMP3 (–1612 5A/6A) and 
annexin A5 (–1 C/T) on the risk of pre-eclampsia using a case-control design. We selected 
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these polymorphisms because they are functional promoter polymorphisms and may affect 
transcription rate and amount of protein synthesized12,13,14.
MATERIAL AND METHODS 
Study group 
Women for the case-control study were recruited from the obstetric clinics of the Leiden 
University Medical Centre (n=99 per group) and the St. Joseph Hospital Veldhoven, The 
Netherlands (n=64 per group) as has previously been described15. Women who had 
developed pre-eclampsia during their first pregnancy (n=163) and control subjects (n=163) 
were selected from a computer database and patient charts. The study protocol was 
approved by the local Ethics Review Board. Data were analyzed anonymously.  
Pre-eclampsia was defined by means of strict criteria: as a rise of blood pressure (30 mm 
Hg systolic or 15 mm Hg diastolic over values in the first 20 weeks or, if blood pressure 
was unknown before 20 weeks gestation); late-pregnancy hypertension (defined as an 
absolute blood pressure 140/90 mm Hg); and proteinuria (2+ [1 g/l] on a voided 
specimen or 1+ [0.3 g/l] on a catheterized specimen). Severe pre-eclampsia was defined 
as an absolute diastolic blood pressure of 110 mm Hg and proteinuria (2+ [1 g/l]) on a 
catheterized specimen on admission. HELLP (haemolysis, elevated liver enzymes, and low 
platelets) was defined as thrombocytes <100x109/l, and both ASAT (aspartate 
aminotransferase) and ALAT (alanine aminotransferase) >70 U/l and LDH (lactate 
dehydrogenase) > 600 U/L. 
Control subjects were selected according to the following criteria: first pregnancy, no rise 
in blood pressure, no hypertension or proteinuria, similar age (5 years) and a delivery 
date as close as possible to the delivery date of the case subject. Both cases and controls 
that had multiple pregnancies, chronic hypertension, renal disease, diabetes, collagen 
vascular diseases, cancer, or thrombosis before their first pregnancy were excluded from 
the study. Clinical characteristics of both groups have been described before15. Data 
concerning smoking were explored in the medical record, which were noted during the 
first antenatal visit.
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Genotyping of polymorphisms in MMP9, MMP3 promoter region and annexin A5 
Blood was collected from the antecubital vein into Monovette tubes (Sarstedt, Nümbrecht, 
Germany) containing 0.106 mol/L trisodium citrate. High-molecular-weight 
deoxyribonucleic acid (DNA) was isolated from leukocytes and stored at -20oC.  
The –1562 C/T polymorphism (rs3918242) in the promoter of the MMP9 gene was 
analyzed using polymerase chain reaction (PCR). The reaction mixture contained 6.25 
pmol of each primer (forward primer: 5’-GCC TGG CAC ATA GTA GGC CC-3’, reverse 
primer: 5’-CTT CCT AGC CAG CCG GCA TC-3’), 1 * 104 pmol of each nucleotide, 1.3 
U of Taq DNA polymerase (Amersham Biosciences) and 5 ng of genomic DNA. The PCR 
started with 4 min denaturation at 96C, followed by 33 cycles of 1 min at 95C, 1 min at 
53C and 2 min at 72C. Subsequently, the 434 bp PCR product was digested with the 
restriction enzyme SphI (Roche), the digested products separated on a 1.5% agarose gel 
and visualized using ethidiumbromide. The C allele remains undigested (434 bp) while the 
T allele is digested in fragments of 193 and 241 bp. 
The –1612 5A/6A polymorphism (rs3025058) in the MMP3 gene was analyzed using the 
Taqman allelic discrimination assay (Applied Biosystems, Foster City, Calif). Primer and 
probe sequences were optimized using the SNP assay-by-design service of Applied
Biosystems (for details, see http://store.appliedbiosystems.com). Reactions were performed 
with the Taqman Prism 7900HT 384 wells format and started with 10 min denaturation at 
95ºC, followed by 40 cycles of 15 sec at 92°C, and 1 min at 60°C for annealing/extension. 
The results were analyzed with the Taqman Analyser and its special software.   
The –1 C/T polymorphism in the annexin A5 gene (rs11575945) was analyzed by RFLP:
Exon 2 of the annexin A5 gene was amplified out of genomic DNA by PCR. The PCR 
reaction was carried out in a final volume of 50 l reaction mixture containing 50 ng 
genomic DNA, 1.5 U Taq DNA polymerase (Pharmacia), 5 l PCR reaction buffer (10x) 
containing 1.5 mM MgCl2, 0.2 mM of each dNTP and 10 pmol of forward (5’-CGC TAA 
GCC CGA GGT TTC T-3’) and reverse (5’-CGC AGC ATA CAA AGT TGT GG-3’) 
primer. The PCR reactions were performed in a Perkin Elmer 9700 thermocycler (PE 
Applied Biosystems). Cycling conditions for PCR were as follows, an initial denaturation 
at 94C for 10 min followed by 35 cycles of denaturation at 94 C for 30 s, annealing at 61 
C for 30 s and elongation at 72 C for 30 s. The last cycle was followed by an additional 
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elongation step of 72C for 7 min and a cooling step to 4 °C.  The amplicons were 
subsequently digested with the restriction enzyme NcoI, and analysed by PAGE (7%), 
after staining by ethidium bromide. The T allele remains undigested (130 bp) and the C 
allele was digested in fragments of 64 and 66 bp. Impaired cleavage occurs in the presence 
of the -1 C/T polymorphism. Laboratory personnel were blinded to case-control status. In 
each PCR run samples with known genotypes were included. We also re-analyzed 10% of 
the samples (at random), and the results were confirmed.  
Genotyping was unsuccessful in 30/326 subjects for MMP9 (–1562 C/T), in 4/326 for 
MMP3 (–1612 5A/6A) and in 3/326 subjects for annexin A5 (–1 C/T). At least three 
attempts were made to genotype the samples. In the analysis, positive controls were added 
and confirmed as well as negative controls.
Statistical analysis 
In this case-control group, we calculated based on a population frequency of the T allele of 
the MMP9 (-1562C/T) polymorphism of 13% that with a power 80% and =0.05, an Odds 
Ratio (OR) of 2.2 would be detected for carriers of the T allele. The power calculations 
were not performed for the subgroups (eclampsia, HELLP). Odds ratios are calculated by 
logistic regression and are not affected by the correction made for the total number of cases 
and / or controls and successfully genotyped cases and / or controls. The odds ratios were 
calculated as estimates of the relative risks by simple cross-tabulation for the –1562 C/T 
polymorphism in the promoter of the MMP9 gene, the  -1612 5A/6A polymorphism in the 
promoter of the MMP3 gene and the –1 C/T polymorphism of the annexin A5 gene. We 
analyzed the association between carriership of the rare alleles (-1562 T) MMP9, (-1612
5A) MMP3 and (-1T) annexin A5 with pre-eclampsia using unconditional logistic 
regression techniques that allowed adjustments for other risk factors for pre-eclampsia like 
a family history of hypertension, smoking, a high body mass index (BMI>25). The odds 
ratios are not affected by the correction made for the total number of cases and / or controls 
and successful genotyped cases and / or controls. The statistical analysis has been 
calculated by the SPSS package program (SPSS 12).
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RESULTS 
The frequency of the MMP 9 (-1562 T) allele was 0.06 in women with pre-eclampsia and 
0.12 in controls. Women carrying the T-allele were less likely to develop pre-eclampsia 
when compared with women with the CC genotype (Table 1). Adjustment in the logistic 
analysis for clinical parameters previously associated with pre-eclampsia like familial 
hypertension, obesity and smoking did not influence the association of the MMP9 (–1562 
T) allele and the risk of pre-eclampsia (Table 2). As expected a trend was observed 
towards an increased risk for pre-eclampsia in women with a history of hypertension in the 
family and in women with a high body mass index, whereas a trend towards a lower risk 
was observed for smoking. In this study we did not observe an association between the 
presence of the –1562 T allele (CT+TT genotypes) with severe pre-eclampsia, eclampsia 
or HELLP. 
Table 1 Genotype frequencies of the MMP9 (–1562 C/T) polymorphism in women 
with pre-eclampsia and control subjects 
# odds ratios were determined using logistic regression analysis  
CI = confidence interval 
Odds ratio#
(95% CI)
Genotype
MMP 9
CC 128 88.3 118 78.1 1
CT 16 11.0 31 20.5 0.48 (0.25 – 0.91)
TT 1 0.7 2 1.3 0.46 (0.04 – 5.16)
CT+TT 17 11.7 33 21.9 0.48 (0.25 – 0.90)
Women with pre-eclampsia 
(n=145)
Control subjects 
(n=151)
No. % No. %
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Table 2 Ratios and odds ratios for different genotypes after adjustment 
in the logistic analysis for clinical parameters previously associated  
with pre-eclampsia  
# odds ratios were determined using logistic regression analysis 
High body mass is defined as a BMI > 25 
The observed frequency of the MMP3 5A allele was 0.49 in women with pre-eclampsia 
and 0.54 in controls (Table 3). There was no significant difference in the frequency of the 
three genotypes of the MMP 3 (5A5A, 5A6A, 6A6A) gene or the presence of the 5A allele 
(5A5A, 5A6A) between women who developed pre-eclampsia and control subjects. The 
presence of the 5A allele (5A5A, 5A6A genotypes) was not associated with severe pre-
eclampsia, eclampsia or HELLP.  
The observed frequency of the annexin A5 T allele was 0.14 in women with pre-eclampsia 
and 0.13 for controls. There was no significant difference in the frequency of the three 
genotypes of the annexin A5 gene (CC,CT,TT) gene or the presence of the T allele 
(CT,TT) between women who developed pre-eclampsia and control subjects. The presence 
of the T allele (CT,TT genotypes) was not associated with severe pre-eclampsia,  
eclampsia or HELLP.  
Ratio cases versus 
controls
Odds ratio#
Variable (number 145/151) (95% CI)
MMP 9 –1562 CT+TT 17/33 0.51 (0.28 – 0.92)
Hypertension in family 8/12 1.53 (0.95 – 2.48)
High body mass index 8/11 1.48 (0.91 – 2.42)
Smoking 1/10 0.48 (0.24 – 0.96)
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Table 3 Genotype frequencies in the MMP3 (-1612 5A/6A) gene in women with pre- 
eclampsia and control subjects 
# odds ratios were determined using multiple logistic regression analysis 
CI = confidence interval 
No synergistic effects were found for the various combinations of the polymorphisms in 
the matrix metalloproteinase 9 (–1562 C/T), matrix metalloproteinase 3 (–1612 5A/6A) 
and annexin A5 (–1 C/T) gene were found (0.48 (CI 95% 0.26 – 0.91), 1.03 (CI 95% 0.78 
– 1.37), 0.93 (CI 95% 0.65 – 1.76), respectively).  
For all three polymorphisms the genotypic distributions were in agreement with Hardy 
Weinberg equilibrium. 
Table 4 Genotype frequencies in the annexin A5 (–1 C/T) polymorphism in women 
with pre-eclampsia and control subjects 
# odds ratios were determined using logistic regression analysis 
CI = confidence interval
Odds ratio#
(95% CI)
Genotype No. % No. %
MMP 3
5A/5A 38 23.9 48 29.4 1
5A/6A 79 49.7 80 49.1 0.80 (0.47 – 1.36)
6A/6A 42 26.4 35 21.5 0.66 (0.36 – 1.22)
5A/5A + 5A/6A 117 73.6 128 78.5 1.12 (0.86 – 1.45)
Women with pre-eclampsia 
(n=159)
Control subjects 
(n=163)
Odds ratio#
(95% CI)
Genotype
annexin A5
CC 117 72.2 120 74.5 1
CT 44 27.2 39 24.2 0.86 (0.52 – 1.43)
TT 1 0.6 2 1.2 1.95 (0.17 – 21.8)
CT+TT 45 27.8 41 25.5 0.88 (0.54 – 1.46)
Women with pre-eclampsia
(n=162)
Control subjects
(n=161)
No. % No. %
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DISCUSSION 
In women with pregnancies complicated by pre-eclampsia abnormal placentation can be 
partly explained by the inadequate trophoblast invasion and maladaptation of the spiral 
arteries early in pregnancy. The rare T-allele of this polymorphism has been previously 
associated with increased MMP9 levels16. Our findings of a lower prevalence of the rare T 
allele of the MMP9 polymorphism in women with pre-eclampsia suggest that women with 
uncomplicated pregnancies have more often increased MMP9 levels and may therefore 
have an increased capacity of restructuring the extracellular matrix at the foetal-maternal 
interface. In addition, the decreased MMP9 activity has been reported in primary cultures 
of cytotrophoblasts isolated from placentas obtained from women with pre-eclampsia 
(assuming that the maternal genotype is inherited)17. However, no differences in MMP9 
expression in early pregnancy in chorion villous biopsies were described between women 
who later developed pre-eclampsia and women who had an uncomplicated pregnancy18.
Differences in sample size, definition of pre-eclampsia and methodology of 
metalloproteinase detection (protein or RNA expression) may explain the differences19.
The frequencies of the MMP9 (–1562 C/T) genotypes in the control subjects were similar 
to those reported previously in a population of the United Kingdom and France16,20.
MMP9 (-1562 C/T) has also been described as a predictor of cardiovascular disease20-24.
Data from epidemiological studies suggest that cardiovascular disease and pre-eclampsia 
share common biological pathways, being endothelial cell dysfunction and risk factors for 
atherosclerosis. Moreover, epidemiological studies have found an association of pre-
eclampsia and cardiovascular disease in later life and therefore pregnancy may be 
considered as a test for risk of atherosclerosis later in life25. Surprisingly, we found a lower 
frequency of the T allele of the MMP9(–1562 C/T) polymorphism in women with pre-
eclampsia. In order to speculate on the underlying mechanism of this finding, we suggest 
that the MMP9 induction has a different role at the fetal-maternal interface than in the 
vascular remodelling during atherogenesis. Apoptosis and degradation of the 
cytotrophoblastcells are normal, physiologic constituents of trophoblast turnover26. High 
MMP9 concentrations, as found in cytotrophoblasts in human placental tissue7, might in 
fact be essential for the trophoblast apoptosis and degradation, which is needed for the 
development of an adequate fetal-maternal interface early in pregnancy. In contrast, in pre-
eclampsia normal apoptotic release is reduced resulting in an inadequate fetal-maternal 
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interface and finally endothelium dysfunction due to aberrant gene-environment interaction 
including low MMP9 levels. In this respect it is of interest to note that smoking, which is 
associated with increased plasma MMP9 levels20 is a risk factor for cardiovascular disease 
but protects against preeclamspia27. Moreover, MMP3 and annexin A5 have been reported 
to play a role in both abnormal placentation and cardiovascular disease in later life28,14.
MMP3 and MMP9 activity was found to be decreased in extracts of umbilical cord artery 
taken from control newborns compared to those taken from newborns delivered by 
mothers with pre-eclampsia29.
Recently Pöllänen et al. observed a concerted action of the MMP3 and MMP9 gene 
promoter polymorphisms as risk factors for the development of complicated coronary 
artery plaques30. Therefore we analyzed the effects of the simultaneous presence of 
polymorphisms in MMP9 (–1562 C/T), MMP3 (–1612 5A/6A) and annexin A5 (–1 C/T) 
on the risk of pre-eclampsia. In atherosclerosis the balance between proliferation and cell 
death is highly dependent on matrix remodelling by growth factors, cytokines and MMPs 
leading to proliferation or differentiation as well as to apoptosis. The absence of such an 
association between the co-expressed alleles of MMP3, MMP9 and annexin A5 and pre-
eclampsia in our study suggests that environmental and other genetic factors may be 
involved in abnormal placentation and the development of atherosclerosis in later life. 
However, this will need to be confirmed in larger studies.  
In conclusion, we found a lower prevalence of the rare T-allele of the MMP9 (–1562C/T) 
polymorphism in women with pre-eclampsia suggesting a genetically determined 
mechanism, which protects women against pre-eclampsia.   
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INTRODUCTION 
The aim of the present thesis was to elucidate risk factors in early pregnancy and markers 
for placental related disorders, in particular pre-eclampsia, and in line with these findings
gain more knowledge about the etiology of placental related pregnancy disorders. We will 
summarize the main findings, followed by an outline of interpretations of the findings. 
First, definitions of several placental disorders are discussed followed by risk factors, 
markers and biophysical tests, and the associations with placental disorders. Second, 
implications for pathogenesis are discussed. Finally, we discuss implications of our results 
for clinical practice and future research. 
SUMMARY OF FINDINGS 
Risk factors 
Several easily accessible risk factors in early pregnancy for development of pregnancy-
induced hypertension or pre-eclampsia were confirmed. Some risk factors seem to apply to 
both complications of pregnancy whereas others differ between pregnancy-induced 
hypertension and pre-eclampsia. This may point at differences in the pathophysiology of 
the two disorders. In addition, we added the question whether risk factors are different not 
only for both disorders but also for nulliparous and multiparous women. Table 1 shows the 
risk factors for pregnancy-induced hypertension and pre-eclampsia for nulliparous and 
multiparous women (chapter 2.1). Interestingly, we found that headache, which is not often 
described before, especially in the first trimester is associated with pregnancy-induced 
hypertension and pre-eclampsia in multiparous women. In chapter 2.2 and 2.3 we 
described more into detail that low educated pregnant women had an increased risk for 
pregnancy-induced hypertension and pre-eclampsia compared with high-educated women. 
A clinical prediction model consisting of three variables (maternal weight, diastolic blood 
pressure and systolic blood pressure) easily available to midwives and obstetricians 
demonstrated adequate performance for classifying women according to their risk of 
developing hypertension before 36 weeks of gestation. We described in chapter 2.4 the 
validation study of this prediction model. In our study the predictive ability of the model, 
that can accurately identify women at very low (<1%) and very high risk (>16%) of 
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becoming hypertensive during pregnancy before 36 weeks of gestation was confirmed. We 
could identify using this model 13.4 % women at very low risk and 12.8% women at very 
high risk. In daily practice we use personal interviews for the risk assessment in pregnancy 
as a sole source of exposure information. Our study showed that the validity of the 
maternal self-reported pre-eclampsia per se is moderate (50%), however, for hypertension 
in pregnancy relative adequate (81%)(chapter 2.5).  
Table 1 Risk factors for pregnancy-induced hypertension and/ or pre-eclampsia 
              Disorder
Risk factor
Pregnancy-induced hypertension Pre-eclampsia
nulli multi nulli multi
Age > 40 years 0 0 + 0
Increased body mass + + + +
European ethnicity + 0 0 -
Surinamese ethnicity 0 0 + 0
History of hypertensive 
disorders
- + - +
Low maternal birth 
weight
0 0 + 0
Twin pregnancy 0 0 + 0
Chronic hypertension 0 +
Headache 0 + 0 +
0 no association, + positive association (higher risk), - negative association (lower risk) 
Markers 
Six components of the fibrinolytic systems (tissue-type plasminogen activator (tPA) 
urokinase-type plasminogen activator (uPA), plasminogen-activator-inhibitor 1 (PAI-1), 
plasminogen-activator-inhibitor 2 (PAI-2), tPA/PAI-1 and uPA/PAI-1) were described 
longitudinally from the preconception period onwards throughout pregnancy up to 6 weeks 
after pregnancy (chapter 3.1). Profound changes in concentrations of the 
plasminogenactivator system in blood of women with uneventful pregnancy indicates the 
presence of a delicate gestational balance between activators and inhibitors of fibrinolysis. 
PAI-2, soluble fms-like tyrosine kinase-1 (sFlt-1), placental growth factor (PlGF) 
concentrations in early pregnancy in association with pregnancy outcomes were 
subsequently studied (chapter 3.2). Table 2 shows the associations of  PAI-2, sFlt-1 and 
PlGF concentrations in first and second trimester and the risk of  pre-eclampsia, 
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intrauterine growth restriction or spontaneous preterm birth.  Lower PAI-2 concentrations 
in the first trimester are associated with a higher risk of intrauterine growth restriction, but 
not with pre-eclampsia. We found that first trimester sFlt-1 concentrations do not seem to 
be a valuable predictor for adverse pregnancy outcomes. Lower PlGF concentrations are 
associated with increased risk of pre-eclampsia, intrauterine growth restriction and preterm 
birth (in second trimester). Finally, in chapter 3.3, we described a lower prevalence of the 
rare T allele of the matrix metalloproteinase 9 polymorphism (MMP9 (-1562C/T)) in 
women with pre-eclampsia which is suggested to protect against maladaptation of the 
spiral arteries and decreased decidual degradation. This finding suggests a genetically 
determined mechanism, which protects women against pre-eclampsia. 
Table 2 Associations of PAI-2, sFlt-1, PlGF, sFlt-1/PlGF ratio  
and MMP9 and pre-eclampsia, intrauterine growth restriction or  
spontaneous preterm birth 
Disorder
Markers 
Pre-eclampsia Intrauterine growth  
restriction
Spontaneous preterm 
birth
<18 
weeks
18-25 
weeks
<18 
weeks
18-25 
weeks
<18 
weeks
18-25 
weeks
PAI-2 0 + 0
sFlt-1 0 0 0 0 0 0
PlGF + + + + 0 +
sFlt-1/PlGF ratio + 0 0 0 + 0
MMP9 (-1562C/T) -
0 no association, + positive association (higher risk), - negative association (lower risk) 
INTERPRETATION OF FINDINGS 
Placental related disorders 
The two stages model of pre-eclampsia is widely accepted1. The first stage, poor 
placentation, occurs in the first half of pregnancy when there are no clinical features of the 
disorder. The second stage, arises from factors released by the placenta. Defective deep 
placentation has been associated with a spectrum of complications of pregnancy, including 
pre-eclampsia, intrauterine growth restriction and spontaneous preterm birth2. By what 
exact mechanism the placenta is disturbed in women who develop adverse placental 
related pregnancy disorders is unknown. Identification of risk factors for placental related 
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disorders may help us to elucidate the etiology of placental related disorders. In addition, 
the identification of risk factors for placental related disorders at an early stage of 
pregnancy, increasing awareness and focused surveillance.
Pre-eclampsia is a common complex disease, an important cause of maternal death 
worldwide. All definitions of pre-eclampsia are attempts to describe what is observed in 
clinical terms. Pre-eclampsia is better defined as a syndrome3. A syndrome cannot be 
precisely defined in terms based on its etiology or defined pathogenesis. Pre-eclampsia is a 
multi-system disorder characterized by the new onset of hypertension and either 
proteinuria or end-organ dysfunction in the last half of pregnancy4. It is possible that 
within the syndrome there may be different phenotypes with pathogenic pathways that 
differ between the subtypes (pregnancy-induced hypertension, pre-eclampsia, HELLP and 
eclampsia). The capacity to recognize and to exploit different subtypes is of obvious 
importance for prediction, prevention, and treatment.   
Intrauterine growth restriction is a second, complex disease which is also defined by 
clinical terms. Studies have been hampered by the widespread practice of using the terms 
intrauterine growth restriction and small for gestational age synonymously4. However, 
small for gestational age refers to a birth weight below a given threshold for its gestation, 
but a significant proportion of smallness due to constitutional or physiological causes is 
not pathological5. This means that the association between pathological smallness and 
adverse outcome is blurred; According to the standards mentioned before pathological 
smallness is not always pathological and normal could be pathological. 
For a long time spontaneous preterm birth (70 % of all premature births) was viewed as an 
unpredictable and inevitable fact of life. Medical efforts thus focused on improving the 
consequences of prematurity rather than preventing its occurrence. Neonatal outcomes has 
been improved, but it remains one of the biggest problems in obstetrics in terms of both 
suffering infants and their families and the economic burden on society7. In addition, the 
world’s preterm birth rate has been consistently rising8. Therefore, identification early in 
pregnancy and subsequent prevention is needed in order to improve health of the next 
generation and decrease costs related to long term effects of prematurity.  
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Risk factors 
Redman described different stages of pregnancy9. This thesis describes risk factors for 
hypertensive disorders in pregnancy which can be identified in different stages of 
pregnancy (figure 1)9. Stage 1 and 2 of pre-eclampsia are generally accepted. Earlier stages 
are hypothetical. As suggested by Redman, stage -1 comprises maternal toleration to 
paternal antigens expressed in semen or on sperm. Stage 0 comprises preconception early 
recognition by uterine decidual immune cells of paternal antigens expressed on trophoblast 
immediately after implantation extending to the time that uteroplacental circulation opens 
into the intervillous space. It is proposed that poor recognition leads to reduced trophoblast 
and placental growth9. 
Figure 1 Risk factors or symptoms for hypertensive disorders in the different stages9
Stages of pregnancy
Preconception
(stage -1)
Conception
(stage 0)
Poor 
placentation
(Stage 1)
Systemic phase
(stage 2)
No 
symptoms
Symptoms
Risk factors
Maternal 
factor
-advanced
maternal age
-parity
-obesity
-ethnicity
-education
-socioeconomic
status
-disease#
-history of
hypertension in
pregnancy
-maternal birth
weight
-familial disease
-disease #
-smoking
-alcoholics
-headache
-multiple 
gestation
-nutrition
-smoking
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Advanced or low maternal age, obesity, maternal disease, non-Caucasian ethnicity, low 
socio economic factors, history of pre-eclampsia, intrauterine growth restriction or preterm 
birth and familial history are risk factors associated with different placental related 
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disorders known before conception. Among women considered as high risk (including 
women with a history of pre-eclampsia, multiple pregnancy, family history, nulliparity, a 
raised body mass, maternal age > 40 years) approximately 25% will develop pre-eclampsia 
compared with the 5% in the general population10. Advanced maternal age and obesity 
suggest endothelial dysfunction involved in placental related disorders in pregnancy11,12. 
Almost half of the overall occurrence of pre-eclampsia may be related to nulliparity. In 
terms of public health, nulliparity is therefore the most important risk factor for pre-
eclampsia13. In terms of pathophysiology, it is often suggested that mechanisms may differ 
between nulliparous and multiparous women14. Differences in immunological responses, 
angiogenic factor profile or reactivity to insulin resistance between first pregnancies and 
subsequent pregnancies are described15. Simon et al. showed in a systematic review that 
parity is largely ignored in randomized controlled trials concerning the prevention of pre-
eclampsia, which raises difficulties in interpreting results16. However, increased awareness 
of parity will gain more insight in the different mechanisms of placental related diseases 
(nulliparous versus multiparous hypertensive complications in pregnancy). In the 
following paragraph we will discuss potential risk factors to identify high risk pregnancies 
for pre-eclampsia in an assessment in early in pregnancy. 
Firstly, there is a concern that a higher maternal age (>40years) may be associated with an 
increase in obstetric complications secondary to a revealing of underlying medical disease 
or diminished ability to adapt to physical stress that may accompany ageing17,18. The 
increased incidence of chronic hypertension and pregnancy-induced hypertension have 
been confirmed in prior studies and mostly reflects these age-related changes19. Therefore, 
obstetric complications associated with advanced maternal age are not associated only with 
advanced maternal age per se but also with the  concurrently maternal underlying diseases. 
Secondly, obesity is characterized by a systemic inflammatory response in non-pregnant 
individuals20. Several of the metabolic and inflammatory disorders that characterize an 
increased body mass index have also been documented in pregnant women21. An 
inflammatory response is amplified in obese individuals because of the pro-inflammatory 
output from adipose tissue and this may account for the increased susceptibility of obese 
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pregnant women to fail the stress test of pregnancy, contributing to the clinical 
manifestation of pre-eclampsia. Other important mediators of obesity may be oxidative 
stress, insulin resistance, reduced immune function, other markers of dyslipidemia, or 
lifestyle factors such as poor prenatal diet and prenatal physical inactivity. Therefore, in 
addition to advanced maternal age, obesity is an important risk factor for complicating a 
pregnancy by pre-eclampsia and adds its unfavorable outcome by several pathologic 
pathways. 
Further, ethnicity and familial history of pre-eclampsia imply a genetic component in the 
development of placental related disorders. A woman who becomes pregnant by a man 
whose previous partner had pre-eclampsia is also at a higher risk of developing pre-
eclampsia22. From an epidemiologic point of view paternal risk factors should be 
associated with pregnancy-induced hypertension or pre-eclampsia. In this thesis we were, 
however, not able to confirm this. Recently, Boyd et al. described in a large study with 
almost 1.4 million pregnancies limited associations between paternal family history of pre-
eclampsia and the risk of pre-eclampsia23. The association between maternal genetic 
polymorphisms and development of diseases in pregnancy is an active area of 
investigation. Studies of candidate genes have been on a small scale and have not yielded 
clinical reliable results24. Genetics plays an important role in the development of placental 
related disorders. Interesting is theoretically that the paternal genes are likely to play a role 
in pre-eclampsia since the fetus consists of 50% foreign to the mother, however research is 
still searching for the proven role of paternal genes.  
Fourth, women with a low socioeconomic status seem to have a lower chance of 
uncomplicated  pregnancy. They are more likely to develop hypertension disorders in 
pregnancy  as described in this thesis. There is evidence that women with hypertension in 
pregnancy have a higher risk for future hypertension and cardiovascular diseases. 
Hypertensive disorders in pregnancy and cardiovascular diseases share risk factors as well 
as underlying metabolic abnormalities suggesting similarities in etiology. Both 
hypertensive disorders in pregnancy and cardiovascular diseases in later life have been 
proposed to be associated with the presence of endothelial dysfunction prior to pregnancy. 
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Further, we demonstrated a strong association between previous gestational hypertension 
and pre-eclampsia, and the risk of pregnancy induced hypertension and pre-eclampsia in a 
subsequent pregnancy (up to a tenfold increased risk for pre-eclampsia). This supports the 
idea that the first pregnancy is a stress-test for later life: women who fail the test, i.e. 
develop hypertension during pregnancy are at increased risk for development of 
hypertensive diseases in a subsequent pregnancy and of cardiovascular events later in life
due to an unfavorable risk factor profile25,26. A large study from Denmark suggested that 
the timing of pre-eclampsia onset should be taken into consideration if pre-eclampsia 
heritability and etiology are to be unraveled. In their study previous early-, intermediate-,
or late-onset pre-eclampsia increased the risk of recurrent pre-eclampsia with the same 
time of onset 25.2 times, 19.7 times and 10.3 times, respectively, compared with having no 
such history23. A history of pre-eclampsia or pregnancy-induced hypertension gives 
information about the etiology of placental related disorders but also about future risks of 
the woman and should be added to the early assessment in pregnancy for high-risk 
pregnancy. 
Six, maternal low birth weight associated with pre-eclampsia supports the hypothesis of 
fetal origin of an adult disease. There is evidence to link low birth weight with endothelial 
dysfunction in adults especially in hunger winter studies27. Low birth weight is associated 
with cardiovascular diseases in later life as well28. Maternal predisposition for 
cardiovascular disease might contribute to impaired placentation and subsequent 
subclinical maternal endothelial dysfunction might predispose to the development of pre-
eclampsia and therefore should be added to the early assessment in pregnancy for high-risk 
pregnancy. 
Further, headache in early pregnancy appeared to be associated with pre-eclampsia later in 
pregnancy. The association of headache in early pregnancy and pre-eclampsia has not been 
described before. Headache can be diagnosed as a primary headache or secondary 
headache29. Most headaches seen in women are primary headaches (migraine, tension-type 
headache, and occasionally cluster headache). A secondary headache is secondary to a  
pregnancy complication or condition that presents during pregnancy (eg, eclampsia). 
Several studies have explored a possible association between migraine and pre-eclampsia 
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with contradictory results. Adverse perinatal outcomes, characterized by ischemic 
placental disorders, are noted to be increased among pregnant women with migraine30.
Observed associations of migraine and pre-eclampsia are biologically plausible. Abnormal 
vascular reactivity, increased platelet aggregation, and a high underlying ischemic stroke 
or cardiovascular risk profile may account for observed associations. Williams et al. 
described elevated blood pressures among pregnant women with migraine compared to 
pregnant women without migraine31. Low birth weight and preterm birth are recognized to 
be more common among pregnant women with migraines as well32,33. In our study the 
association of headache in early pregnancy and pre-eclampsia could not be explained by 
maternal age, migraine, consuming of coffee or an increased body mass index in our study. 
The relationship between pre-eclampsia and headache in early pregnancy is interesting. 
Headache in early pregnancy could be an early sign of placental related diseases or 
migraine. 
Finally, the negative effect of smoking on fetal health is well established. Cigarette 
smoking has been associated with intrauterine growth restriction and preterm birth. While 
the pathophysiology is not completely understood, several possible mechanisms related to 
impaired gas exchange, direct toxicity, and sympathetic activation have been proposed34.
Surprisingly, a meta-analysis has shown that maternal cigarette smoking is associated with 
a significant reduction in the risk of pre-eclampsia35. However, possible benefits of a 
reduced risk of pre-eclampsia does not outweigh the multiple medical and obstetrical risks 
associated with smoking during pregnancy both for the mother, her fetus and her 
environment. In addition, evidence on whether quitting smoking before or in early 
pregnancy reduces the risk remains inconclusive35. Based on an in vitro experiment, one of 
the mechanisms involved  may be that cigarette smoke reduces fms-like tyrosine kinase-1
(sFlt-1), which is the opposite of the changes observed in women who develop pre-
eclampsia36.  
In this thesis we showed that pregnancy-induced hypertension and pre-eclampsia share 
some risk factors, but not all. In women with an underlying disease, including chronic 
hypertension, a higher body mass index, diabetes or a metabolic syndrome, a pregnancy 
could provoke a maternal syndrome, including pre-eclampsia in the clinical phase during 
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pregnancy. This maternal syndrome starts in early pregnancy or even is existing before 
pregnancy and can be reflected in different phenotypes of hypertension in pregnancy. This 
may indicate different pathophysiological mechanisms leading to another disease as a 
result of different linking mechanisms between placental stage and systemic stage 
(symptomatic or non symptomatic). Or both diseases have the same underlying 
mechanism, where maternal susceptibility associated with genetic and environmental 
factors leads to different phenotypes. Poon et al. showed that certain risk factors with 
different subsets of factors performed  better in the prediction of early pre-eclampsia 
(previous history of pre-eclampsia, ethnicity, chronic hypertension and ovulation 
inductors) than in late pre-eclampsia37. Their findings showed that screening for pre-
eclampsia by maternal characteristics and previous history to define the intensity of 
antenatal care is potentially useful only when the various factors are incorporated into a 
combined algorithm derived by multivariate analysis. In such case, the estimated detection 
rates for early-PE, late-PE and GH are about 37, 29 and 21%, respectively, at a 5% false 
positive rate. The alternative strategy of treating each of the risk factors as a separate 
screening test would have falsely classified two thirds of the obstetric population as high 
risk and in need of intensive monitoring. 
In this thesis we did not investigate risk factors for intrauterine growth restriction or 
preterm birth. However, from literature we know that hypertensive disorders in pregnancy, 
intrauterine growth restriction and preterm birth share similar placenta pathology and share 
some risk factors in all stages of pregnancy. In addition, risk factors described for 
intrauterine growth restriction can be classified according to similar stages of pregnancy as 
in pre-eclampsia (figure 2). Intrauterine growth restriction may be caused by fetal, 
placental and maternal factors38. Fetal factors include structural or chromosomal 
anomalies, inborn errors of metabolism and fetal infection. Maternal factors can affect 
placental transfer of nutrients such as low pre-pregnancy weight, under nutrition, substance 
abuse or severe anemia. Medical conditions can also affect placental implantation and 
vasculature and hence transfer such as pre-eclampsia, autoimmune disease, 
thrombophilias, renal disease, diabetes and hypertension. 
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Many maternal factors have been associated with an increased risk of spontaneous preterm 
birth, including previous preterm birth, smoking, alcohol consumption, low maternal body 
mass index, advanced maternal age and a short interval between pregnancies39. 
Figure 2 Risk factors or symptoms for intrauterine growth restriction according to different 
stages, described for hypertension by Redman9  
Stages of pregnancy
Preconception
(stage -1)
Conception
(stage 0)
Poor placentation
(Stage 1)
Systemic phase
(stage 2)
Risk factors
Maternal 
factor
-teenage
-obesity
-ethnicity
-education
-socioeconomic status
-maternal disease
-history IUGR, 
-stillbirth, pre-
eclampsia
-uterine anomalies*
-family history IUGR
-genetics
-malnutrition
-smoking
-substance abuse
-medication
-environmental
pollution
-maternal 
infection
-maternal history 
of pre-eclampsia
-infection
-multiple 
gestation
-malnutrition
-smoking
-alcoholics
-substance abuse 
-medication
-hypertensive
disorders
Paternal 
factor
genetics
Fetal factor -chromosomal 
abnormality
-malnutrition
In italics risk factors are shown that differ from those in hypertensive disorders 
*large myomata, septa, synechia
Markers 
The plasminogen activator/inhibitor pathway and the matrix metalloproteinases play a key 
role in cellular invasion by degrading the extracellular matrix. In addition to its well-
researched action of stimulating endothelial cell proliferation and migration, vascular 
endothelial growth factor-A is known to stimulate metalloproteinase activity of the 
endothelial cells. The vascular endothelial growth factor family of angiogenic growth 
factors are important molecules regulating early placental vascular changes (placental 
angiogenesis and maternal spiral artery remodeling). These pathways with different 
markers play a role in placental development and placental disorders. For recognizing, 
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prevention and treatment of placental disorders it is important to find these markers as 
early as possible. Our results imply that pre-eclampsia and intrauterine growth restriction 
are both diseases which have an impaired placental development but with different 
biological determinants. 
PAI-2 
Low concentrations of PAI-2 in the third trimester have been associated with pre-
eclampsia40. However, it is uncertain whether the altered concentrations of PAI-2 precede 
the clinical onset. Clausen et al reported higher concentrations of PAI-2 at 18 weeks 
gestation in women who developed pre-eclampsia41. In line with Akolekar, we found no 
associations between PAI-2 concentration in early pregnancy and development of pre-
eclampsia42. 
Decreased PAI-2 concentrations seem to indicate decreased placental function and 
intrauterine growth retardation as a result43,44. These results are consistent with recent 
findings of a positive association between PAI-2 concentrations in early pregnancy and 
intrauterine growth at a mean of 12.4 weeks gestation by Crown Rump Length (CRL)45.
The association between PAI-2 and spontaneous preterm birth has not been described 
before. Gibson et al. described an association between PAI-2 and a PAI-2-polymorphism46.
However, recently a major susceptibility locus for preterm birth has been localized on 
chromosome 18q21.33-q23. A strong positional candidate gene in the 18q linked region is 
PAI-247. In our study, we found a trend for a negative association between a low PAI-2
concentration and the risk for preterm birth. 
Decreased PAI-2 concentration in early pregnancy acts as a marker of impaired placental 
function and could be used as a predictor for intrauterine growth restriction and preterm 
birth, but not pre-eclampsia. These data suggest a different pathway for development of 
pre-eclampsia and intrauterine growth restriction or preterm birth. 
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sFlt-1 
Prospective cohort studies have demonstrated that serum/plasma concentrations of PlGF, 
sFlt-1 and the sFlt-1/PlGF ratio may be useful biomarkers in the prediction of pre-
eclampsia. However, due to its limited sensitivity, these biomarkers are still not useful 
early in gestation to permit intervention48. A meta-analysis of such studies concluded that 
the test accuracies of serum PlGF and sFlt-1 before 30 weeks' gestation are too poor for 
accurate prediction of pre-eclampsia in clinical practice49. The deviation of the 
plasma/serum concentrations of these biomarkers from the normal reference ranges are 
more pronounced in women with earlier onset pre-eclampsia. Okhuchi et al. suggest 
thresholds for sFlt-1/PlGF ratio measured between 26 and 31 weeks of gestation may be 
useful for detecting pre-eclampsia with onset before 36 weeks of gestation50. Most cases of 
intrauterine growth restriction are associated with placental insufficiency. Recently Heraiz 
showed in a case-control-study that pregnancies with fetal growth restriction or pre-
eclampsia as well as pregnancies with pre-eclampsia and fetal growth restriction had 
higher values of sFlt-1/PlGF ratio than control pregnancies51. However, the differences 
among the case subgroups were not statistically different. We, like other large studies, 
were unable to confirm an association between a high sFlt-1 concentration in early 
pregnancy and pre-eclampsia. 
High sFlt-1 concentration in early pregnancy was not associated with intrauterine growth 
restriction. High sFlt-1 concentration was positively associated with birth weight and 
placental weight. These results were in line with the positive association of sFlt-1
concentration in early pregnancy and CRL described recently45. Bouwland-Both et al. 
suggest in early pregnancy higher sFlt-1 concentration may potentially reflect a low and 
stable environment needed for early placental and embryonic development. Research has 
shown that low oxygen concentration increases sFlt-1 concentration in cytotrophoblasts. 
Whereas higher sFlt-1 concentration in second and third trimester may reflect the response 
to fetal-placental hypoxia, which is associated with placental impairment. 
In early pregnancy, high sFlt-1 concentration is not associated with placental related 
disorders. sFlt-1 concentration in early pregnancy reflects a different pathway than in 
second or third trimester. 
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PlGF 
PlGF is expressed during early embryonic development. Transcripts encoding mouse PlGF 
were abundant in trophoblastic giant cells associated with the parietal yolk sac at early 
stages of embryogenesis suggesting a role to coordinate vascularization in the deciduum 
and placenta during early embryogenesis52. In addition, PlGF is expressed at a low level in 
several other organs including the heart, lung, thyroid, skeletal muscle, and adipose tissue 
under normal physiological conditions52. We demonstrated an association between a low 
PlGF concentration in first and second trimester and development of pre-eclampsia. 
Previous studies have reported that in pre-eclampsia and intrauterine growth restriction 
reduced concentrations of PlGF are apparent from the first trimester of pregnancy. The 
underlying cause for this decrease has been attributed to impaired placentation leading to 
early and persisting placental hypoxia.  
A low PlGF concentration in early pregnancy was in our study associated with a higher 
uteroploacental vascular resistance in midpregnancy, a lower placental weight and birth 
weight, and considerably higher risks for intrauterine growth restriction. These significant 
associations between low early pregnancy PlGF concentrations and high uteroplacental 
vascular resistance in midpregnancy may indicate early placental insufficiency. Bouwland-
Both showed that low PlGF concentration in early pregnancy was associated with a low 
CRL as well45. These data may imply that vascular placental development can influence 
early fetal development, which can have implications for subsequent development and 
outcome. Low PlGF concentration in early pregnancy is an early predictor for placental 
related disorders, reflecting early placental impairment, with higher uteroplacental vascular 
resistance in midpregnancy and finally placental disorders.  
Although early onset pre-eclampsia and intrauterine growth restriction are often considered 
together as consequences of placental insufficiency, Gosh et al. noted that women with low 
concentrations of PlGF at 20-22 weeks of gestation were more prone to develop 
intrauterine growth restriction than pre-eclampsia (34% developed early pre-eclampsia and 
intrauterine growth restriction versus 66% developed early intrauterine growth restriction 
only)53. They showed no significant difference in median PlGF concentrations between the 
different groups. In other words they suggest utero-placental insufficiency at the same 
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level in both groups, but the eventual outcome is different. However, Burton suggested that 
there are many common features in the placental changes seen in pre-eclampsia and 
intrauterine growth restriction and, isolated intrauterine growth restriction and that the 
differences are mostly a matter of degree of placental changes54. The two conditions may 
represent different points along a spectrum of placental pathologies secondary to deficit 
spiral artery conversion. Thus maternal and fetal constitutional factors may modulate how 
the placenta responds to the maternal vascular insult, and how the mother is affected by the 
placental factors released. 
Recently cross-reactivity of the PlGF assay has been described55. PlGF exists in at least 4 
isoforms due to alternative mRNA splicing of the PlGF primary transcript, but the major 
ones are thought to be PlGF-1 and PlGF-252. The main difference between the 4 isoforms 
is that PlGF-1 and PlGF-3 are non-heparin binding and can potentially affect targets in a 
paracrine manner, whereas PlGF-2 and PlGF-4 have additional heparin-binding domains 
and most likely work in an autocrine way52 . The first stage, at 11-13 weeks' gestation, 
should be primarily aimed at the effective prediction and prevention of severe early-onset 
disease. Although in the first trimester a high cross-reactivity of the PlGF assay to PlGF-2 
may be detrimental to the performance of the screening, Nucci et al. suggest that this may 
not be the case in screening during the third trimester56.
MMP 9 
Matrix metalloproteinases (MMPs) play a crucial role in restructuring the extracellular 
matrix by activating the secretion of gelatinases, collegenases and proteolytic enzymes. 
Cytotrophoblast MMP9 activity has been shown to be increased in human placental 
tissue57. A second matrix metalloproteinase important for placenta development is matrix 
metalloproteinase 3 (MMP3). MMP3 is produced by first trimester decidual cells and 
cytotrophoblast cells. MMP3 activates MMP9 and MMP2, and is implicated in connective 
tissue destruction and associated with endothelial cell dysfunction. Our findings of a lower 
prevalence of the rare T allele of the MMP9 polymorphism in women with pre-eclampsia 
suggest that women with uncomplicated pregnancies have more often increased MMP9 
concentrations and may therefore have an increased capacity of restructuring the 
extracellular matrix at the fetal maternal interface. MMP9 (-1562 C/T) has also been 
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described as a predictor of cardiovascular disease59. We suggest that the MMP9 induction 
has a different role at the fetal maternal interface than in the vascular remodeling during 
atherogenesis. Apoptosis and degradation of the cytotrophoblast cells are normal, 
physiologic constituents of trophoblast turnover. In addition, MMP activity is associated 
with preterm birth as well60. When contractions begin or the membranes rupture, MMP 
activity in the amnion and chorion increases and levels of interstitial and basement 
membrane collagens decrease. Regional activation of MMP’s near delivery may trigger a 
cascade of events that reduce fetal membrane integrity and promote rupture at specific 
sites. Therefore, we suggest a potential role for MMP and development of placental related 
disorders. 
Biophysical tests 
Abnormal early placentation can lead to higher uterine and umbilical artery resistance 
patterns, which can be measured by Doppler wave forms61. Umbilical, and to a lesser 
extent uterine, artery Doppler are used as markers to evaluate placental dysfunction62.
Several studies have demonstrated that mean arterial blood pressure (MAP) and increased 
uterine artery pulsatility index (Ut-Pi), measured between 11-13+6 weeks of gestation, 20-
24 weeks of gestation or 30-33 weeks of gestation can predict women who later develop 
pre-eclampsia63. Recently, a prospective longitudinal study described the temporal changes 
in MAP and Ut-Pi in women with singleton, high risk pregnancies who developed 
hypertension or not. MAP and Ut-Pi decreased with gestational age between 12 and 24 
weeks and then increased in women with a normal outcome64. MAP and Ut-Pi were shown 
to be higher from early pregnancy and the difference for both increased in women who 
developed preterm pre-eclampsia compared to women with a normal outcome. MAP was 
shown to be increased from 12 weeks and Ut-Pi is significantly increased from 33 weeks 
onwards in women who developed term pre-eclampsia64. Our study showed that sFlt-1, 
PlGF and PAI-2 concentrations in early pregnancy were associated with uterine artery 
pulsatility index. High sFlt-1 concentration in early pregnancy was associated with lower 
uterine artery pulsatility index in the second trimester. High sFlt-1 concentration was not 
associated with uterine artery pulsatility indexand placental disorders. Low PlGF 
concentration was associated with higher uterine artery pulsatility index in the second 
trimester. And finally, low PAI-2 was associated with higher uterine artery pulsatiliy index 
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in the second trimester. These results imply a different role for sFlt-1 in early pregnancy 
than in second or third trimester in relation to development of placental related disorders.  
IMPLICATIONS FOR PATHOGENESIS 
Placental disorders are complex with different pathways leading to several subtypes. Our 
data showed that different risk factors and markers in early pregnancy are associated with 
placental disorders or subtypes. Therefore in each stage of pregnancy different pathways 
can lead to impaired placental development.  Impaired placental development is 
associated with defects in endovascular extravillous trophoblast invasion, where some 
arteries are not invaded at all and some are superficially invaded, leading to a lack of the 
normal physiological adaptation of spiral arteries to pregnancy, reduced blood flow into 
the intervillous space, and relative hypoxia/ ischemia. Environmental, immunological, 
inflammatory and genetic factors all appear to play a role in this process. 
Development of placenta starts after fertilization. Defective trophoblast differentiation and 
accompanying ischemia are thought to be the primary events. Hypoperfusion appears to be 
both a cause and a consequence of abnormal placental development. Immunologic 
abnormalities, similar to those observed in organ rejection graft versus host disease have 
been observed in pre-eclamptic women65. A conflict between maternal and paternal genes 
is believed to induce abnormal placental implantation through increased natural killer cell 
activity. Both maternal and paternal contributions to fetal genes may have a role in 
defective placentation.  
The clinical features of pre-eclampsia can be explained as responses to generalized 
endothelial dysfunction. Placentation requires extensive angiogenesis for the establishment 
of a suitable vascular network to supply oxygen and nutrients to the fetus. Proangiogenic 
and antiangiogenic factors are elaborated by the developing placenta. A disturbed balance 
of production of angiogenic factors results in the systemic endothelial dysfunction The 
vascular endothelial growth factor family of angiogenic factors are important molecules 
regulating early placental vascular changes. The key molecules VEGF-A and PlGF and the 
receptors, sFlt-1 and VEGF-2 are expressed in the human placenta throughout gestation. 
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The VEGF family is known to regulate placental angiogenesis and maternal spiral artery 
remodeling. Pre-existing endothelial damage due to pre-existing vascular disease may 
contribute to development of the clinically disease as well.  
Further the correlation between placental volume and the risk of pre-eclampsia is also 
confirmed66. Effendi showed that first-trimester placental volume is strongly associated 
with fetal and placental growth67. There was a correlation between placental volume in 
early pregnancy and placental volume at birth and birth weight. The extent and the degree 
of defective deep placentation may explain the different clinical presentations68. Placental 
vascular lesions are different in pregnancies complicated by pre-eclampsia (predominant 
maternal vascular supply lesions), by intrauterine growth restriction (predominant fetal 
vascular supply lesions) and by pre-eclampsia with intrauterine growth restriction (both 
maternal and fetal compartments are involved). The levels of angiogenic factors in 
maternal blood reflect different biological processes and stages of placentation and 
maternal adaptation during pregnancy. The elevated maternal sFlt-1 levels in early 
pregnancy may reflect the low and stable oxygen environment needed for early placental 
development. The elevated sFlt-1 levels in later stages of pregnancy may reflect the 
response of fetoplacental hypoxia, which is associated with placental impairment. 
Maternal endothelial dysfunction is mainly attributed to defective placentation. However, 
there is increasing evidence to suggest abnormal placentation may not be the sole reason 
for altered endothelial function. The shared risk factors for both pre-eclampsia and later-
life vascular diseases, as well as the familial segregation of all these disorders suggest that 
these diseases share a common genetic predisposition that interacts with the environment 
and may predispose individuals to vascular disorders which manifest at different time 
points throughout the life course69. The timing of pre-eclampsia onset should be taken into 
consideration if pre-eclampsia heritability and etiology are to be unraveled. Early pre-
eclampsia appears to have a large genetic component, whereas environmental factors likely 
contribute most to late onset pre-eclampsia23.
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IMPLICATIONS FOR CLINICAL PRACTISE AND FUTURE RESEARCH 
In this thesis we used the model in which different stages in pregnancy are described. In 
each stage different risk factors and markers for placental related disorders could be 
identified. Pre-pregnancy planning and health promotion offers the possibility to improve 
pregnancy outcomes. Modifiable risk factors known before conception include obesity, 
smoking, advanced maternal age and multiple embryo transfer with artificial reproductive 
technology. Important non modifiable risk factors known before pregnancy to consider 
include education, socioeconomic status and maternal diseases. More healthy women 
before pregnancy will result in more healthy pregnancies and less maternal morbidity and 
mortality. In addition, identifying risk factors at the different points in pregnancy gives the 
opportunity to unravel the etiology of placental complications of pregnancy. 
Perspectives for prevention 
Until now research on prediction models focus on specific pregnancy outcomes. And so far 
first-trimester screening tests for pre-eclampsia have low positive predictive value, and 
there are no data demonstrating that they lead to improved outcomes70. However, ideally a 
prediction model will focus on different adverse outcomes, including hypertensive 
disorders, intrauterine growth restriction and preterm birth. A prediction model for 
placental related disorders in early pregnancy would ideally consist of maternal risk 
factors, markers of defective placentation and markers of abnormal vascular adaptation to 
pregnancy. Maternal risk factors (even modifiable) should include eg smoking, alcoholics, 
body mass index, maternal low birth weight, history of hypertensive disorders, maternal 
diseases, maternal age and headache. Markers of defective placentation in early pregnancy 
should include PlGF and PAI-2. Markers of abnormal vascular adaptation to pregnancy 
include uterine artery Doppler velocimetry. After selecting women with high risk 
pregnancies, at different points in pregnancy ongoing risk stratification may allow for early 
detection of adverse outcomes. 
Low-dose aspirin has been shown to reduce severe pre-eclampsia and other complications 
in women who started taking it before 16 weeks, but these studies used clinical risk factors 
to identify the women who could benefit from taking it70. Velauthar showed in a meta 
analysis that first-trimester uterine artery Doppler is a highly speciﬁc test for predicting 
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early-onset pre-eclampsia with moderate sensitivity71.The speciﬁcity for predicting pre-
eclampsia and fetal growth restriction at any gestational age is high, but the sensitivity is 
low. The number needed to treat with aspirin to prevent early-onset pre-eclampsia after 
uterine artery Doppler screening is comparable to that based on the ‘high-risk’ clinical 
factors currently being used71. Until now this test is not recommended because of the quite 
high false positive rate of this test, leading to excessive patiente anxiety and health care 
costs. 
Future research 
For a first-trimester risk assessment for pre-eclampsia to be useful in clinical practice, 
future screening tests will need to have sensitivities and positive predictive values, high 
enough to accurately identify women who will develop pre-eclampsia, and interventions 
will need to be available that improve clinical outcome in women who test positive70.
Research should focus on a composition of tests in early pregnancy to detect the risk for 
developing placental related pregnancy disorders in early pregnancy, combined with the 
currently routine screening tests for fetal abnormalities. Identification of adverse outcomes 
in early pregnancy will give the opportunity to facilitate targeted antenatal surveillance and 
possibly intervention. 
Furthermore research should focus on development of prediction models, incorporating the 
clinical characteristics with uterine artery Doppler to increase the accuracy of risk 
assessment. An individual patient data meta-analysis will allow development of optimal 
testing strategies for prediction of maternal and fetal complications72. 
Prospective cohort studies with the aim of collecting data on relevant clinical, 
environmental and lifestyle risk factors coupled with longitudinal measurement of 
angiogenic factors, endothelial function and genetic variations in candidate gene pathways 
will be beneficial in establishing interactions which predispose to placental related 
disorders of pregnancy in line with the hypothesis of several stages of placental disorders 
and possibilities of interactions at different stages. 
CONCLUSION 
The findings from this thesis suggest that in the different stages of pregnancy risk factors 
and markers of placental related disorders will help us to predict hypertensive diseases of 
4206 │ Chapter 4
pregnancy, intrauterine growth restriction and preterm birth, and unravel the pathology of 
these diseases (figure 3). Placental related disorders start in early pregnancy or even is 
existing before pregnancy and can be reflected in different phenotypes of hypertension in 
pregnancy. This may indicate different pathophysiological mechanisms leading to another 
disease as a result of different linking mechanisms between placental stage and systemic 
stage (symptomatic or non symptomatic). Or both diseases have the same underlying 
mechanism, where maternal susceptibility associated with genetic and environmental 
factors leads to different phenotypes. 
Figure 3 Risk factors, markers and biophysical tests to predict placental related 
complications of pregnancy in different stages of pregnancy 
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SUMMARY OF THIS THESIS 
Hypertensive disorders, intrauterine growth restriction and preterm birth are complications 
of pregnancy with unknown origins. These complications of pregnancy are important 
causes of maternal and perinatal diseases and death. Previous studies showed that placental 
development plays (an important) role in the origin of hypertensive disorders and 
intrauterine growth restriction, as well as preterm birth. 
The most important aim of the present thesis is to gain more knowledge about the etiology 
of placental related complications. A general introduction and the aims have been 
described in chapter 1. We describe in chapter 2 the analysis of associations between risk 
factors (maternal, paternal, pregnancy related and family factors, and maternal and paternal 
comorbidity) and placental related pregnancy disorders. In chapter 3 we describe the 
associations between biomarkers (components of blood clotting and extracellular matrix 
degradation, and angiogenesis) measured in blood taken in early pregnancy, and placental 
related complications. 
All studies in chapter 2 were embedded in The Generation R Study, a prospective 
population-based study from early pregnancy onwards in Rotterdam, The Netherlands. It 
aims to gain more insight into environmental, social and nutritional determinants of 
growth, development, and health in a contemporary population based multi-ethnic cohort 
of children from fetal life until young adulthood. Eventually, these results from The 
Generation R Study will contribute to the development of strategies for optimising health 
and healthcare for both pregnant women and their children. 
 In chapter 2.1 we focused on maternal and paternal risk factors in early pregnancy 
for hypertensive disorders. Women who did not develop hypertension in their first 
pregnancy have a low risk for pregnancy-induced hypertension or pre-eclampsia. 
Therefore, we studied similarities and differences in risk factors for pregnancy-induced 
hypertension and pre-eclampsia in nulliparous as well as multiparous women (table 1). An 
increased BMI (>25kg/m2) was associated with development of pregnancy-induced 
hypertension and pre-eclampsia in nulliparous and multiparous women. Previous 
hypertensive disorders in pregnancy were associated with a higher risk for pregnancy-
induced hypertension and pre-eclampsia in multiparous women. Women with development 
of hypertension in their first pregnancy had an increased risk for hypertension in the next 
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pregnancies (pregnancy-induced hypertension as well as pre-eclampsia). However, women 
with a normotensive first pregnancy had a low risk for hypertensive disorders in their 
subsequent pregnancies (<1%). The first pregnancy seems to be a stress test for next 
pregnancies. A low maternal birth weight was associated with pre-eclampsia in nulliparous 
women. Headache in early pregnancy was associated with pregnancy-induced 
hypertension and pre-eclampsia in nulliparous and multiparous women. The risk factors 
for pregnancy-induced hypertension and pre-eclampsia in nulliparous and multiparous 
women are presented in table 1. Some risk factors in early pregnancy seem to differ 
between pregnancy-induced hypertension and pre-eclampsia, as well as between 
nulliparous and multiparous women, exclusively an increased body mass index. 
Table 1. Risk factors for pregnancy-induced hypertension and pre-eclampsia 
Disease Pregnancy-induced 
hypertension
Pre-eclampsia
Risk factor nulli multi nulli multi
Age>40years 0 0 + 0
Increased body mass
(>25kg/m2)
+ + + +
European ethnicity + 0 0 -
Surinamese ethnicity 0 0 + 0
Previous hyertensive 
disorders
+ +
Low maternal birth 
weight
0 0 + 0
Twin pregnancy 0 0 + 0
Chronic hypertension 0 +
Headache 0 + 0 +
Paternal arthralgia 0 0 0 +
0 geen associatie, + positieve associatie (hoger risico), - negatieve associatie (lager risico) 
In chapter 2.2 we described the associations between maternal education level (as 
measurement of socioeconomic status) and the development of pre-eclampsia. Women 
with a lower education level had an increased risk for pre-eclampsia. We found a strong 
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educational gradient, where the lowest educational subgroup of pregnant women had five 
times higher odds compared with the highest educational subgroup to develop pre-
eclampsia. We did not find factors that could explain this association, including financial 
problems, smoking, work related problems and body mass index. So, the association 
between women with a lower educational level and a higher risk for pre-eclampsia is 
mainly unexplained. 
As described in chapter 2.3, women with relatively low levels of education had a 30 
to 50% higher risk for pregnancy-induced hypertension than women with a high 
educational level. Obesity and the relatively high blood pressure at enrolment were 
associated with a higher risk for pregnancy-induced hypertension in lower educated 
women. These findings suggest that pregnancy-induced hypertension in women with a low 
educational level could reflect to a predisposition for chronic hypertension, emerged by 
physiological stress of pregnancy.  
Prediction of hypertensive disorder in pregnancy at intake is difficult, especially in a 
low risk population of nulliparous women. A prediction model usable in daily clinical 
practise is needed to select women at intake with a high risk for development of 
hypertensive disorder in pregnancy. Recently, a prediction model for development of 
hypertension (≥140 and/or 90mmHg) determined before 36 weeks gestation has been 
described. This model uses clinical variables collected for routine control at intake of 
pregnancy before 16 weeks of gestation. Nulliparous women from Tilburg and Amsterdam 
have been studied. The prediction model has been derived from a regression model and 
transformed to a scorecard usable for daily practise. A score can be calculated using 
maternal weight, diastolic and systolic blood pressure (measured before 16 weeks of 
gestation). Women with a low score had a low risk for pregnancy-induced hypertension 
(<1%) and women with a high score had a high risk for pregnancy-induced hypertension 
(>16%). 
In chapter 2.4 we investigated the accuracy of a prediction model in the Generation 
R population. The incidence of hypertension (≥ 140 and/or 90mmHg) was 5.9%.  Of the 
women with a low score (13.4% of the population), none developed hypertension before 
36 weeks of gestation. In those with a high score (12.8% of the population) the risk was 
15.9%. This validation study confirms the predictive ability of the previous model, that can 
accurately identify women at very low and very high-risk of becoming a hypertension in 
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pregnancy before 36 weeks of gestation. Application of the model may lead to a reduction 
in frequency of antenatal visits for low-risk and increased surveillance for high-risk 
women. 
In general, large epidemiological studies use questionnaires to collect their data. 
Chapter 2.5 provides the validation of pre-eclampsia which is necessary for interpretation 
of self-reported pre-eclampsia. We investigated 4330 women, 2% developed a pre-
eclampsia according to the ISSHP definition. From 152 women who reported a pre-
eclampsia, 50% did not have a pre-eclampsia. From 4178 women who reported no pre-
eclampsia, actually 0.3% had a pre-eclampsia. The sensitivity and specificity of self-
reported pre-eclampsia was 0.87 and 0.98, respectively. Higher education and parity are 
associated with a better self-reported diagnosis of self-reported pre-eclampsia. A clear 
diagnosis based on criteria of hypertension and proteinuria, which is clear for the doctor 
and patient, is essential for preconception care, the management of a subsequent 
pregnancy, and possible prevention of cardiovascular disease in later life. In our study the 
validity of the maternal recall of self-reported pre-eclampsia was moderate. 
 In chapter 3 of this thesis, we investigated the involvement of the 
hemostasis (components of blood clotting), fibrinolysis (extracellular matrix degradation) 
and angiogenesis, and development of placental related complications in pregnancy. The 
associations between biomarkers and pre-eclampsia, intrauterine growth restriction and 
spontaneous preterm birth are presented in table 2.  
Hemostasis is a complex balance between inhibitory and activating pathways 
resulting in coagulation and lysis. Normal pregnancy contributes to a state of relative 
hypercoagulation, while in complicated pregnancies hypercoagulation is even more 
profound. Chapter 3.1 describes the concentrations of the activator (tissue-type 
plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA)) and 
inhibitor (plasminogenactivator-inhibitor type-1 (PAI-1) and plasmingenactivator-inhibitor 
type-2 (PAI-2)) components of the plasmingen activator-inhibitory system to gain more 
insight in longitudinal data during pregnancy until 6 weeks postpartum. For this study, we 
used blood samples from a subgroup of 41 women, from a multicentre study coordinated 
by the University Medical Centre of Nijmegen. The longitudinal changes in concentrations 
of this system might be helpful in the understanding of pregnancy complications, including 
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pre-eclampsia. The concentration of tPA and uPA decreased in the first 10 weeks of 
gestation, followed by an increase in the third trimester and finally a decrease 6 weeks 
postpartum to the preconceptional concentration. PAI-2 concentration increased with 
gestational age until term and declined to undetectable levels 6 weeks after delivery. A 
decreased production of PAI-2 is thought to be a result of impaired placental function. A 
relative hypercoagulation appear to be in normal pregnancy as described before: in the 
third trimester a decrease of activating tissue-type plasminogen-activator (tPA) and 
urokinase-type plasminogen-activator (uPA) and an increase of inactivating plasminogen-
activator-inhibitor type 2 (PAI-2) components of the plasminogen-activator-inhibitor 
system. 
In chapter 3.2, we described PAI-2 concentration <18 weeks gestation in relation 
to development of placental related pregnancy complications, spontaneous preterm 
delivery, intrauterine growth restriction and pre-eclampsia. This study was embedded in 
the Generation R study. Low PAI-2 concentration was associated with a lower birth weight 
and a lower placental weight. Since PAI-2 has been produced by trophoblastcells, we 
suggest that a defective placentation will result in a smaller placenta with less 
trophoblastcells. In addition, low PAI-2 concentration was associated with a higher risk of 
preterm birth and intrauterine growth restriction, but not pre-eclampsia.  
Many studies have been focused on the angiogenesis and development of pre-
eclampsia. Especially soluble fms-like tyrosine kinase-1 (sFlt-1) and placenta growth 
factor (PlGF) might be potential factors in the early placental stage in association with 
defective development of placenta. High sFlt-1 concentration was associated with pre-
eclampsia, even 5 weeks before the clinical onset. And low PlGF concentration was 
associated with pre-eclampsia as well as intrauterine growth restriction. These results 
suggest placental impairment in early pregnancy.  
Chapter 3.2 describes besides PAI-2 associations also the associations between sFlt-1 and 
PlGF concentration measured before 18 weeks of gestation and between 18 and 25 weeks 
of gestation, and uterine artery resistance index, placental weight, birth weight, preterm 
birth, intrauterine growth restriction and pre-eclampsia. High sFlt-1 concentration 
(measured before 18 weeks and between 18 and 25 weeks of gestation) was associated 
with a lower uterine artery resistance index in second trimester and a higher birth weight. 
In our study, high sFlt-1 concentration was not associated with preterm birth, intrauterine 
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growth restriction or pre-eclampsia. sFlt-1 do not seem to be a valuable predictor in early 
pregnancy of placental related complications. Low sFlt-1 concentration in first trimester 
seems to be an expression of low angiogenesis as a result of placental impairment. Fetal-
placental hypoxia reflects a response of abnormal development of the placenta, with an 
elevation of angiogenesis subsequently in pregnancy. Low PlGF concentration (measured 
<18 weeks and between 18 and 25 weeks of gestation) was associated with a higher uterine 
artery resistance index and a lower birth weight. Lower PlGF concentration before 18 
weeks of gestation was associated with preterm birth, intrauterine growth restriction and 
pre-eclampsia. PlGF seems to be a potential marker usable in early pregnancy to predict 
placental related complications. 
Table2 Biomarkers for preterm birth, intrauterine growth restriction and  
pre-eclampsia 
Disease Preterm birth Intra-uterine 
growth 
restriction
Pre-eclampsia
Biomarker
<18 
weeks
18-25 
weeks
<18 
weeks
18-25 
weeks
<18 
weeks
18-25 
weeks
PAI-2 0 +- 0
sFlt-1 0 0 0 0 0 0
PlGF 0 + + + + +
sFlt-1/PlGF 
ratio
+ 0 0 0 + 0
0 no association, + positive association (higher risk), - negative association (lower risk) 
In chapter 3.3 we described the functional polymorphisms of MMP3 (-1562 C/T), 
MMP3 (-1612 5A/6A) and annexin A5(-1 C/T) and the risk of pre-eclampsia. These 
polymorphisms are functional promoter polymorphisms and influence the amount of 
protein production. Matrix metallopreinases (MMP’s) play an important role in early 
pregnancy by influencing the degradation of the extracellular matrix, which is a process 
necessary for a successful trophoblastinvasion. MMP3 has been produced in early 
pregnancy by decidual- and trophoblastcells. MMP3 activates MMP9 and MMP2 and 
these proteins have been associated with endothelial dysfunction. Annexin A5 has been 
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produced by syncytiotrophoblast- and endothelialcells and they play an important role in 
apoptosis. For this study, we used blood samples of a case-control study coordinated by the 
Leids Medical Centre. In our study, the rare T allele of MMP9 was associated with a lower 
risk for pre-eclampsia. No associations were found between MMP3 and annexin A 5 
polymorphism, and pre-eclampsia.  
 In chapter 4 we provide a general discussion in which the studies observed in this 
thesis are described in a broader context and implications for future research are discussed. 
Awareness of risk factors for hypertensive disorders in pregnancy, intrauterine growth 
restriction and preterm birth gives the opportunity to improve pregnancy outcome. 
Prediction models with maternal risk factors (table 1), biomarkers of abnormal 
placentation (table 2) and markers of an impaired vascular adaption in pregnancy (Doppler 
velocimetry artery uterine) will help us to select women with a higher risk for placental 
related complications. Future research will focus on a prenatal test in early pregnancy. 
Blood will be screened for fetal (and placental) markers associated with placental related 
complications of pregnancy. 
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SAMENVATTING VAN DIT PROEFSCHRIFT 
Hypertensieve aandoeningen, intra-uteriene groeivertraging en spontane vroeggeboorte 
zijn zwangerschapscomplicaties waarvan de ontstaanswijze grotendeels onbekend is. Deze 
zwangerschapscomplicaties zijn belangrijke oorzaken van zowel maternale als perinatale 
sterfte en ziekte. Eerder onderzoek heeft aangetoond dat de ontwikkeling van de placenta 
een (belangrijke) rol kan spelen in de ontstaanswijze van zowel hypertensieve 
aandoeningen in de zwangerschap als intra-uteriene groeivertraging, maar ook van een 
spontane vroeggeboorte. De belangrijkste doelstelling van dit proefschrift is meer inzicht 
te geven in de ontstaanswijze van deze placentagerelateerde zwangerschapsaandoeningen. 
Een algemene inleiding en doelstellingen zijn beschreven in hoofdstuk 1. We beschrijven 
in hoofdstuk 2 de analyse van de associaties van risicofactoren (maternale, paternale, 
zwangerschap gerelateerde en familiaire factoren, en maternale en paternale comorbiditeit)
en placentagerelateerde zwangerschapsaandoeningen. In hoofdstuk 3 beschrijven we de 
associaties van biomarkers (componenten van bloedstolling en extracellulaire 
matrixafbraak, en angiogene factoren) die gemeten zijn in bloedmonsters afgenomen in 
een vroeg stadium van de zwangerschap met placentagerelateerde 
zwangerschapscomplicaties. 
De studies beschreven in hoofdstuk 2 zijn uitgevoerd binnen de Generation R 
Studie. Generation R is een groot, Rotterdams cohort studie met als doel meer inzicht te 
verkrijgen in omgeving -, sociale - en voeding determinanten van de groei, de 
ontwikkeling en de gezondheid in een multi-etnisch cohort vanaf de foetale periode tot aan 
de jongvolwassene leeftijd. Uiteindelijk zullen de resultaten van Generation R bijdragen 
aan de ontwikkeling van strategieën ter optimalisering van de gezondheid en zorg van 
zowel zwangere vrouwen als hun kinderen. 
 In hoofdstuk 2.1 hebben we ons gericht op maternale en paternale risicofactoren 
voor hypertensieve aandoeningen in de zwangerschap, die in een vroeg stadium van de 
zwangerschap bekend zijn. Het is bekend dat vrouwen die geen hypertensie hebben 
ontwikkeld in de eerste zwangerschap een laag risico hebben om een 
zwangerschapshypertensie of pre-eclampsie te ontwikkelen. We hebben daarom gekeken 
naar overeenkomsten en verschillen in risicofactoren voor zwangerschapshypertensie en 
pre-eclampsie voor zowel nulli- als multi-para (tabel 1). Een verhoogde body mass index 
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(> 25) is geassocieerd met het ontstaan van zwangerschapshypertensie en pre-eclampsie bij
zowel nulli- als multi-para. Een voorgeschiedenis met hypertensieve aandoeningen in de 
zwangerschap is geassocieerd met een verhoogd risico voor zowel 
zwangerschapshypertensie als pre-eclampsie bij multipara. Deze vrouwen hadden een tien 
maal verhoogd risico op de ontwikkeling van pre-eclampsie. Als er een hypertensieve 
aandoening ontstaat in de eerste zwangerschap heeft de vrouw daarmee een verhoogd 
risico op hypertensie in de volgende zwangerschappen (zowel zwangerschapshypertensie 
als pre-eclampsie). Als de eerste zwangerschap daarentegen niet gecompliceerd wordt door 
een hypertensieve aandoening is het risico op hypertensieve aandoeningen in de volgende 
zwangerschappen klein (< 1%). De eerste zwangerschap lijkt een stress-test voor de 
komende zwangerschappen. Een laag geboortegewicht van de moeder zelf is geassocieerd 
met pre-eclampsie bij nullipara. Hoofdpijn in het eerste trimester van de zwangerschap is 
geassocieerd met zwangerschapshypertensie en pre-eclampsie bij multipara. In tabel 1 zijn 
de risicofactoren voor zwangerschapshypertensie en pre-eclampsie voor nullipara en 
multipara weergegeven. Er is dus een verschil in risicofactoren tussen vrouwen die 
zwangerschapshypertensie of preeclampsie ontwikkelen en nullipara en mulipara met als 
uitzondering een verhoogde BMI die voor alle groepen een risico factor is. 
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Tabel 1. Risicofactoren voor zwangerschapshypertensie en pre-eclampsie  
Ziektebeeld
Risicofactoren
Zwangerschapshypertensie Pre-eclampsie
nulli multi nulli multi
Leeftijd > 40jaar 0 0 + 0
Verhoogde body mass index + + + +
Europese ethniciteit + 0 0 -
Surinaamse ethniciteit 0 0 + 0
Hypertensieve aandoeningen 
in de voorgeschiedenis
+ +
Laag maternal 
geboortegewicht
0 0 + 0
Tweelingzwangerschap 0 0 + 0
Preexistente hypertensie 0 +
Hoofdpijn 0 + 0 +
Paternale gewrichtsklachten 0 0 0 +
O geen associatie, + positieve associatie (verhoogd risico), - negatieve associatie (beschermend) 
In hoofdstuk 2.2 hebben we de associaties beschreven tussen opleidingsniveau 
van de zwangere vrouw (als maat van de socio-economische status) en het ontstaan van 
pre-eclampsie. Naarmate vrouwen een lager opleidingsniveau hadden, nam het risico op 
pre-eclampsie toe. We vonden dat zwangere vrouwen met het laagste opleidingsniveau een 
vijfmaal verhoogd risico hadden op pre-eclampsie vergeleken met de vrouwen met het 
hoogste opleidingsniveau. We hebben geen factoren gevonden zoals financiële 
moeilijkheden, roken, werk gerelateerde problemen en body mass index die deze associatie 
zouden kunnen verklaren; de associatie tussen vrouwen met een lager opleidingsniveau en 
verhoogd risico op preeclampsie blijft hiermee grotendeels onverklaard. 
 In hoofdstuk 2.3 hebben we beschreven dat vrouwen met een relatief laag 
opleidingsniveau een 30 tot 50% hoger risico op zwangerschapshypertensie hebben dan 
vrouwen met een laag opleidingsniveau. Obesitas en een relatief hoge bloeddruk bij de 
lager opgeleid vrouwen bij inclusie waren geassocieerd met een hoger risico op 
zwangerschapshypertensie. Deze bevindingen suggereren dat zwangerschapshypertensie 
bij vrouwen met een laag opleidingsniveau mogelijk gerelateerd is aan een aanleg tot een 
chronische hypertensie dat door de fysiologische stress van de zwangerschap tijdelijk 
zichtbaar wordt . 
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 Het voorspellen van hypertensieve aandoeningen bij intake is moeilijk met name 
bij laag-risico nullipara. Er bestaat behoefte in de dagelijkse klinische praktijk aan 
predictiemodellen voor een laag-risico populatie om bij intake vrouwen te selecteren met 
een hoger risico op hypertensieve aandoeningen die zich later in de zwangerschap 
ontwikkelen. Recent is een predictiemodel beschreven voor het ontstaan van hypertensie 
(≥ 140 en/ of 90mmHg) vastgesteld voor de 36e week van de zwangerschap. Dit model 
maakt gebruik van klinische variabelen die routinematig verzameld worden tijdens de 
intake van de zwangere vrouw voor de 16e week van de zwangerschap. Hiervoor zijn 
nullipara afkomstig uit Tilburg en Amsterdam onderzocht. Het predictiemodel is 
voortgekomen uit een regressiemodel en getransformeerd tot een scorekaart bruikbaar voor 
de dagelijkse praktijk. Met behulp van het maternale gewicht, de diastolische en 
systolische bloeddruk (gemeten voor de 16e week van de zwangerschap) kan een score 
berekend worden. Vrouwen met een lage score hebben een laag risico op 
zwangerschapshypertensie (<1%) en vrouwen met een hoge score hebben een hoger risico 
op zwangerschapshypertensie (>16%).  
In hoofdstuk 2.4 hebben we de validiteit van dit predictiemodel onderzocht in de 
Generation R populatie. De incidentie van hypertensie (≥ 140 en/ of 90mmHg) was 5.9%. 
Van de vrouwen met een lage score (13.4% van de populatie) ontwikkelde geen enkele 
vrouw een hypertensie. Bij de vrouwen met een hoge score (12.8% van de populatie) was 
het risico op hypertensie 15.9%. Deze validatie studie bevestigt het voorspellend vermogen 
van dit predictie model; Vrouwen met een laag risico en vrouwen met een hoog risico op 
hypertensie vastgesteld voor de 36e week van de zwangerschap kunnen accuraat worden 
onderscheiden. Toepassing van dit model zou kunnen leiden tot minder 
zwangerschapscontroles van vrouwen met een laag risico en intensievere controle van 
vrouwen met een hoog risico. 
In epidemiologische studies worden vaak zelf ingevulde vragenlijsten gebruikt om 
risicofactoren te bestuderen. In hoofdstuk 2.5 hebben we de validatie van zelf 
gerapporteerde pre-eclampsie in vragenlijsten gepresenteerd. We onderzochten 4330 
vrouwen waarvan 2% van de vrouwen een pre-eclampsie had ontwikkeld volgens de 
ISSHP definitie. Van de 152 vrouwen die zelf rapporteerden dat ze een pre-eclampsie 
hadden gehad, bleek 50% niet een pre-eclampsie te hebben gehad. Van de 4178 vrouwen 
die aangaven geen pre-eclampsie te hebben gehad, bleek 0.3% een pre-eclampsie te 
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hebben gehad. De sensitiviteit en specificiteit van zelf gerapporteerde pre-eclampsie was 
respectievelijk 0.87 en 0.98. Een hogere opleiding en pariteit waren geassocieerd met een 
betere zelf gerapporteerde diagnose van pre-eclampsie. Een juiste diagnose is voor zowel 
de dokter als de patiënt belangrijk. Deze diagnose is essentieel voor preconceptie zorg, de 
behandeling van een volgende zwangerschap en mogelijk preventie van cardiovasculaire 
aandoeningen op oudere leeftijd. In onze studie was de validatie van de zelf gerapporteerde 
pre-eclampsie matig. 
In hoofdstuk 3 van dit proefschrift hebben we hemostase (componenten van 
bloedstolling), fibrinolyse (extracellulaire matrixafbraak) en angiogenese, en het ontstaan 
van placentagerelateerde complicaties in de zwangerschap bestudeerd. In tabel 2 zijn de 
biomarkers en de associatie met pre-eclampsie, intra-uteriene groeivertraging of spontane 
vroeggeboorte weergegeven. 
Voor een goede hemostase is er een complexe balans tussen inactiverende en 
activerende proteïnen noodzakelijk, die resulteert in een evenwicht tussen coagulatie en 
lysis. In een normale zwangerschap is er een relatieve hypercoagulatie. Een sterkere 
neiging tot  hypercoagulatie wordt gezien bij bepaalde zwangerschapscomplicaties.  
Hoofdstuk 3.1 beschrijft de concentraties van de activerende (tissue-type 
plasminogeen activator (tPA) en urokinase-type plasminogeen activator (uPA)) en 
inactiverende (plasminogeenactivator-inhibitor type-1 (PAI-1) en plasmingeenactivator-
inhibitor type-2 (PAI-2)) componenten van het plasminogen activator-inhibitor systeem 
om zo meer inzicht te krijgen in dit systeem gedurende de gehele zwangerschap tot 6 
weken postpartum. Voor deze studie hebben we gebruik gemaakt van bloedmonsters van 
een subgroep van 41 vrouwen, van een multicenterstudie die werd gecoördineerd door het 
Universitair Medisch Centrum Nijmegen. Inzicht in de longitudinale veranderingen in 
concentraties van de verschillende proteïnes van dit systeem kunnen ons helpen om 
zwangerschapscomplicaties, zoals pre-eclampsie beter te begrijpen. De concentraties van 
tPA en uPA daalden in de eerste 10 weken van de zwangerschap, waarna een stijging 
volgde in het derde trimester, om vervolgens weer tot preconceptionele waarde te dalen 
postpartum. De concentratie van PAI-2 nam toe gedurende de zwangerschap tot de 
geboorte en daalde tot een niet aantoonbare waarde ongeveer 6 weken postpartum. Een 
verminderde productie van PAI-2 zou mogelijk kunnen komen door een afwijkende 
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placentatie. Er lijkt een relatieve hypercoagulatie in een normale zwangerschap zoals 
eerder beschreven: in het 3e trimester door afname van activerende (tissue-type 
plasminogeen activator (tPA) en urokinase-type plasminogeen activator (uPA)) en toename 
van inactiverende plasmingeenactivator-inhibitor type-2 (PAI-2)) componenten van het 
plasminogen activator-inhibitor systeem.  
In hoofdstuk 3.2 beschrijven we de PAI-2 concentratie bepaald bij een 
zwangerschapsduur onder de 18 weken in relatie tot de ontwikkeling van 
placentagerelateerde afwijkingen, zoals vroeggeboorte, intra-uteriene groeivertraging en 
pre-eclampsie. Dit onderzoek werd uitgevoerd binnen de Generation R studie. Een lagere 
concentratie PAI-2 was geassocieerd met een lager geboortegewicht en een lager 
placentagewicht. Omdat PAI-2 wordt geproduceerd door trofoblastcellen, suggereert dit 
dat bij een abnormale ontwikkeling van de placenta, het trophoblastvolume kleiner is. Een 
lagere PAI-2 concentratie is ook geassocieerd met een grotere kans op spontane 
vroeggeboorte en intra-uteriene groeivertraging, maar niet met een verhoogd risico op pre-
eclampsie. 
Vele studies hebben de laatste tijd zich gericht op de angiogenese en de 
ontwikkeling van pre-eclampsie. Soluble fms-like tyrosine kinase-1 (sFlt-1) en placenta 
growth factor (PlGF) zijn factoren die al in een vroeg stadium van de zwangerschap 
geassocieerd worden met een abnormale placenta ontwikkeling. Een hoge concentratie 
sFlt-1 is door anderen geassocieerd met pre-eclampsie, zelfs aantoonbaar 5 weken voor de 
klinische manifestatie van de ziekte. En een lage concentratie van PlGF wordt geassocieerd 
met zowel pre-eclampsie als intra-uteriene groeivertraging. Deze resultaten suggereren een 
malplacentatie vroeg in de zwangerschap. 
Hoofdstuk 3.2 beschrijft naast PAI-2 ook de associaties van sFlt-1 en PlGF 
concentraties bepaald bij een zwangerschapsduur onder de 18 weken en tussen de 18 en 25 
weken met de uteroplacentaire vasculaire weerstand, placenta en geboortegewicht, en 
spontane vroeggeboorte, intra-uteriene groeivertraging en pre-eclampsie. Een hoge sFlt-1
concentratie (zowel bepaald bij een zwangerschapsduur onder de 18 weken als tussen de 
18 en 25 weken) was geassocieerd met een lagere uteroplacentaire weerstand in het tweede 
trimester en een hoger geboortegewicht. Een hoge sFlt-1 concentratie was in onze studie 
niet geassocieerd met een spontane vroeggeboorte, intra-uteriene groeivertraging of pre-
eclampsie. sFlt-1 lijkt geen factor waarmee al vroeg in de zwangerschap 
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placentagerelateerde complicaties kunnen worden voorspeld. Een lagere concentratie sFlt-
1 in het eerste trimester lijkt meer een uiting van weinig angiogene activiteit als gevolg van 
een abnormale placentatie. Door de abnormale ontwikkeling van de placenta kan 
foetomaternale hypoxie ontstaan, waardoor de angiogene activiteit toeneemt in een verder 
gevorderd stadium van de zwangerschap. Een lage PlGF concentratie (zowel bepaald bij 
een zwangerschapsduur onder de 18 weken als tussen de 18 en 25 weken) was 
geassocieerd met een hogere uteroplacentaire vasculaire weerstand en een lager 
geboortegewicht. Een lage PlGF concentratie bepaald bij een zwangerschapsduur onder de 
18 weken was geassocieerd met spontane vroeggeboorte, intra-uteriene groeivertraging en 
pre-eclampsie. PlGF is dus wel een potentiele marker die al vroeg in de zwangerschap 
gebruikt kan worden om placenta gerelateerde complicaties te voorspellen.
Tabel 2 Biomarkers voor pre-eclampsie, intra-uteriene groeivertraging  
en vroeggeboorte 
Ziektebeelden Pre-eclampsie Intra-uteriene 
groeivertraging
Spontane 
vroeggeboorte
Biomarkers
<18 
weken
18-25 
weken
<18 
weken
18-25 
weken
<18 
weken
18-25 
weken
PAI-2 0 +- 0
sFlt-1 0 0 0 0 0 0
PlGF + + + + 0 +
sFlt-1/PlGF 
ratio
+ 0 0 0 + 0
O geen associatie, + positieve associatie (verhoogd risico), - negatieve associatie (beschermend) 
In hoofdstuk 3.3 hebben we de functionele polymorfismen beschreven van MMP3 
(-1562 C/T), MMP9 (-1612 5A/6A) en anexin-A5 (-1 C/T) in relatie tot het risico op pre-
eclampsie. Dit zijn 3 functionele polymorfismen, die een invloed kunnen hebben op de 
hoeveelheid proteïne die wordt geproduceerd. Matrix metalloproteinases (MMP’s) spelen 
een belangrijke rol in de trofoblastinvasie vroeg in de zwangerschap door hun invloed op 
de afbraak van de extracellulaire matrix, een proces noodzakelijk voor een succesvolle 
trofoblastinvasie. MMP3 wordt in het eerste trimester geproduceerd door decidua- en 
trofoblastcellen. MMP3 activeert MMP9 en MMP2 en wordt geassocieerd met 
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endotheeldysfunctie. Annexin A5 wordt geproduceerd door syncytiotrofoblast- en 
endotheelcellen en speelt een belangrijke rol bij apoptosis. Voor dit onderzoek hebben we 
gebruik gemaakt van bloedmonsters van een case-control studie gecoördineerd door het 
Leids Medisch Centrum. In onze studie bleek dat het zeldzamere T allel van MMP9 
geassocieerd was met een lager risico op pre-eclampsie. Er konden geen associaties 
worden gevonden tussen MMP3 en annexin A5 polymorfisme enerzijds en pre-eclampsie 
anderzijds.  
In hoofdstuk 4 is een algemene discussie opgenomen over de bevindingen die zijn 
gedaan in dit proefschrift. Dit hoofdstuk bevat ook aanbevelingen voor toekomstig 
onderzoek. 
Bewustwording van de risicofactoren voor hypertensieve aandoeningen in de 
zwangerschap, intra-uteriene groeivertraging en vroeggeboorte biedt de mogelijkheid om 
de zwangerschapsuitkomsten te verbeteren. 
Met behulp van predictiemodellen, waarin maternale risicofactoren (zie tabel 1), 
biomarkers van een abnormale placentatie (zie tabel 2) en markers van een gestoorde 
vasculaire aanpassing in de zwangerschap (doppler velocimetrie arterie uterina) zal in de 
verschillende fases van de zwangerschap een risicoselectie kunnen plaatsvinden. 
Toekomstig onderzoek zal zich richten op een prenatale test vroeg in de zwangerschap 
waarin bloed van de zwangere gescreend wordt op foetale (en placenta) markers die 
geassocieerd zijn met placentagerelateerde zwangerschapscomplicaties. 
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